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Abstract 
New Psychoactive Substances (NPS) were designed to be legal alternatives to existing established 
recreational drugs. They have fast become a very popular and up until 2016, NPS were legal, cheap 
and freely accessible via the internet and high street “head shops”. The rapid expansion in the number 
of these drugs has reached epidemic proportions, whereby hundreds of NPS have been developed 
and sold within the last five-year period. As NPS are synthesized in clandestine laboratories there is 
little to no control in the manufacture, dosage and packaging of these drugs.  
The public health risks posed by these drugs are therefore far-reaching. Fatalities and severe adverse 
reactions associated with these compounds have become an ongoing challenge to healthcare services, 
primarily because these drugs have not previously been abused and therefore there is little 
pharmacological information available regarding NPS.  
There are a number of different biological receptors that are implicated in the effects of NPS and the 
mechanism of action for the majority of these drugs is still largely unknown. It is of great importance 
to try and establish an understanding of how various classes of NPS interact on a molecular level. In 
this thesis, structure-based and ligand-based in Silico methodologies were employed to gain a better 
understanding of how NPS may interact with monoamine transporters (MAT). Key findings included 
both molecular docking studies and a number of robust and predictive QSAR models for the dopamine 
and serotonin transporters provided insight into how promiscuity of NPS between the different MAT 
isoforms could arise.  
In addition, pharmacophore models were generated to identify chemical entities that were 
structurally dissimilar to known existing NPS that had the potential to interact with the cannabinoid 1 
receptor (CB1) and hence were hypothesised could elicit similar biological responses to known potent 
synthetic cannabinoids. 
Thirteen of these compounds were identified and carried forward for in vitro and ex vivo analyses, 
where preliminary results have shown that two compounds activate the CB1 receptor. Further 
optimisation of these compounds could yield a novel SC scaffold that was previously unseen. 
Additionally, the compounds identified and the methodology employed in the generation of these 
new chemical scaffolds could be used to guide Early Warning Systems (EWS) and facilitate law 
enforcement with respect to emergent NPS. 
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1.1 Traditional drugs of abuse 
Traditional drugs of abuse include cannabis, heroin, cocaine and ecstasy1, the consumption of these 
substances has been extensively documented throughout the last century. 
Smoking heroin was known as “chasing the dragon” and was initially popularised in Shanghai in the 
1920s2. This practice spread globally until the 1960s, when intravenous use of heroin became more 
common2. Currently heroin is the 2nd most popular narcotic in Europe3 and the global amount of heroin 
seized reached a record high of 91 tonnes in 20164.  
Cocaine use in the 1980s was mainly associated with the wealthier members of society5, which 
ultimately gave rise to the cheaper smokable freebase alternative “crack”5. Both forms of this drug 
have become a global health burden6. Cannabis plants have also been cultivated by man for centuries 
and used for textile purposes (hemp) and the medicinal purposes of cannabis have been reported 
throughout history. The last century has seen the popularity of cannabis rise to a point where it has 
become the most widely abused drug globally3,4. 
Psychoactive/Psychotropic substances derived from plant based origins such as opium, khat, cannabis, 
coca leaves and magic mushrooms have also been abused for centuries7 . In 1961, when opium 
smoking had become a serious public health threat, legislation was brought into effect to make the 
supply and use of narcotic substances illegal. Thus, the 1961 single convention on narcotic drugs8 was 
introduced, which prohibited the production and supply of traditional drugs of abuse such as heroin, 
cocaine and opium. This began the process of criminalising drugs, drug-use and psychoactive 
substances in general. A number of subsequent drug laws9,10 were brought in and enforced following 
the 1961 single convention on narcotic drugs, in order to guard against the risks to health and society 
at large that these substances posed. Despite the increase in legislation and its enforcement, suppliers 
of illicit narcotics continued to exploit the vulnerable and addicted, and in an effort to maximize their 
profits began to ‘cut’ their narcotics with other substances11–15. For example, in the late 90’s there was 
a decrease in purity of traditional drugs such as cocaine16  and it is believed that this was one factor 
that accelerated  the growth of an emergent category of compounds called “Legal Highs” or New 
Psychoactive Substances, which users, often referred to in the literature as “psychonauts17”, pursued 
as legal, and somewhat erroneously presumed safer replacements to the traditional drugs of abuse.  
1.1.1 New Psychoactive Substances (NPS) 
A New Psychoactive Substance (NPS) is defined by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) as 'a new narcotic or psychotropic drug, in pure form or in preparation, that is 
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not controlled by the United Nations drug conventions, but which may pose a public health threat 
comparable to that posed by substances listed in these conventions’18.  
Historically NPS were highly popularized in the mid-2000s and commonly referred to as “herbal highs”, 
“designer drugs”, “research chemicals” and “legal highs”16 aptly named due to their legal status in the 
UK prior to the 2016 Psychoactive Substance Act19. “Legal highs” were easily purchased from high 
street “head shops” and online retailers at a much lower cost than more typical recreational drugs 
such as cocaine and MDMA20. 
1.1.2 NPS Classification 
Categorisation of NPS varies greatly. Some literature, particularly that aimed at devising appropriate 
clinical intervention to treat NPS intoxication, will classify NPS according to their pharmacological 
effects using, for example, the following categories: stimulants, cannabinoids, hallucinogens and 
depressants21.  
The United Nations office on Drugs and Crime (UNODC) uses a semi-systematic classification system 
which divided NPS into nine categories based on their drug class i.e. aminoindane, tryptamines , 
synthetic cathinones, synthetic cannabinoids, plant-based substances, piperazines, phenethylamines, 
other substances and phencyclidine-type substances22.  
The European Monitoring Centre for Drugs and Drug Abuse (EMCDDA) expands on this and classifies 
NPS according to 13 types, some of which overlap with the UNODC classification system. These groups 
are:  Aminoindanes, Arylalkylamines, Arylcyclohexylamines, Benzodiazepines, Cannabinoids, 
Cathinones, Indolalkylamines (i.e. tryptamines), Opioids, Others, Phenethylamines, Piperazine 
derivatives, Piperidines & Pyrrolidines and Plants & Extracts23,24. Similar to the classification system 
employed by the UNODC, the groups used by the EMCDDA are not systematic groups and can relate 
to the psychoactive effect of a compound e.g. cannabinoids, the chemical structure of the compounds 
e.g. cathinones or the source from which the substances have been extracted (e.g. plant material). 
Differences in classification and nomenclature of NPS add to the complexity of identifying and 
ameliorating the risks associated with this already diverse group of compounds22. 
Over the last 8 years, 560 previously unseen NPS have been identified in Europe25 (Figure 1.1), these 
include compounds from the EMCDDA classes of Piperazines, Benzodiazepines Arylamines, 
Tryptamines, Opioids, Phenethylamines, Others, Synthetic cathinones and Synthetic cannabinoids26 
(SC).  
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Figure 1.1: Graph showing the increasing number and type of NPS26 being reported by the EMCDDA 
over a 12 year period (left), and the total number per category (right). 
1.2 NPS Pharmacology 
A large number of NPS are believed to interact in the body with monoamine transporter (MAT) 
proteins. MATs structurally consist of 12 transmembrane helices and play an active role in the release 
and re-uptake inhibition of the monoamine neurotransmitters (MNt); dopamine (DA), norepinephrine 
(NE) and serotonin (SER). The biological roles DA, NE and SER play within the body are varied and 
include mood stabilisation, appetite and aggression regulation, sexual arousal, cognition, mental 
wellbeing and decision making27. Neurotransmitter modulation can be carried out by their 
counterpart transporter proteins i.e. for dopamine DAT, for norepinephrine NET and for serotonin the 
SERT transporter. As MNt all play extensive roles in cognitive and emotional processes, the desire to 
alter their levels within the brain to elicit some form of psychoactive response has paved the way for 
recreational drug abuse.  
The diverse biological roles of these compounds have led to the development of synthetic analogues 
and mimetics i.e. NPS, which are abused in order to elicit the desired recreational effects. As an 
example, dopamine mediates the sensation of pleasure in the brain. Unsurprisingly, given their 
structural similarity to dopamine, drugs such as cocaine, amphetamine, methamphetamine and 
methylphenidate mimic the effect of dopamine, by either promoting its release or preventing its 
reuptake, this means that these drugs are routinely abused.  
NE transmission is associated with the flight or fight response and arousal. Clinical studies have 
demonstrated that low levels of NE in the brain are linked to depression28,29. As higher levels are 
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associated with heightened levels of arousal and/or feelings of wellbeing, chemically inducing an 
increase of NE in the brain to simulate arousal and/or euphoria have been achieved via the use of 
narcotics such as cocaine and amphetamines. As these compounds are illegal and subject to controls, 
NPS were initially developed to achieve the same results whilst circumventing the legislation. For 
example, cathinone derivatives such as 3, 4-methylenedioxypyrovalerone (MDPV) or “bath salts” have 
previously been marketed as legal alternatives to 3, 4-methylenedioxymethamphetamine (MDMA), 
amphetamine and cocaine30. 
1.2.1 Monoamine Transporters 
All MATs consist of 12 transmembrane helices connected via both intra and extracellular loops located 
in monoaminergic neurons (Figure 1.2). These proteins are responsible for re-uptake of monoamine 
neurotransmitters using sodium and chloride ion gradient systems to transport the monoamines31. All 
3 MAT have been studied extensively with relation to depression and addiction. It has been well-
established that the transporters are responsible for the reuptake of monoamines which is indicated 
by the process being inhibited by antidepressants drugs. However, the mechanism of action for this 
inhibition of re-uptake is not fully understood32.  
Figure 1. 2: Figure 1.2: 2D representation of the MAT33 the 12 transmembrane helices are illustrated 
and the binding site circle in red. 
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There is a degree of promiscuity between the monoamines and MAT receptors as a consequence of 
their chemical structure similarities (Figure 1.3). This promiscuity of binding can also be seen with a 
variety of other molecules. For example, a number of antidepressants and appetite suppressant drugs 
(sertraline, fluoxetine, nisoxetine and Mazindol), have been found to have affinities with all three MAT 
34,35.  
 
Figure 1. 3: Chemical structures of dopamine, norepinephrine and serotonin 
The rapid emergence of NPS caused a number of NPS related poisonings and fatalities, and as these 
compounds had not previously been abused, the pharmacological effects of many of them were 
largely unknown36. The mechanism of action for NPS is not yet fully understood. It is known that the 
there is a high level of promiscuity between some NPS and the MAT isoforms. Given that each MAT is 
responsible for a large number of cognitive processes, and that such processes are altered with the 
use of NPS, compounds with the potential to interact with all three isoforms pose a potent potential 
threat to public health. 
1.2.2 Dopamine Active Transporter – DAT 
Dopamine concentrations in the brain are modulated by DAT. Ligands that interact with the protein 
will either inhibit reuptake of dopamine (cocaine) which will result in feelings of euphoria, or stimulate 
the release of synaptic dopamine (amphetamine) which often produces increased levels of confidence 
and energy37. Uncontrolled levels of dopamine in the brain are reported to be responsible for many 
neurological disorders such as depression, bipolar, Parkinson’s disease and attention deficit 
hyperactivity disorder (ADHD)38. The mechanism of action for ADHD is associated with low levels of 
dopamine, drugs such a methylphenidate are known to stimulate the release of dopamine into the 
extracellular space to help manage this condition39. 
1.2.3 Norepinephrine Active Transporter – NET 
NET recycles NE as well as DA and SER from the synapse to presynaptic neurons. There are fewer NET-
selective ligands that have been investigated in comparison to DAT and SERT34. It has been suggested 
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that NET requires a secondary extracellular site for norepinephrine transport40, as this feature is not 
common among all three MATs and NET has a high binding affinity to DA it could indicate that there 
is a similar transport mechanism between DAT and NET41.  
1.2.4 Serotonin Active Transporter – SERT  
SERT is responsible for maintaining normal concentrations of serotonin in the brain. When the 
reuptake mechanism doesn’t function properly unregulated concentration of this monoamine can 
result in depression, anxiety, stress, appetite deregulation and impaired cognition42. Disorders caused 
by the imbalance of serotonin have given rise to a group of drugs known as selective serotonin 
reuptake inhibitors (SSRI). Antidepressant drugs such as fluoxetine and citalopram work by blocking 
the reuptake of serotonin back into the serotonergic neurons, as it is believed that increasing the level 
of serotonin at the synaptic cleft is responsible for antidepressant activity43. 
Understanding structural differences between the MAT isoforms will provide insight into the 
neuropharmacological effects of psychostimulants. Identification of crucial protein-ligand interactions 
of NPS to a specific MAT isoform may highlight structural features that are required for selectivity 
between DAT, NAT and SERT. This thesis will set out to establish what the structural differences 
between the MAT isoforms are, and how those differences can be exploited to understand the 
selectivity of DAT, NET and SERT for a number of NPS 
1.3 Factors influencing the rise in popularity of NPS: Perceived legality of NPS 
Many drug users have revealed that it was their impression that the term “legal highs” implied that 
these compounds were safe44 and the idea of “consequence-free” drug use has been one of the driving 
forces behind the popularity of this group of compounds. Up until 2016 these substances were not 
considered controlled substances, despite being based on the chemical structures of known illicit 
compounds. The NPS differed from controlled, illegal compounds as a consequence of small 
modifications to the illicit compound’s chemical structure, which resulted in the circumvention of the 
law and afforded the new molecule “legal” status.  
An example of this was the compound mephedrone, which is structurally similar to cathinone a 
naturally occurring stimulant found in the khat plant (Catha edulis)19. Figure 1.4 shows the chemical 
similarity between cathinone and mephedrone. The minor modification to the chemical structure of 
mephedrone, in comparison to cathinone, circumvented the then existing legislation, making the 
provision and consumption of that compound legal as it was not prohibited by the 1971 Misuse of 
Drugs Act9.  
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Figure 1. 4: The chemical structures of Cathinone and mephedrone, identical sections of the 
compounds are highlighted in red. 
Mephedrone gained notoriety in 2008-9 and was a highly sought after party-drug  as its physiological 
effects were likened to those of cocaine and amphetamines45. Figure 1.5 highlights the high degree of 
chemical similarity between mephedrone, Methylone and methylenedioxypyrovalerone (MDPV), and 
as such it is clear to see why these compounds would elicit similar physiological responses.  
 
Figure 1. 5: The chemical structures of the most widely abused synthetic cathinones reported in 
201446, mephedrone (4-methyl methcathinone), Methylone (3,4-methylenedioxymethcathinone) and 
MDPV (3,4-methylenedioxyprovalerone) The part of the molecules that are identical between the 
structures are highlighted in red 
The popularity of mephedrone, and other NPS,  was enhanced by their potency, easy access and legal 
status45. NPS  have seen a rapid emergence onto the market47 and the continued growth in numbers 
of these compounds has caused detrimental effects that have been felt across the globe48. For 
example, a number of NPS (from classes such as synthetic cannabinoids, cathinones30 and 
phenethylamines) have been attributed as a causative agent  in a number of reported fatalities from 
around the world 4,5,6. The discovery of mephedrone gave rise to over 130 synthetic cathinones46, 
However the authorities were quick to recognize the potential danger of these compounds,  and 
mephedrone is now illegal in the UK. It became one of the first NPS to be banned under a modification 
to the 1971 Misuse of Drugs Act when on April 16 2010 it, and other substituted cathinones were 
made “Category B” substances49. 
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1.3.1 Enhanced Potency and reduced costs of NPS compared to traditional drugs of abuse. 
The demand for customer satisfaction, market competition and the battle to circumvent increasing 
amounts of legislation has fuelled a continual supply of new chemically diverse NPS50. Customer 
satisfaction, in this instance, is defined as ease of access to NPS, low cost and high potency. For 
example, the NPS N-Benzylpiperazin (BZP) is similar in terms of its chemical structure to amphetamine, 
but is marketed at lower costs (BZP approx. £2 per tablet in comparison to approx. £8-12 per gram of 
amphetamine according to the EMCDDA51 and until recently circumvented the UK legislation on 
controlled psychoactive substances, despite being  reported to have 10 times greater potency when 
compared to amphetamine52. Synthetic cannabinoids are 2-10053 times more potent than traditional 
cannabis, and users of the popular SC cocktail “Spice” require a smaller quantity of the drug to achieve 
a more intense high54 enhancing the appeal of NPS to drug users. 
1.3.2 The role of the internet in access to NPS 
The growing popularity of NPS was thought to be due to several factors including marketing strategies 
e.g. buy one get one free and colourful packaging55. The packaging associated with NPS has been 
cleverly designed, using names that are synonymous with known illicit drugs, such as “Gogaine” a 
previously legal alternative to cocaine which is known to contain ethylphenidate an analogue of the 
prescription drug methylphenidate (Ritalin)56. Online retailers of NPS would commonly employ a 
marketing strategy to name products after movies, social media sites and celebrities that were socially 
relevant at the time of distribution (e.g. Facebook, Charlie Sheen and Black Widow)57. 
The online distribution of NPS has facilitated the ease of access for both new and experienced drug 
abusers, which enhances the public health risks associated with these substances51. Online studies 
carried out stated that NPS users found the ease of acquisition, legality of sale57 and variety of NPS via 
the internet as one of the greatest benefits of NPS use58. Online NPS forums and social media have 
provided a community whereby NPS users can candidly discuss their opinions and experiences of 
NPS59, this coupled with home delivery via internet purchasing has facilitated the growth and interest 
in NPS60. 
The availability of NPS via online retail has reduced since the Psychoactive Substances Act61, however 
through the use of cryptocurrency and the “Dark Net” NPS are still available62. The Dark Net /Deep 
Net/ Cryptomarket is an intentionally hidden marketplace for a diverse range of illegal activity 
including the sale of illicit drugs. The digital footprint of users of the Dark Net is untraceable and 
obfuscated as it is  only accessible through specially configured browsers63, which mask IP addresses 
and other digital identifiers. The technology used to hide users’ activity also includes the anonymous 
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method of buying and selling items using a digital currency i.e. Bitcoin64. The use of this technology to 
almost eliminate the chance of detection means that despite the introduction of legislation to ban 
NPS, the popularity and use of these compounds continues almost unabated65, with a reported drop 
in use for those aged 16-59 of only 0.3%. Although this is a reduction, there is evidence that some of 
those using NPS prior to the introduction of the ban having returned to using traditional drugs of 
abuse66. 
1.3.3 Public Health Concerns regarding NPS 
The ease of availability, coupled with the diverse range of NPS being offered, has culminated in a global 
health concern. The number of fatalities and drug poisonings attributed to NPS abuse is on the 
rise23,67,68 The latest trend in NPS relates to the abuse of the fentanyl family of compounds69 (opioid 
analgesic) with nearly 6000 deaths being reported from 2012-201470 in the USA. Although the fentanyl 
epidemic appears to be localized to America, there have been reports of overdoses in the UK, where 
the reported number of fentanyl-related deaths stands at 58, and opioid overdoses have doubled (597 
to 1209) in a four year period (2012-16)71. Concerns are growing around Europe that the prevalence 
of fentanyl is increasing, and there is an urgent need for effective harm reduction strategies to be put 
in place72. However, fatalities and drug overdoses are not limited to opiates, and have also been linked 
to the following NPS categories; Cathinones73, Phenethylamine67, Synthetic Cannabinoids74 and 
Benzodiazepines45. 
Another key public health issue for NPS is the lack of information available about what type and 
amount of NPS are being abused, and the risks associated with the consumption of these new 
compounds. Many NPS have not previously been widely used and appear only briefly on the 
market58,59,62,75. Therefore, the clinical and pharmacological data associated with the risks for these 
compounds are not readily available for use by clinicians in the treatment of NPS overdoses6.  
1.3.4 Psychoactive Substances Act 
In an effort to combat the burgeoning public health crisis posed by the advent of so-called “legal 
highs”, the UK introduced a blanket ban of all NPS as of April 2016. The Psychoactive Substance Act 
201619 prohibits the sale, possession and possession with intent to sell of psychoactive compounds, 
including the previously legal NPS, but makes provision for research institutions to be exempt from 
the act. The ability to effectively enforce this act has raised concerns and the ability of the blanket ban 
on these compounds to address public health concerns raised by NPS has been subject to criticism. 
Firstly, it has been argued that as a result of the elimination of online retailers, the NPS market may 
merge with already established traditional drug trading market and will focus the sale of these drugs 
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towards the most vulnerable groups and individuals76. Consequently, although this may reduce NPS 
availability it is argued that it will not reduce overall drug-related harm. Secondly, many academics 
view the act to be legally, and scientifically, flawed and any possible prosecutions will be costly. In 
addition,  proving the psychoactive nature of seized contraband, given the number and chemical 
diversity of new compounds entering the market, may be problematic77. 
1.4 Synthetic Cannabinoids 
As the diversity and availability of NPS has increased, the number of seizures associated with common 
drugs of abuse such as cocaine and heroin has become less frequent25. However, the use of cannabis 
does not seem to have been impacted to the same extent. 
Cannabis is the most commonly abused recreational drug amongst young adults aged 12 and over, 
according to a national health survey conducted by the U.S Government78. Similarly, UK authorities 
have stated that 29% of people aged 16-59 have used the drug during their lifetime79. In 2013 over 
670,000 seizures of cannabis/cannabis products were reported25 with approximately 360 tonnes of 
cannabis (plants, resin and herbal cannabis) being seized in the UK in 20163. As such, it is not surprising 
that the synthetic cannabinoids have amassed so much popularity3, constitute the greatest number 
of new NPS entering the market over the last twelve years, and comprise a significant proportion of 
those NPS most recently seized (2.5 tonnes in 2015) . Synthetic Cannabinoid Receptor Agonists (SCRA) 
interact with the CB1 and CB2 cannabinoid receptors and elicit psychoactive effects designed to mimic 
the effect of THC, which is the primary psychoactive component of cannabis. 
A report that has recently been published by the EMCDDA stated that there are currently 179 synthetic 
cannabinoids being monitored by the EU early warning system80. The increase in the use of SC is 
thought to be due to the ease of access, affordability, a more potent cannabis like psychoactive effect 
and the difficulty associated with detection of the compounds in urine samples81. It is likely that there 
will continue to be a substantial increase in this category of NPS, as recent articles have shown that 
both cannabis and synthetic cannabinoids continue to be the most popularly abused recreational 
drugs3,82,83. Again, the relatively mainstream nature of cannabis, lulls users of the synthetic 
cannabinoids into a false sense of security regarding the harmful nature of these compounds. Figure 
1.6 highlights the increase in the number of SC poisonings in the US over a four-year period (2011-
2015), and compares this to the trend in reported poisonings from other NPS and traditional drugs of 
abuse, reiterating that abuse of SC is a genuine global public health risk. 
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Figure 1. 6: line graph showing the number of reports to US poison control centres for SC (red), “bath 
salts” (cathinones) (green), marijuana(purple), cocaine (blue) and heroin (orange)84. 
1.4.1 Rise of Spice in UK prisons 
In 2008 the EMCDDA first detected a new NPS called Spice85, commonly sold as an all-natural smokable 
herbal mixture that was being advertised as a marijuana substitute85. Spice is also sold under brand 
names such as K286 and Black Mamba53 often containing  one ,or a mixture of synthetic cannabinoids, 
mimicking the effect of Δ9-THC. The commonly detected constituents of Spice include but are not 
limited to JWH-018, JWH-073, HU-210 and CP-47,49786, see figure 1.7 for chemical structures. 
 
Figure 1. 7: Chemical structures of JWH-018, JWH-073, HU-210 and CP-47,497 
There has been a rise in the use of Spice in UK prisons and a move away from using traditional cannabis 
products. It is commonly thought that this trend is due to a number of factors including SC being 
substituted for, e.g. marijuana, to facilitate the avoidance of drug detection, as SC have a much less 
detectable smell than traditional cannabis products, and do not show up in traditional drug screening 
such as urine tests. The compounds also tend to have a higher potency than plant-based 
cannabinoids87. Staff members within English prisons have claimed that the use of SC is endemic, 
causing significant problems for staff and prisoners54 and that quantity of SC seized in English and 
Welsh prisons is now far greater than cannabis and heroin88. The far-reaching effect of SC is causing 
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chaos globally and although there have been attempts by government policies to eradicate NPS the 
use of SC is still prevalent. 
Trends in the abuse of NPS are continuously changing, and it is therefore imperative that research 
communities investigate the compounds that could be exploited as the next generation of NPS by 
investigating the mechanisms by which molecules interact with the endocannabinoid system. 
1.4.2 Endocannabinoid system (ES) 
The endocannabinoid system is highly complex, consisting of endocannabinoids (endogenous 
cannabinoids), enzymes associated with the synthesis and degradation of endocannabinoids and two 
cannabinoid receptors (CB1 and CB2)89. The ES is one of the most important biological systems for 
mammals for homeostatic control of mood regulation, response to pain90, energy expenditure, 
temperature regulation, regulation of the immune system and neural transmission91. The work 
presented in this thesis will focus solely on CB1 receptors, however it should be noted that in addition 
to CB1 and CB2 two other receptors are known to be implicated in the mediation of endocannabinoids 
these include the transient receptor potential (TRP) and the peroxisome proliferator activated 
receptors (PPAR’s)92. The cannabinoids receptor (CB1 and CB2) are G-Protein coupled receptors 
(GPCR), which primarily couple to G proteins of the Gi and Go classes92. Under specific conditions CB 
receptors have also been known to couple to both Gs and Gq G-proteins93. The activation of these 
receptors result in inhibition of adenylate cyclase activity causing a cascade of biochemical pathways 
being activated94. The CB2 receptor has an overall sequence identity of 44% (68% within the 
transmembrane reigions90) with CB1. Structural similarity between these two receptors means that 
cannabinoid-like molecules will likely bind to both CB1 and CB2 receptors, albeit with varying affinities, 
and as such many research groups90,91,95 have searched for CB1 or CB2 selective ligands for different 
pharmacological reasons.  
1.4.3 CB1 receptors 
CB1 receptors are mainly located in the central nervous system and are involved in the psychoactive 
effect of Δ9-tetrahydrocannabinol. They are  the most abundant GPCRs in the brain89. The regions of 
the brain that are associated with cognitive function, movement, and sensory functions are known to 
contain densely populated regions of CB1 receptors96, and hence molecules that bind to these 
receptors, such as the SC, can have marked effects on these functions. In 2016, the crystal structure 
for the CB1 receptor was elucidated97 (see Figure 1.8). The publication of this structure, in the context 
of the work presented in Chapter 5 and 6 has provided reassuring results when compared to results 
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obtained from computational models of the receptor, carried out before the experimental structure 
was available. 
 
Figure 1. 8: Ribbon diagram depicting the secondary structural elements of the X-ray crystal structure 
of the human CB1 receptor (PDB accession 5TGZ), (image produced in MOE98) 
1.4.4 CB2 receptors 
CB2 receptors are found in peripheral tissues and are implicated in the immune system96, they are 
highly expressed in primary immune cells (leukocytes, macrophages, neutrophils and both B and T 
lymphocytes94). Due to the location and expression of CB2 receptors, drug discovery projects based 
on this receptor focus mainly on inflammation and pain treatment90. However due to the structural 
similarity between the two cannabinoid receptors, attempts in finding novel drugs that can treat a 
wide range of diseases without the psychoactive side effects have proved challenging90. 
1.4.5 Endocannabinoids  
In 1964 the chemical structure of Δ9-THC (Figure 1.9) was elucidated and identified as the main 
psychoactive constituent of marijuana99. This gave rise to the research into the numerous different 
compounds present in a cannabis plant and subsequently led to the discovery of endocannabinoids. 
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Figure 1. 9: Chemical Structure of Δ9-THC (A) and the endogenous cannabinoids anandamide (B) and 
2-arachidonyl glycerol (C). 
Endogenous cannabinoid ligands (endocannabinoids) are a family of intercellular signalling 
molecules100. In 1992, the first endogenous cannabinoid anandamide (AEA, Figure 1.8) was discovered. 
This compound was shown to have equivalent binding activity as Δ9-THC at the CB1 receptor, which 
inspired research into a selective CB2 ligand101. The endogenous agonist 2-arachidonyl glycerol (2-AG, 
Figure 1.8) was sought out as CB2 specific. However, it was found that this particular molecule had 
similar binding affinities at both CB1 and CB2, again equivalent to THC102. Therefore, it is clear to see 
that scientists have previously carried out studies into identifying new chemical compounds with the 
potential to bind to the CB receptors, for therapeutic benefits. One tool that could be exploited by the 
research communities to facilitate their efforts is computer-aided drug-design.  
1.5 Computer Aided Drug Design (CADD) 
The last five decades has seen the implementation of CADD in the pharmaceutical industries going 
from strength to strength and it has played an important role in the discovery of novel, therapeutically 
active molecules. Two common approaches to CADD are structure-based drug design (SBDD) and 
ligand-based drug design (LBDD), Figure 1.10 summarises typical methodologies employed in CADD.  
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Figure 1. 10: A typical workflow employed in CADD pipeline adapted from Sliwoski et al103. 
A number of structure-based, and ligand-based CADD methodologies used in this thesis will be briefly 
introduced below. 
1.5.1 Molecular Docking 
Molecular docking uses computational representations of the protein and small molecule drug 
candidate structures to investigate how these small molecules may interact in the binding site of a 
target protein. The two key aspects of docking are the placement of a ligand within a binding site and 
a scoring or evaluation step in terms of the overall protein-ligand complex. 
This process requires accurate information regarding the size, shape and composition of the binding 
sites of the receptors being investigated, and as such relies heavily on the availability of high-quality 
experimental structures of the receptors of interest. These structures are most commonly elucidated 
via means of X-ray crystallography or solution nuclear magnetic resonance (NMR) imaging.  Molecular 
docking studies using high-quality crystal structures provide valuable information regarding protein 
ligand interactions and have been commonly employed in CADD. 
Molecular docking uses an algorithm to form a protein ligand (P-L) complex, and the reliability of a 
docking algorithm lies in its ability to predict valid P-L complexes. Firstly, the search algorithm needs 
to comprehensively evaluate the potential energy landscape to establish the lowest energy 
conformation between both protein and ligand104 and secondly the scoring function needs to 
accurately distinguish likely protein-ligand conformations from those that are unlikely 
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In this context, scoring functions are a set of mathematical models used to predict the binding affinity 
of a small molecule within an active site of a protein105 and commonly estimate the energies 
associated with protein-ligand binding. An ideal scoring function would be able to predict absolute 
binding affinities and be able to appropriately rank different P-L conformations in order of binding free 
energy values106. However, this is not currently achievable with the state-of-the-art algorithms 
available. This is because scoring functions are calculated using approximations of the protein-ligand 
binding process and, as such, there are some associated limitations106. A fundamental limitation of a 
scoring function is the accuracy and availability of experimental data. Many scoring functions are 
calibrated on known and experimentally derived protein-ligand complexes and common P-L 
interactions. As it is not possible to account for all known P-L conformations in the development of a 
scoring function, there are inherent limitations of the functions ability to accurately predict the 
binding of chemical structures that have not been used in its development and testing. However, the 
accuracy of a scoring functions to rank molecules in order of their known binding affinities has shown 
to be improved if the study utilises a consensus model66. This method used a combination of scoring 
functions107, in an effort to overcome inherent bias and/or limitations in a single model. This consensus 
scoring methodology has been employed in Chapter 3 of the thesis. 
1.5.1.1 Experimental Receptor Structures 
Numerous experimentally derived structures are available via publicly accessible repositories, such as 
the Protein Data Bank (PDB). At the time of writing , there are 143,840 structures available for 
download108 and as previously mentioned the most common techniques used to elucidate high-
resolution experimental structures are x-ray crystallography (89.5% of structures in the PDB) and 
solution NMR (8.5% of structures in the PDB), although no NMR-derived structures were investigated 
as part of these studies.  
One way in which the quality of an x-ray crystal structure can be assessed is by looking at its resolution 
(usually measured in Å). Crystal resolution is a measure of the level of detail that can be accurately 
ascertained from the diffraction pattern obtained from the crystallographic experiment. The lower 
the number, the more detail in the structure can be resolved.  A  high resolution structure (of 1 Å or 
less) is detailed enough to show the presence of each atom in the electron density map109, but such 
levels of precision are difficult to achieve, and it is possible to garner useful information about ligand-
protein interactions from lower resolution structures. A common threshold that has been used for the 
development of docking algorithms and scoring functions is structures with resolution values of 2.5Å 
or lower.  
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1.5.1.2 Homology models 
It is not trivial to obtain experimental receptor structures for all receptors of interest, especially those 
receptors that are membrane bound. Therefore, in the absence of available experimentally-derived 
structures, homology models of these proteins are often substituted for experimental structures in 
molecular docking studies. 
A homology model is constructed by taking the known amino acid sequence of a protein and aligning 
the sequence to an experimentally derived 3D structure of a similar protein. This is called the 
template, and the homology model is referred to as the target. Homology models that have been 
refined and carefully validated can have a wide range of applications in drug discovery110. 
Online homology model libraries (e.g. SWISS-MODEL111 and Protein Model Portal112) contain a number 
of freely accessible models that can be used in docking experiments, and these repositories were 
utilised during these studies. However, although homology models are useful tools in CADD they must 
be used with care as, with all models, they are interpreted and not derived directly from empirical 
evidence, and therefore may be subject to errors. For example,  an error in the sequence alignment 
used to generate a homology model, can result in changes to the putative binding site for a modelled 
protein, and give misleading information when attempting to understand how small molecules may 
bind to that protein113.  
Given that protein structure is crucial for its function, and therefore the basic sequence alignment 
must be correct in order to produce a valid homology model. It is important to identify any 
shortcoming in homology models prior to using them in experiments. Assessing model quality should 
be conducted using a variety of independent and complementary techniques that examine the overall 
quality of the protein fold from a number of perspectives. Examples of protein validation 
methodologies that were used as part of this thesis are Ramachandran Plots114, which assess the 
quality of the overall fold of a protein, Verify 3D115 which looks at the quality of the immediate 
environment an amino acid residue resides in, and Errat116 which examines non-bonded distances 
between pairs of atoms which gives an indication of the electronic quality of the protein (See Chapter 
2 for details on how each of these methodologies works). All these protein validation programmes are 
available via free-to-use online servers which can result in a cost-effective way to ensure the quality 
of homology models prior to embarking on docking studies. 
1.5.2 Quantitative structure-activity relationships (QSAR) 
In the absence of either experimentally derived structures, or high-quality homology models, the 
research scientist can turn to ligand-based drug design (LBDD). For example, the use of Quantitative 
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Structure-Activity Relationship (QSAR) models  to rationalize the differences between experimentally 
measured biological activities for a series of analogues as a function of their differing physicochemical 
properties was first conceptualized by Corwin Hansch in 1962 and since then has been widely used in 
industry and academia117.  QSAR has been used in this thesis to try and understand what drives 
selectivity between the MAT isoforms, DAT, NET and SERT (Chapter 4).  
QSAR is a statistical method  of correlating the biological response (quantitative) of a series of 
analogue molecules to their physicochemical properties via a  set of molecular descriptors118. 
Typically, QSAR studies start with a database of biologically active compounds with experimentally 
measure biological activities. These compounds are divided into a training set (typically 80% of 
compounds) which are used to build the model, and a test set (20% of total compounds) which are 
used to assess the generalizability of the model generated by the training set. 
 A series of molecular descriptors that capture the physicochemical properties of the compounds in 
the dataset such as their steric, electronic and lipophilic characteristics, are calculated, and then using 
techniques such as multiple linear regression (MLR)119 the descriptors that are responsible for 
explaining the variation in biological activity are identified.  
Hence, a simple equation is generated based-on the relationship between the descriptors identified 
as important. This equation is then used to predict the activity of the compounds in the test set. The 
QSAR model is assessed according to the  correlation between predicted  and experimentally derived 
activity values120 for the test and training sets, where a correlation coefficient of 1 indicates a perfect 
fit between experimental and predicted results. 
1.5.3 Pharmacophores 
According to the IUPAC definition a pharmacophore can be defined as “an ensemble of steric and 
electronic features that is necessary to ensure the optimal supramolecular interaction with a specific 
biological target and to trigger (or block) its biological response”121. Pharmacophore modelling can 
either be structure-based whereby the target (active site of a protein) is analysed so that 
complementary chemical features (between ligand and complex) can be identified or ligand-based 
which identifies common chemical features from a set of 3D ligands that are deemed important for 
biological activity121. Pharmacophores have proven to be exceptionally useful for efficient virtual 
screening of large chemical databases. Chapter 5 focuses on the development of pharmacophore 
models which were used to search the ZINC database which contains over 17 million chemical 
structures122. The aim of this study was to identify a library of chemically dissimilar, wholly novel 
compounds that displayed the potential to interact with the CB1 receptor. 
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1.5.4 Virtual screening and High Throughput Screening 
Virtual screening is widely used in drug discovery, whereby large, virtual libraries of compounds are 
systematically and quickly assessed against a predetermined criterion, such as the degree of fit to a 
pharmacophore as described above without the need to purchase or synthesize the compounds123.The 
aim of virtual screening is in identifying novel compounds that are likely to bind to a specific drug 
target. Virtual screening is an alternative to High-throughput screening (HTS), especially in projects 
where resources are limited. HTS is a technique that experimentally assesses the biological activity of 
up-to millions of compounds by conducting automated individual biochemical assays124. This method 
is highly sophisticated and well established125, and commonly employed after molecular docking 
,pharmacophore and virtual screening development studies. High-throughput can often be expensive 
and time consuming126 so the concept of “cherry picking”127 the most ideal compounds is a 
sophisticated way of producing a library of the most suitable candidates possible that can be taken 
forward for biological evaluation.  
The research presented in this thesis has used virtual screening in conjunction with pharmacophores 
to search a diverse library of commercially available compounds, with the additional step of filtering 
virtual hits resulting in a library of optimized compounds (Chapter 5).  
Having identified those compounds which are predicted to bind to the receptor of choice, it is 
important to conduct experimental biological evaluations as the final measure of the predictive ability 
of these models. 
1.6 Biological Evaluation 
When a novel compound with a predicted potential to bind is identified the next stage in the drug 
discovery pipeline is the evaluation of biological activity, this is conducted by the use of biological 
assay. Commonly employed assays  include functional assays which assess the inhibition of a 
substrate’s uptake128and is an example of functional assay. Radioligand binding assays (example of a 
binding assay which use a radioactively labelled molecules which can be used to measure the rate of 
binding and binding affinity129.  
There is a lack of pharmacological data associated with NPS in general130,131, and developing 
pharmacological profiles on NPS can be useful in generating vital information with the public health 
risks this class of drugs pose36. There are a wide range of receptors involved in forming interactions 
with NPS, these include, monoamine transporters, Cannabinoid 1 and 2 receptors, GABA and opioid 
receptors128.  As more pharmacological data becomes available, the mechanisms of action associated 
with NPS are being better understood and the toxicology132 and epidemiology of addiction133 can be 
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treated more effectively.  Functional assays were used here to investigate the binding of virtual 
screening hits to the CB1 receptor (Chapter 6). Commonly employed pharmacological tests that are 
routinely used to evaluate biological evaluation of cannabinoids include in vitro competitive binding 
affinity studies. This method uses radiolabelled cannabinoid molecules which are used to identify 
binding affinity (Ki) at the CB receptors53. Other methods include the use of behavioural studies 
whereby Tetrad tests are used to investigate the effect cannabinoids have on locomotive suppression, 
hypothermia, analgesia and catalepsy81. Organ bath studies are also used to identify the effect of 
cannabinoids on isolated segments on smooth muscle tissue134. 
1.6.1 Aims  
There has been a massive expansion in the number and type of novel NPS that have been report in 
the past decade, although much research has gone into investigating already established NPS there is 
a gap in the market for methodologies in identifying novel NPS that have yet to be exploited.  
A number of NPS are known to mimic the effect of known illicit drugs (cocaine and amphetamines) 
and the mechanism of action of these drugs has been well documented in the literature, therefore in 
Silico techniques can be applied to gain a better understanding of how NPS are acting within known 
receptors. 
Therefore, the broad aims of the research laid out in this thesis is to:  
• Establish if in Silico methodologies can be used to identify what physicochemical properties 
are required to convey selectivity for one receptor over another for NPS. 
As stated by the literature there is a large degree of promiscuity of NPS with MAT, identifying 
structural differences between NPS may provide insight into why. The use of molecular modelling and 
homology models will provide insight into how reliable this methodology is terms of replicating the 
available biological data. The data obtained from docking studies will hopefully explain what gives rise 
to selectivity and differences in the affinity of small molecules between DAT, NET and SERT. 
• Build predictive models that can be applied to a range of molecules that could potentially elicit 
psychoactivity. 
The development of predictive models to determine a molecules ability to interact with one or more 
of the MAT is a methodology that can be applied to large virtual libraries. The identification of 
potential psychoactive chemicals may prove useful in determining which direction the NPS market 
could take. The number of NPS has increased rapidly over the last decade, the diversity of chemicals 
that have already been exploited as NPS is staggering. Identification of potentially psychoactive novel 
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scaffolds or novel chemical structures, as a pre-emptive measure could be used to advise early 
warning systems already in place. The information obtained from newly identified chemicals could be 
used to guide research into the mechanism of action of NPS or molecules that elicit psychoactivity. 
• Identify at least one novel chemical scaffold that will interact with the CB1 receptor.  
Synthetic cannabinoids are currently the most abundant NPS that have been reported, the aim of 
identifying novel SC-like molecules will provide information on chemical structures that have not been 
exploited as cannabinoids. The biological evaluation conducted on the novel virtual hits identified can 
provide information on the mechanism of action of SC. The molecules evaluated will be designed to 
be as structurally distinct from known SC, this will establish new chemical scaffolds that interact with 
the CB1 receptor. Any molecules found to demonstrate an affinity for the CB1 receptor can be further 
investigated to highlight pharmacological properties that are associated with SC. In addition, 
identifying previously unseen potential psychoactive chemical entities can be used to provide law 
enforcement and global organizations such as the EMCDDA an early warning system of potential drug 
structures that could be used to elicit psychoactivity. 
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Chapter 2 
 In Silico Methodologies 
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This chapter will focus on providing an overview of the different computational techniques employed 
throughout this thesis. A summary of the methodologies used is presented in Figure 2.1 
 
Figure 2. 1: An overview of the methodologies employed in the in Silico studies presented in this thesis. 
2.1 Homology Models: Evaluation 
The use of homology models is common practice in the absence of an available experimentally 
determined structure. Quality assessment of these models is a very important step in ensuring the 
reliability of model before they are used to test hypotheses. A number of complimentary, yet 
independent techniques were used in this thesis to assess the quality of homology models. 
2.1.1 Ramachandran Plot (RAMPAGE, Chapter 3) 
Evaluation of the stereochemical quality of the polypeptide backbone was carried out using a 
Ramachandran plot obtained from Rampage135 (see Figure 2.2). Residues are placed into allowed and 
disallowed regions on the Ramachandran plot, based on the dihedral angles within the peptide bonds 
of the simulated structure. The torsion angles around the bonds between N-Cα denoted by φ (Phi) 
and the bond between Cα-C’ denoted by ψ (Psi) are responsible for the flexibility required for the 
protein to adopt its characteristic secondary structure. The third torsion angle is denoted by ω 
(Omega) and accounts for the Cβ-N bond which is fixed to 180 degrees due to the partial double bond 
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character of the peptide bond. This plot allows for easy visual representation of the distribution of 
amino acid residues in a protein structure according to where you would expect to find the residue 
within a secondary structure (i.e. α helices or β-sheets). Atoms are treated as simple impenetrable 
spheres with dimensions corresponding to their van der Waals radii. Therefore, phi and psi angles 
which cause spheres to collide correspond to sterically disallowed conformations of the polypeptide 
backbone. Protein models that have 90% or more residues in the allowed region are largely accepted 
as being reliable models136. 
 
Figure 2. 2: A Ramachandran plot for the homology model for DAT (accession code Q01959112), 
Ramachandran analysis plots the torsional angles (, x-axis and, y-axis) of all the residues. The plot 
is split into areas according to secondary structure (regions labelled B/b for β-sheets, A/a for α-helices 
and L/l for left handed helices). The conformations of residues are categorised into four groups: most 
favoured (which are found in the red sections), allowed residues (plotted in the yellow sections of the 
graph) additionally allowed conformations (cream) and disallowed conformations found in the white 
sections of the graph. 
2.1.2 Verify3D (Chapter 3) 
Verify3D137 establishes the compatibility of a protein’s amino acid sequence with a known 3D structure 
by assigning the amino acid to a common protein structural classes i.e. α- helices, β-sheets, based on 
its environment and the surrounding residues. Verify3D works by reducing the 3D environment of 
34 
 
each individual residue to one dimension and assigning an average score derived from a 21-residue 
sliding window based on solvent accessibility, the polarizability of the residues and the preference for 
protein secondary structure. Amino acid residue type (polar, non-polar, hydrophobic etc.) are giving a 
score with respect to solvent accessibility e.g. polar residues will be assigned a large positive score if 
they are solvent exposed. However, if this same type of residue is found to be buried in a deep 
hydrophobic pocket the residue will be assigned a large negative score. It is the sum of the scores for 
each of the residues that describes the overall quality of the protein. Regions of poor model quality 
will have a score less than 0.2. Using data for the comparison of 1D and 3D structures Verify 3D is able 
to give information about the quality of the overall model at the residue level. Figure 2.3 is an example 
of a Verify3D plot for the NET homology model (accession code P23975) the open source software 
Structure Analysis and Verification Server (SAVES) metaserver ( http://nihserver.mbi.ucla.edu/SAVS/ 
) was used in order to produce Verify3D138 plots. 
 
Figure 2. 3: Verify 3D plot for the Net homology model (accession code P23975112). The blue dots 
denote the average score for each amino acid residue, a value of 0.2 or greater indicates the residue 
is in a favourable amino acid environment. 
2.1.3 Errat (Chapter 3) 
ERRAT139 is a program that uses error values in the distances between pairs of non-bonded atoms as 
an indication of model quality. It assesses the distribution of different types of atoms with respect to 
one another in the protein models, after having categorised them as either C, O or N and thus defining 
six possible pairwise interactions (CC, CO, CN, OO, ON, NN). Statistical analysis of the non-bonded 
atom-atom interactions is plotted on a graph that highlights residues that can be rejected (i.e. those 
that have not adopted an expected conformation) at the 95% and the 99% confidence levels. ERRAT 
is the most sensitive method of protein model validation in comparison to the Ramachandran plot, 
which is a more coarse grained approach examining overall fold and Verify3D138, which focuses on 
assessing the quality of amino acid environment. In combination all three provide a powerful way of 
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identifying likely areas of protein misfolding in homology models. Figure 2.4 is the Errat plot output 
for the SERT homology model (accession code P31652112). 
 
Figure 2. 4: Errat plot obtained for the SERT homology model (accession code P31652112). ERRAT plots 
assess the distribution of different atom types. Values are plotted as a function of the position of a 
sliding 9-residue window. The 95% and 99% error lines on the graph show at what confidence level 
the residues can be rejected for not having the correct distribution between atom types. 
2.2 Scoring Functions (Chapter 3) 
Scoring functions are used to evaluate protein-ligand interactions and are typically classified into three 
categories; force-field-based, empirical and knowledge-based140.  
Force-field based scoring functions are based on physical atomic interactions141 and attempt to 
calculate the atomic interaction energies of a protein-ligand interaction. A force-field scoring function 
is calculated using both experimental data and ab initio quantum mechanical calculations106. 
Empirical scoring functions use weighted energy terms to estimate the binding affinity of a protein 
ligand complex, the energy terms considered for this scoring function are VDW energy, electrostatics, 
hydrogen bonds, desolvation, entropy and hydrophobicity106. 
Conversely, knowledge based scorning functions are derived from crystal structures and are calculated 
by taking the sum of pairwise statistical potentials between protein and ligand140. 
The utilisation and success of each category of scoring function in docking studies and structure based 
drug design is well established105. What follows is a closer examination of the scoring functions that 
were used as part of the studies that comprise this thesis.  
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2.2.1 London dG (Chapter 3 and Chapter 5) 
The London dG98 is an empirical scoring function, which estimates the free energy of binding of the 
ligand from a given pose. The functional form of the scoring function is a sum of terms as described in 
Equation 2.1 and Table 2.1: 
 
Equation 2.1: One of the two equations used in the calculation of London ΔG scoring98. 
Table 2. 1: The composite terms used to calculate the overall London dG scoring function values. 
Subscript Description 
c the average change of rotational and translational entropy 
Eflex energy loss of ligand flexibility 
ƒHB measure of geometric imperfections of hydrogen bonds 
cHB energy of an ideal hydrogen bond 
ƒM measure of geometric imperfection of metal ligations 
cM energy of an ideal metal ligation 
D I the desolvation energy of an atom 
 
The difference in desolvation energies, ΔDi (Equation 2.2) is calculated according to the following 
formula, the terms of which are explained in Table 2.2. 
ΔDI=ciR3i{∫∫∫|u|-6du-∫∫∫|u|-6du} 
                      uɇ AuB           uɇB 
Equation 2.2: the equation used to calculate the difference in desolvation energies for the London dG 
scoring function98. 
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Table 2. 2: The terms used to calculate the difference in desolvation energies which is used to calculate 
the London dG scoring function. 
Subscript Description 
A, B protein and or ligand volumes with I belonging to volume B 
Ri is the solvation radius of the atom I (taken as the OPLS-AA VDW sigma 
parameter plus 0.5 Å) 
ci is the desolvation coefficient of atom i 
u is an energy term relating to the desolvation energy of the atom 
2.2.2 GBVI/WSA ΔG (Chapter 3 and Chapter 5) 
The GBVI/WSA ΔG98  (Equation 2.3) is a force-field-based scoring function, which estimates the free 
energy of binding of the ligand from a given pose. It has been trained using the MMFF94x and 
AMBER99 force-field on the 99 protein-ligand complexes of the SIE training set142. The functional form 
is a sum of terms: 
ΔG= c+ α[⅔(ΔEcoul + ΔEvdW + β ΔSAweighted 
Equation 2.3: The equation used in the calculation of GBVI/WSA ΔG scoring function, the terms for 
this equation are defined in Table 2.3. 
Table 2. 3: the terms used to calculate the GBVI/WSA  ΔG scoring function (see equation 2.3)98 
Subscript Description 
c Represents the average gain/loss of rotational and translational entropy. 
α, β Are constants which were determined during training (along with c and, are force-field 
dependent). If not using an AMBER force-field, the parameters will be set by default to 
the MMFF trained parameters. 
ECoul Is the coulombic electrostatic term which is calculated using currently loaded charges, 
using a constant dielectric of εi=1. 
Esol Is the solvation electrostatic term which is calculated using the GB/VI solvation model.  
EvdW Is the van der Waals contribution to binding. 
SAweighted Is the surface area, weighted by exposure. This weighting scheme penalizes exposed 
surface area. 
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2.2.3 ASE (Alpha Spheres and Excluded Volume, Chapter 3) 
 
The Alpha Spheres and Excluded Volume (ASE) scoring function143 Is a knowledge-based, shape-based 
scoring function where the score is “proportional to the sum of the Gaussians R1R2e-d2/2 over all ligand 
atom–receptor atom pairs and ligand atom–alpha sphere pairs. R1 and R2 are the radii of the atoms in 
Å, or are 1.85 Å for alpha spheres, d is the distance between the pair in Å. The proportionality constant 
has a default value of 0.035 kcal/mol98”. 
2.2.4 Affinity ΔG98 (Chapter 3) 
This knowledge-based scoring function estimates the enthalpic contribution to the free energy of 
binding using a linear function (Equation 2.4): 
 
Equation 2.4: The equation used in the calculation of Affinity ΔG scoring98. 
Where the ƒ terms fractionally count atomic contacts of specific types and the Ϲ's are coefficients that 
weight the term contributions to the affinity estimate (Table 2.4).  
Table 2. 4: A table of the terms used to calculate the Affinity ΔG scoring function (see equation 2.4). 
Subscript Description 
hb Interactions between hydrogen bond donor-acceptor pairs. An optimistic view 
is taken; for example, two hydroxyl groups are assumed to interact in the most 
favourable way. 
ion Ionic interactions. A Coulomb-like term is used to evaluate the interactions 
between charged groups. This can contribute to or detract from binding affinity. 
mlig Metal ligation. Interactions between nitrogen/Sulphur and transition metals are 
assumed to be metal ligation interactions. 
hh Hydrophobic interactions, for example, between alkane carbons. These 
interactions are generally favourable. 
hp Interactions between hydrophobic and polar atoms. These interactions are 
generally unfavourable. 
aa An interaction between any two atoms. This interaction is weak and generally 
favourable. 
ΔG = Ϲhb ƒhb + Ϲion ƒion + Ϲmlig ƒmlig + Ϲhh ƒhh + Ϲhp ƒhp+ Ϲaa ƒaa 
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2.2.5 BALLaxy144 (Chapter 3) 
Biochemical Algorithms Library (BALL) is an open-access software that provides a service for rescoring 
docking conformation generated using other software, using three different scoring functions. The 
first scoring function used is MM145, an AMBER-based (Assisted Model Building with Energy 
Refinement) scoring function which is of the molecular mechanics type (Equation 2.5).  
 
Ebinding = Ecomplex – (Ereceptor + Eligand)  
 
Equation 2.5: the equation used to calculate values for the BALLaxy MM scoring function. Ebinding is the 
calculated binding energy of a protein-ligand interaction devised from the energy terms associated 
with the protein-ligand complex (Ecomplex), the energy term associated with the protein/receptor 
(Ereceptor) and the energy term associated with the ligand (Eligand). 
 
The MM score estimates the binding energy of a protein-ligand interaction by optimising the atom-
based relationships via the amber force-field. Energy values are calculated for the following 
1. Atom types 
2. Bond and angle parameters 
3. Dihedral parameters 
4. van der Waal parameters 
5. Electrostatic energies 
 
The second scoring function in BALLaxy is PB which is a Poisson-Boltzmann scoring function, i.e. 
another molecular mechanics-based model. This scoring function estimates the free energy binding 
ΔG using the following equation (Equation 2.6). For each protein-ligand complex, the ligand is 
subjected to up to 1000 steps of Cartesian coordinates minimization within the fixed protein structure 
using the Szybki minimizer and the MMFF94s force field146. 
 
ΔGbind= Δ𝐻𝑒𝑙𝑒𝑐
𝑠𝑜𝑙  + Δ𝐻𝑣𝑑𝑊 - TΔ𝑆𝐻𝑃ℎ𝑜𝑏 - TΔ𝑆𝑅𝑜𝑡𝐵 
 
Equation 2.6 where by Δ𝐻𝑒𝑙𝑒𝑐
𝑠𝑜𝑙  represents the Poisson-Boltzmann electrostatics calculated by ZAP (a 
multilevel, multigrid solver)147 (OpenEye, Santa Fe, NM, 2006) with Bond radii. Δ𝐻𝑣𝑑𝑊 is the van der 
Waals energy146. 
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TΔ𝑆𝐻𝑃ℎ𝑜𝑏 is calculated using Equation 2.7 and the temperature-dependent change in entropy due to 
the rotatable bonds in the complex becoming fixed upon complexation of the protein and ligand 
TΔ𝑆𝑅𝑜𝑡𝐵 is calculated using Equation 2.8
146 
 
TΔ𝑆𝐻𝑃ℎ𝑜𝑏 = (surface area buried upon complex formation) x 0.006 kcal/mol Å
2 
 
Equation 2.7 - where the surface area term is computed with ZAP (OpenEye, Santa Fe, NM, 2006). The 
coefficient 0.006 kcal/mol Å2 accounts for the partitioning of solute molecules between aqueous and 
organic phases146. 
 
TΔ𝑆𝑅𝑜𝑡𝐵 = number of rotatable bonds x 0.7 kcal/mol 
 
Equation 2.8 a rotatable bond penalty term, from the BALLaxy PB scoring function included to account 
for the loss of binding energy due to the freezing of the internal degrees of freedom of the ligand, 
upon binding to the protein to form a protein-ligand complex146. 
 
The third scoring function used is PLP which uses pair/piece wise linear potentials and is 
empirical148,144,149. This scoring function is a pairwise sum over all ligand and protein heavy atoms that 
estimates the binding potential of a molecule. The parameters used in the PLP scoring function are 
based on four different ligand atom types (donor, acceptor, both and nonpolar), which interact via 
steric and hydrogen bond potentials with the protein atom type150. Each pair of atoms has only one 
type of interaction, primary and secondary amines are classed as donors, oxygen and nitrogen atoms 
(without hydrogens) are classed as acceptors, OH groups, and water molecules are classed as both 
and carbon and nonpolar150. Figure 2.5 illustrates the how the pairwise linear potentials are derived. 
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Figure 2. 5: The piecewise linear pairwise potential functions used for the protein-ligand interaction 
energy and a table to show the parameters of the atomic pairwise protein-ligand potentials. Values 
for A, B, C and D are distances (in Å) for two different interaction types (steric and hydrogen bond). 
The values for E and F are arbitrary energy units (for both steric and hydrogen bond interactions) and 
the letter r denotes interatomic distance. The diagram was adapted from Gehlhaal et al150 
2.2.6 GoldScore & ChemScore (Chapter 3) 
The GoldScore fitness function is the original scoring function provided with GOLD151, and is the one 
selected by default for GOLD versions 5.0 and earlier. It has been optimised for the prediction of ligand 
binding positions and takes into account factors such as H-bonding energy, van der Waals energy, 
metal interaction and ligand torsion strain. 
The GoldScore function is made up of four components152:  
1. protein-ligand hydrogen-bond energy  
2. protein-ligand van der Waals energy  
3. ligand internal van der Waals energy  
4. ligand torsional strain energy  
 
The GoldScore fitness score is derived from the following equation 
GOLD Fitness = Shb_ext + Svdw_ext + Shb_int + Svdw_int 
Equation 2.9: the equation used to calculate a GOLD fitness score where Shb_ext is the protein-ligand 
hydrogen bond score, Svdw_ext is the protein-ligand van der Waals score, Shb_int is the contribution 
to the fitness due to the intramolecular hydrogen bonds in the ligand and Svdw_int is the contribution 
due to the intramolecular strain in the ligand153. 
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The ChemScore fitness function, which is an alternative scoring function implemented in the GOLD 
software, estimates a term, ΔG that represents the total free energy change that occurs on ligand 
binding, and was trained by regression against binding affinity data for 82 complexes154. The 
ChemScore fitness function also incorporates a protein-ligand atom clash term and an internal energy 
term. ChemScore takes account of hydrophobic-hydrophobic contact area, hydrogen bonding, ligand 
flexibility and metal interaction. Although partly derived using binding affinity data, ChemScore values 
should not be used explicitly as values for binding energy or binding affinity as the data set the scoring 
function is based on is limited to 82 complexes and does not account for all possible protein-ligand 
interactions. 
 
The ChemScore function was defined as 
∆GGOLD-ChemScore = ∆G0 + ∆Ghbond + ∆Gmetal + ∆Glipo+ ∆Grot 
Equation 2.10: Where by ∆G0 is the free energy change of reaction. ∆Ghbond is the hydrogen bond 
contribution to overall binding, ∆Gmetal and ∆Glipo are metal-ligand and lipophilic binding contributions 
(respectively) and ∆Grot is a term that penalises flexibility.  
2.3 Docking (Chapter 3 and Chapter 5) 
2.3.1 Identification of putative binding sites in protein models in MOE (Chapter 3 and 
Chapter 5) 
MOE's Site Finder uses the relative positions and accessibility of the receptor atoms to identify 
potential binding sites (areas of accessible tightly packed atomic regions with minimal solvent 
exposure). This is done by identifying hydrophilic or hydrophobic alpha spheres using two different 
probe radii: probe radius 1 is the radius of a hypothetical hydrophilic hydrogen bonding atom and 
probe radius 2 is the radius of a hypothetical hydrophobic atom. Individual alpha spheres are collected 
into separate sites by a double-linkage clustering algorithm.  
2.3.2 Docking using MOE (Chapter 3 and Chapter 5) 
Figure 2.6 is an overview of the docking methodology, for MOE, employed in both Chapter 3 and 
Chapter 5. 
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Figure 2. 6: an overview of the stages of a docking study adapted from MOE98 
The MOE docking methodology employed in Chapter 3 and chapter 5 uses the following steps; 
Placement - the placement stage of a docking study is conducted using the triangle matcher 
application, poses are generated by aligning ligand triplets of atoms on triplets of alpha spheres. Figure 
2.7 illustrates the triangle placement method. Each of the generated poses is then assigned a score.  
 
Figure 2. 7: Illustration of how the triangle placement method works. A triangle is formed based on a 
triplet of atoms within a ligand (represented by the blue circles), the triangle is then placed into the 
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binding site (illustrated by the yellow boundary), when the triangle matches with a triplet of atoms 
formed by the residues in the binding site (orange circles) a docked posed is established. 
Initial Scoring - poses generated by the placement methodology can be rescored using one of the 
available methods. Typically, scoring functions emphasize favourable hydrophobic, ionic and 
hydrogen bond contacts. 
Refinement - poses resulting from the placement stage can be refined using either the explicit 
molecular mechanics force-field method (eleven force-field parameters are available in MOE) or a 
grid-based energetics method. 
Final Scoring - the final poses can be rescored using one of scoring schemes available in MOE. 
2.3.3 Docking using Genetic Optimisation for Ligand Docking (GOLD) (Chapter 3) 
GOLD uses a genetic algorithm (GA) to generate docked protein-ligand conformations. This type of 
algorithm uses the principles of biological evolution to discover optimal solutions to problems 
associated with molecular modelling and docking151.  
Identification of docked poses is carried out in five main steps: 
The process begins with the development of a population, in the case of docking each docked pose is 
considered an individual and this particular pose (individual) is characterised by a set of variables 
termed “genes” which are used to form a “chromosome”.  
A fitness function is then assigned to each individual, the function equates to how well the individual 
competes with others in the population. 
Based on the fitness function, the best individuals (docked pose) are selected to pass on their genes 
to the next generation of docked poses. 
The fitness function is evaluated in six stages 
1. Conformation of both ligand and binding site is generated 
2. Least square fitting procedure 
3. A hydrogen-bonding energy term is evaluated for the complex. This is the sum of individual bond 
energies for all ligand and protein donor hydrogen and acceptor atoms across the entire complex. 
4. A pairwise steric interaction energy for all of the protein ligand atoms is calculated using a 
softened 4-8 Lennard Jones Potential (Equation 2.10) 
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Eij = A/rij8 - B/rij4 
Equation 2.11: 4-8 Lennard Jones Potential, where Eij= the interaction energy between the atom pair, 
and r is the distance between the atoms. Adjustments are made for atoms involved in a hydrogen 
bond (Eij = 0, r is scaled by a factor of 1.43), and all pairwise interactions across the complex are 
summed to give an overall ‘complex energy’. 
5. A value for the internal energy of the ligand in the ligand receptor complex is then calculated using 
a 6-12 Lennard-Jones potential (Equation 2.11) and the Tripos force-field torsional (Equation 2.12). 
Eij = C/rij12- D/rij6 
Equation 2.12: 6-12 Lenard Jones potential equation, where Eij is the interaction energy between the 
atom pair and r is the distance between atoms. C and D represent constants dependent upon the 
identities of the atoms involved. 
Eijki = 1/2 Vijki [1 + (nijki/|nijki|).cos(nijki.ω ijki)] 
Equation 2.13: Tripos force-field torsional, where Eijki is the torsional energy associated with four 
consecutively bonded atoms, ω is the torsional angle, n is the periodicity and V is the barrier to 
rotation. 
6. The three calculated energy terms (Equations 2.10, 2.11 and 2.12) are added together to give an 
overall fitness 
A pair of parent individuals are mated and a crossover point is chosen at random and “offspring” poses 
are created from the parent poses. 
Mutation is introduced to certain new offspring as a way of maintaining diversity within the 
population. Finally, when the genetic algorithm can no longer produce offspring that are significantly 
different to the established population a termination step is introduced, and the docked pose is 
returned 
2.3.4 Spearman’s Rank (Chapter 3) 
Spearman’s rank (ρ) is a statistical method employed to assess correlation between two ranked 
datasets (see Equation 2.13155) and is used in this thesis to compare the rankings of conformations 
generated for a dataset of small molecules in different docking experiments, to their relatively ranked, 
experimentally determined biological activities against a given receptor. 
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𝜌 = 1 − 6∑𝑑2/(𝑛3 − 𝑛) 
Equation 2.14: equation used to calculate Spearman rank correlation coefficients (ρ), where d is the 
difference between the ranked values across the 2 ranked datasets and n represents the number of 
individual members of the dataset.  
2.4 QSAR (Chapter 4) 
2.4.1 Identification of Diverse subsets 
In order to identify diverse subsets to exploit in the building and testing of QSAR models, the diverse 
subset algorithm in MOE was used. The MOE Diverse Subset application assigns a diversity ranking 
order to all entries in a database. The N reference set entries (molecules included in the database) are 
all given a rank of 1. The diverse subset entries are given ranks 2 (highest rank) to (M+1), where M is 
the number of diverse entries to be ranked.  
Hence, the diverse subset is selected by choosing entries that are the farthest from both the N 
reference entries and the currently-ranked entries. 
The farthest entries were determined using FP:MACCS representations of the molecules (see Section 
2.6.3) as a discriminant. Distance was computed using the FP:MACCS calculated from both the N 
reference entries and the entries that had yet to be ranked. The diverse subsets were then identified 
using the following steps; 
1. The minimum of its distances between the ranked entries and the reference set are computed 
2. The entry with the largest such minimum distance is deemed to be the farthest from the 
reference entries. 
2.4.2 Similarity coefficients (Chapter 4 and 5) 
 Similarity coefficients can be calculated, and average coefficients used as a measure of how similar a 
molecule is to other molecules in a dataset. Tanimoto coefficients (Tc) were calculated using the 
following equation (Equation 2.15): 
 
 
Tc =          Nab 
Na + Nb - Nab 
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Equation 2.15: The equation used to calculate Tc where Na  is the number of bits on a set in molecule 
A, Nb the number of bits on a set in molecule B and Nab the number of bits set on common to both 
molecules156. 
2.4.3 Building and evaluating QSAR models (Chapter 4) 
A QSAR model is a numerical formula that is developed using a predetermined training set and 
evaluated for its predictive ability be using a test set of molecules, representative of those in the 
training set, but critically which have not been used to derive the QSAR model. The MOE QuaSAR suite 
produces linear regression models, which can be used to predict experimental results and compared 
to experimentally derived data. In its simplest form, a linear model specifies the relationship between 
a dependent (response) variable Y, and a set of predictor variables (X). 
A correlation coefficient (r2 value) between experimentally derived data and predicted values is 
generated in addition to a cross-validated correlation coefficient (q2 value) and both are used as 
measures of model quality. The parameters of the linear models were determined using the method 
of Partial Least Squared (PLS). 
2.4.3.1 Partial least squares 
Partial least squares is a statistical method used for developing predictive models when there are 
many factors involved and these factors are highly collinear. Development of QSAR models can include 
the use of hundreds of different molecular descriptors and it is the aim of model development to 
identify which descriptors are important for predictivity. In PLS, the descriptors are described as latent 
factors/variables.  
The identification of latent variables important for predictivity is achieved by establishing a 
relationship between two data sets. Latent variables are chosen in such a way as to provide maximum 
correlation with the dependent variable, e.g. biological activity. Figure 2.4 illustrates a hypothetical 
data set with two variables (X1 and X2) from graph a it can be seen that the variables are highly 
collinear. From this, two latent (orthogonal) variables can be applied (t1 and t2) that are a linear 
combination of the original variables. This produces a model that relates the activity to the first latent 
variable t1. 
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Figure 2. 8: Change of original descriptors to latent variables (a) and construction of activity model 
containing one PLS factor (b)157. 
2.4.3.2 Leave One Out Cross validation  
Leave one out Cross-validation is a procedure by which portions of the training set are systematically 
“left out” of the model building and subsequently used to simulate "new" models, the predictive 
ability of which are compared to the original. This is conducted for each of the variables (data points) 
within the training set and the differences in values obtained from each leave one out cross validation 
are used to calculate the root mean square of error of cross validation (RMSECV) and the revised 
correlation coefficient. This latter value is often referred to at the q2 value119. 
Cross validation in this manner gives an indication of how sensitive the models are to the training set 
used to generate them, and gives an indication via the q2 value how robust the model is.  
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2.5 Pharmacophores (Chapter 5) 
2.5.1 Clustering systems 
JChemAxon was employed as a clustering method, using the Maximum Common Substructure (MCS) 
approach in ChemAxon158.  In essence this means that structurally similar molecules are clustered with 
one another in a hierarchical manner.  
This method treats all molecules as initial separate clusters.  All clusters are evaluated for similarity 
and molecules that have similarities are then merged to form a second layer of clusters. This process 
will be repeated until all clusters that can be merged are. The forming of new clusters causes the 
dataset to split into levels forming a Dendrogram (see Figure 2.8). The top level of the dendrogram 
contains the smallest common substructure containing at most 9 atoms (as defined by the default 
settings). The bottom level contains all the individual compounds in the dataset which are referred to 
as the “leaves” of the dendrogram. 
 
Figure 2. 9: Diagram to illustrate the method of hierarchical clustering159. 
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2.5.2 Pharmacophore Model generation and validation (Chapter 5) 
2.5.2.1 Flexible alignment  
In order to generate a ligand-based pharmacophore, it is necessary to flexibly align the compounds in 
a dataset to one another. The flexible alignment application in MOE produces flexibly aligned motifs 
based on a collection of small molecules. Each motif is given a score that quantifies the quality of the 
alignment in terms of both internal strain and overlap of molecular features160. 
Alignment motifs are calculated in MOE using the internal energy of the molecules and Gaussian 
feature densities. There are eight Gaussian feature densities used to develop an alignment score. 
These are: 
1. Volume 
2. Aromatic 
3. Donor 
4. Acceptor 
5. Hydrophobe 
6. logP 
7. Molar refractivity  
8. Surface exposure  
The overlap of these features will contribute to the final alignment score. 
Alignments are "sampled" using a RIPS-style (Random Incremental Pulse Search) procedure that 
incorporates the quantitative measure of goodness of an alignment defined above into the 
optimization stage. Such a procedure happens via the following three stages: 
1. Generation of a conformation for each molecule by randomly rotating bonds and inverting 
unconstrained chiral centres followed by performance of a rigid-body optimization of the 
similarity function. 
2. Minimization of the grand alignment score S with respect to the coordinates of all of the 
atoms. S is simply a combination of the similarity measure (see above), and the average strain 
energy of the molecules (denoted by the symbol U). 
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3. If the new configuration has not been seen before (RMSD greater than a predetermined 
threshold, up to topological symmetry), then a value k is set to otherwise, k = k + 1. If k is 
greater than a predefined threshold amount the search is terminated. 
2.5.3 Enrichment Factors (Chapter 5) 
Enrichment factors were calculated as a measure of pharmacophore model ability to extract expected 
compounds preferentially from a virtual screening experiment. The Ef were used to investigate how 
modified pharmacophore models compared to the initial models generated, and if the models 
performed better than random with regards to extracting the expected molecules from a database. Ef 
were calculated at three different stages of the pharmacophore search, to ascertain how well the 
model was able to retrieve selected compounds in the early stages of the pharmacophore search. 
Enrichment rate X% = 
 (% of relevant Synthetic Cannabinoids at X % ÷ % of New Psychoactive Substances database at X %) 
(Total number of Synthetic Cannabinoids ÷ total number of New Psychoactive Substances) 
 
Equation 2.16: The equation161 used to determine the enrichment rate at different stages of the 
pharmacophore search, x% is the percentage of the database screened (2, 5 and 10%). 
The equation in 2.16 was used to calculate Ef for the first 2, 5 and 10% of database screened. 
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2.6 Virtual screening 
2.6.1 Virtual screen of database using pharmacophore model (Chapter 5) 
The Pharmacophore search application in MOE was used to facilitate a virtual screen. The main 
characteristics of a MOE pharmacophore search are described in Table 2.5. 
Table 2. 5: A description of the characteristic used in the MOE pharmacophore search application 
Search Characteristic Description 
Boolean Expression assigns features as donor or not cationic using Boolean 
expressions 
Substructure Matching uses SMARTS patters to search for functional groups 
Volume and Shape Filtering restrictions can be applied to the shape of the matched ligands 
Partial Matching pharmacophore query features can be marked as essential and 
must be matched for a hit to be identified. Other features may be 
left unmatched and considered a “partial match” 
Group Constraints can be applied to match a group of selected query features 
Existing Conformations uses external conformation databases 
Systematic Matching All possible matches of a ligand conformation and the query are 
systematically examined 
 
Virtual hit molecules were identified using the default systematic matching setting and the hits were 
ranked using RMSDx values (weighted RMSD values plus an applied penalty for each missing feature). 
The MOE pharmacophore search compares each molecule conformation from the provided database 
to the designated pharmacophore. The algorithm used for generating matches works as follows: 
1. A single molecule is screened for matches against the query features for the generated 
pharmacophore. 
2. If the molecule does not satisfy the query features it is not reported as a hit. 
3. If the distances between the molecule annotation points do not agree with the distances 
between the matched query features (after discounting the radial tolerances), the molecule 
is rejected. 
4. If the molecule is retained, the molecule annotation points and the matched query features 
are superposed against one another using rigid-body superposition. If the molecule features 
fail to fall within the specified tolerance radii of the matched query features, the mapping is 
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rejected. During the superposition, the relative weights of the matched query features are 
inversely proportional to their radii. 
5. If any of the molecule atoms violate any of the volume restrictions in the query, the molecule 
conformation is rejected. 
6. If the molecule has successfully passed all of the above criteria it is retained as a “hit” against 
the designated pharmacophore. All reported hits are compiled into an output database. 
2.6.2 FP: MACCS structural keys (Chapter 5) 
MACCS structural keys were developed for the purpose of assigning numerical representations to label 
substructures of molecules (hereafter referred to as keys), and then linearly combining these keys 
together to provide an information-rich one-dimensional representation of a three-dimensional 
chemical structure. Each key describes a small substructure consisting of approximately one to ten 
non-hydrogen atoms. FP:MACCS keys are derived from 166 public MDL MACCS structural keys162. The  
166 different descriptive keys used encode for atom types, bond types and aromatic elements162. 
Figure 2.9 illustrates how a four number MACCS key is derived for the molecule diazepam, this 
highlights how informative a 1D representation of a molecule can be. This simplistic way of 
representing 3D information using MACCS keys allows for efficient manipulation of molecular 
databases, and is used in this thesis to differentiate between structurally similar and structurally 
distinct molecules in the derivation of test and training sets for QSAR models, and to ensure that 
maximum structural diversity was ensured in the selection of molecules from the virtual screening 
experiments 
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Figure 2. 10: Diagram to illustrate how a MACCS key fingerprint for diazepam is calculated163. 
2.7 Biological screening (Chapter 6) 
Compounds that have been identified as being potential CB1 agonists were evaluated for their 
biological activity. A cAMP assay was carried out to determine the accumulation of cAMP 
generated by the selected compounds. This method was employed as changes in intracellular 
cAMP has been shown to indicate the activation of the CB1 receptor.  
The second method employed was the use of an electrical field stimulation (EFS) study. An 
organ bath which contained sections (approximately 1 cm in length) of rat ileum submerged 
in Krebs buffer was used to carry out this investigation. Electrical impulses were applied to 
the tissue and simultaneously a potential CB1 agonist was added to the organ bath. This study 
was used to identify any potential activity the compounds of interest had on the contractive 
force of the tissue sample. The details of both these studies are discussed in Chapter 6. 
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Chapter 3 
 In Silico investigations into selectivity between the monoamine 
transporters (MAT) Dopamine Transporter (DAT), Norepinephrine 
Transporter (NET) and Serotonin Transporter (SERT). 
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3.1 Introduction 
Monoamine transporters (DAT, NET and SERT), are located in the plasma membranes of the 
monoaminergic neurons. They consist of twelve transmembrane helices and are responsible for the 
release or reuptake of the monoamines dopamine (DA), norepinephrine (NE) and serotonin 
(SER)31,35,164–166. As monoamines are vital in the role of normal brain function, the regulation of these 
chemicals is critically important167.  
New psychoactive substances (NPS) act in a similar manner to known classic illicit substances24. This is 
due to the structural similarity between NPS and known illegal recreational drugs such as ecstasy, 
amphetamines and cocaine168, (see Figure 3.1).  
 
Figure 3. 1: The chemical structure of MDMA (ecstasy) on the left and mephedrone (bath salts or 
meow meow) a popular NPS on the right. Highlighted in red are the portions of carbon  skeleton of 
the two molecules that are identical. 
Due to similarities in chemical structure with known psychoactive compounds, a large number of NPS 
will act on DAT, NET or SERT24,67,68,169 and in many cases any given NPS will demonstrate affinity, of 
different magnitudes, with all three MAT48,43,52. It is well documented that there is a large degree of 
ligand promiscuity that occurs between the three MAT3,170,27,171 i.e. drug molecules that have a high 
affinity for one MAT are likely to bind to all three MAT, and extensive research has been conducted 
into trying to develop selective monoamine reuptake inhibitors such as the selective serotonin 
reuptake inhibitors (SSRIs)27,37,171–176 
In order to understand how these molecules are forming interactions with the transporter proteins, 
and hence how differences in affinity for a compound between the MAT isoforms may arise, molecular 
docking studies were carried out.  
When the present study was initially conducted (in 2015), there were no experimental structures (e.g. 
X-ray crystal structures) for the human monoamine transporters, and so comparative/homology 
models of human DAT, NET and SERT were used.  Homology models are routinely used in docking 
studies when no experimentally derived structures have been elucidated. Although there are some 
limitations to this method, with the use of protein validation techniques, robust results can be 
obtained177,178.  
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Since the initial study was completed in 2015 a number of dDAT crystal structures complexed with a 
variety of ligands have been published e.g. the model with the PDB accession code 4XP9 which is the 
dDAT crystal structure complexed with D-amphetamine (at 2.8 Å)179. In early 2016 the human 
serotonin transporter X-ray structure complexed with the antidepressant S-citalopram was also 
elucidated180. Consequently, complementary molecular docking studies have been carried out on 
these emergent experimental structures and results compared to those from the initial homology 
modelling studies. The results from the original docking experiments, and the comparison between 
these studies, and the experiments carried out on the crystal structures is discussed in detail in this 
chapter. Conclusions are drawn as to whether or not it is possible to explain the difference in 
experimental affinity between DAT, NET and SERT based on an examination of how the protein and 
ligands interact with each of the isoforms. 
The comparative DAT, NET an SERT models used in the study were derived from the template 4M48 
(Drosophila melanogaster dopamine transporter, dDAT) and accessed from the 
proteinmodelportal.org (2015) server. These models were rigorously validated using complementary, 
yet independent methodologies prior to docking studies beginning, and deemed viable for use in 
molecular docking studies.  
As such, the first aim of this study was to establish if MAT homology models provided a sufficient 
representation of the human protein structure in terms of their ability to replicate trends in observed 
experimental activities via their docking scores. The second aim was to examine whether it was 
possible to use molecular docking as a methodology to help explain what gives rise to selectivity 
between DAT, NET and SERT. The third aim was to compare results obtained from the MAT homology 
to newly available crystal structures. 
3.2 Methods 
3.2.1 Homology models 
Three comparative models of the sodium symporter neurotransmitters (NSS), DAT (accession number 
Q01959), NET (accession number P23975) and SERT (accession number P31645) were obtained as 
protein database (PDB) files from www.proteinmodelportal.org. 
3.2.2 Protein model validations 
 The DAT, NET and SERT homology models were uploaded to the Rampage135 
(http://mordred.bioc.cam.ac.uk/~rapper/rampage.php ) server to generate Ramachandran plots. The 
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Structure Analysis and Verification Server (SAVES) metaserver ( http://nihserver.mbi.ucla.edu/SAVS/) 
was used in order to produce ERRAT139 and Verify3D138 plots for the models. The data obtained from 
Rampage and SAVES was analysed for each of the NSS models and all residues that violated one or 
more of the three validation criteria were recorded. 
As all three models were based on the same template Drosophila melanogaster dopamine transporter 
(PDB accession code 4M48), this structure was also analysed using the Rampage, and SAVES software 
to provide a benchmark from which to compare the quality of the homology models. 
3.2.3 Protein model sequence and identity. 
All three MATs and the template protein were superimposed and aligned using the 
“Align/Superimpose” application in MOE. This generated pairwise percentage sequence and 
percentage identity values between the homology models and the template. 
3.2.4 New Psychoactive Substances dataset 
The dataset used for the docking studies to the homology models and crystal structures was obtained 
from the study conducted by Iversen et al181. It comprises 21 NPS each of which have experimentally 
measured biological activity data (Ki values) for each of the isoforms DAT, NET and SERT. 
3.2.5 Identification of MAT binding sites. 
Binding sites for all three MAT were elucidated in MOE and then cross referenced with available 
literature to ensure that all residues that had been identified as important to binding were contained 
within the putative binding sites defined. The default settings in MOE were used to define the cavities 
i.e. probe radius 1: 1.4 Å probe radius 2: 1.8 Å, connection distance 2.5 Å and a minimum site size of 3 
residues. The residues identified from the literature as being important for protein ligand interaction 
in the MAT that were not identified by MOE were manually added to the binding site composition 
prior to docking studies taking place. 
3.2.6 Docking in MOE 
Protein models were prepared using the “quick prep” application in MOE, and the binding site was 
defined using the “site finder” application. The database molecules were protonated and compiled 
into MDB files for the docking study. Induced fit docking studies were carried out in MOE, using the 
MMFF94 force field. For comparative purposes, a secondary study using the AMBER10: EHT force field 
was also conducted.  
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In the docking application within MOE the default setting was selected. Parameters used are the 
triangle matcher placement, rigid receptor refinement, London dG & Generalised-born volume 
integral/weighted surface area (GWVI/WSA). dG scoring functions were applied. The number of 
docked poses generated was terminated after a maximum of 30 poses had been established or until 
the conformation of the ligand poses reached a default RMSD cut-off of 3.0 Å. 
The 21 molecules from the NPS dataset were docked into each of the MAT models in turn. The docked 
poses for each ligand were analysed based on the scoring function value obtained, ligand interaction 
diagrams and the 3D conformation of the docked ligand. 
3.2.6 Docking in Genetic Optimisation for Ligand Docking (GOLD)  
Genetic Optimisation for Ligand Docking (GOLD) is an alternative piece of docking software that uses 
a genetic algorithm to position the ligands in the binding cavity. This type of algorithm is based on the 
principles of biological evolution182,183. PDB files for DAT (accession number Q01959), NET (accession 
number P23975) and SERT (accession number P31645) were prepared in MOE. The native ligand (DA 
for DAT, NE for NET and SER for SERT) was then docked into the corresponding MAT homology model. 
The protein-ligand complex which had the highest S value was saved as a PDB file and uploaded to the 
GOLD visualizer HERMES.  
To prepare the protein structures for docking the “add hydrogens” application was used. To define 
the binding site, a known binding site residue (see Table 3.1) was isolated for each MAT isoform and 
then using the Cartesian coordinates of the residue (obtained by interrogating the PDB file) a binding 
site cavity was constructed by using the default setting in GOLD which defines the binding site as all 
residues within a 15 Å radius of the selected residue. 
Two scoring functions were implemented during the docking study using GOLD; GOLDscore (an 
empirical scoring function) and CHEMscore (a molecular mechanics-based scoring function, see 
Chapter 2 for details). The Genetic Algorithm default settings were applied with a population size 100, 
selection pressure 1.1, number of operations 100,000, number of islands 5, niche size 2, migrate 10, 
mutate 95, and crossover 95. Once the scoring function and rescore scoring function was selected the 
Iversen dataset was docked and ranked according to the scoring function results. 
3.2.7 Spearman’s Rank () 
To determine the extent of the correlation between the relative rankings of the experimentally 
observed values and the relative rankings of the computationally generated scoring function results, 
Spearman’s rank correlation coefficients (Eq 3.1) were calculated.  
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These pairwise comparison values were calculated for the experimental data with respect to all 
scoring functions used in the docking studies and the individual components of the S scoring function 
used in MOE (i.e. rmsd_refine, E_conf, E_place and E_refine). Correlation coefficients were checked 
for statistical significance using critical value tables184. 
 = 1 - 6∑d2 / (n3-n) 
Equation 3.1: Formula used to calculate Spearman’s rank correlation coefficient () between relatively 
ranked experimental and relatively ranked computationally generated scoring function data.  
Where 
d = the difference in value between experimental and computational rank value, 
n = the number of samples in dataset 
3.2.8 Consensus scoring 
In order to remove potential bias from the docking results, a number of different scoring functions 
were used to recalculate scores for the poses generated by the docking studies. The openly accessible 
server Galaxy/Ballaxy149 (https://ballaxy.bioinf.uni-sb.de/) was used to re-score the docked poses 
created in MOE. The scoring functions used to achieve this were  (1) Molecular Mechanics (MM), (2) 
Pairwise Linear Potential (PLP) and (3) Poisson-Boltzmann (PB)148,185,186.  
The ranked data for all the different scoring functions were then compared to the ranking of the 
experimental data using Spearman’s rank. A Spearman’s rank was calculated based on the ranking 
trend of nine scoring functions. 
Subsequently, a Spearman’s rank value for experimental relative ranking of highest to lowest affinity 
vs predicted relative ranking of highest to lowest affinity was calculated based on all the docked data 
for each of the MAT isoforms. 
3.3 Results 
3.3.1 Homology models 
At the time of the initial study (2015) there were no human crystal structures available for DAT, NET 
or SERT. As such, homology models for human DAT, NET and SERT isoforms were obtained from 
proteinmodelportal.org. The homology models were validated, with regards to their structural 
properties, before being used in subsequent docking studies. Homology models are built on 
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experimental structures (such as x-ray crystals) that share a similar primary structure177 to the desired 
protein, whereby these experimental “templates” are used to predict the likely 3D conformation 
(homology model) for a “target” structure (homology model). For  the DAT, NET and SERT homology 
models the template used was the crystal structure 4M48187. The homology models are available from 
the SWISS-MODEL  repository188. 
The homology models for DAT, NET and SERT have sequence identities with the template ranging from 
53-55% to the 4M48 template. It is generally considered that models that have over 50% sequence 
identity to its template are suitable to be taken forward drug discovery investigation110.  
From Figure 3.2 it can be seen that there is a high level of structural conservation between the 
secondary structural elements in all three MAT’s and the template structure, the difference between 
the structures arises in the orientation of the extracellular loops, which can easily be seen. 
 
Figure 3. 2: Visual representation of the superimposed template 4m48 (blue) and homology models 
of DAT (Q01959, green), NET (P23975, white) and SERT (P31645, magenta) showing a largely 
conserved secondary structure between the template and the MAT models but variation in loop 
regions (circled in black). 
Figure 3.3 is a matrix of the residue identity percentages between the three homology models and the 
template crystal structure. The bigger the percentage, the greater the similarity between two protein 
structures189. As stated by Chothia and Lesk190 homology models that have a sequence identity of >50% 
with the template will provide a close general model. Figure 3.3 shows that the template crystal 
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structure appears to be most similar to the NET homology model but all models have a pairwise 
sequence identity with the template and each of the other isoforms of greater than 50% and as such 
can be taken forwards into docking studies, subject to protein validation. 
 4M48 DAT NET SERT 
4M48  54.8 58.8 53.1 
DAT 54.8  69.9 50.7 
NET 58.8 69.9  52.7 
SERT 53.1 50.7 52.7  
Figure 3. 3: Matrix of residue identity percentage values for 4M48, DAT, NET and SERT. 
  
3.3.2 Homology model validation 
The three homology models and the template structure were analysed for structural validity using 
three protein validation tests: Ramachandran (RC) plot analysis135, Verify3D115 analysis and ERRAT139 
analysis.  
These validation methods were used as a quality sense check of the models and to identify any 
residues implicated in structural errors190, as these could, in turn, produce errors when using the 
models in docking studies. Ramachandran analysis looks at the overall quality of the backbone of the 
protein structure, Verify3D analysis looks at compatibility of the 3D structure of the model with the 
amino acid sequence and ERRAT analysis looks at the distance between pairs of non-bonded atoms 
(CC, CN, CO, NN, NO and OO)116. All techniques are independent, yet complementary to one another 
and are in combination are useful to identify regions of error in a protein model.  
3.3.2.1 Ramachandran Analysis 
Ramachandran plots are a geometric validation method which analyse the three main components of 
a proteins structure135. The components are the backbone conformation, the side chain conformation 
and the Cα geometry135. As protein structure and function are heavily related, it is vital that the protein 
backbone has a structurally appropriate conformation, and a homology model which was unable to 
demonstrate a structurally appropriate conformation would be of limited use in docking studies. 
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Figure 3.4 is a Ramachandran plot generated for the template structure 4M48, and the homology 
models of DAT, NET and SERT using RAMPAGE135. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4: Ramachandran plots for 4M48 (A), DAT (B), NET (C) and SERT (D). RC analysis plots the 
torsional angles (, x-axis and, y-axis) of all the residues. The plot is split into areas according to 
secondary structure (regions labelled B/b for β-sheets, A/a for α-helices and L/l for left handed 
helices). The conformations of residues are categorised into four groups: most favoured (which are 
found in the red sections), allowed residues (plotted in the yellow sections of the graph) additionally 
allowed conformations (cream) and disallowed conformations found in the white sections of the 
graph. 
A B 
C D 
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The number of residues that were in the disallowed region of the RC plot was less than 2% for all of 
the homology models and less than 1% for the template structure (see Table 3.2 for results). Further 
analysis showed that none of the amino acid residues that were found to be in the disallowed region 
on the Ramachandran plots were part of the putative MAT binding sites. This gives confidence that 
the residues that make up the binding site will not produce erroneous docking conformational poses, 
as a consequence of an inappropriate overall protein fold.  
For DAT, NET and SERT the residues that were found in the outlier region of the RC plot were all 
residues that were found in loops on the models. This was not unexpected as the majority of reported 
errors found in homology models are due to poorly predicted loop structures within a protein191. 
3.3.2.2 Verify 3D Analysis 
Verify3D analyses the compatibility of a proteins 3D structure with its 1D structure (amino acid 
sequence). Each residues is categorised based on its environment and location and is used to evaluate 
the overall fitness of the amino acid sequence in relation to its 3D environment115.The results obtained 
for DAT, NET and SERT for Verify3D (Table 3.1 and Figure 3.5) show that between 84-94% of residues 
obtained a positive value which indicated a favourable environment  (conversely a negative value for 
a residue indicates it is in an unfavourable environment). 
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Figure 3. 5: Verify3D plots for 4M48 (A), DAT (B), NET (C) and SERT (D). The blue dots represent the 
average score based on a 21-residue sliding window. A negative average score indicates a residue that 
does not have a favourable 3D-1D compatibility, a positive average score indicates a good 3D-1D 
compatibility.  
3.3.2.3 Errat Analysis 
ERRAT analysis (Figure 3.6) looks at the non-bonded interactions between carbons, nitrogen and 
oxygen atoms within a protein. The results obtained for DAT, NET and SERT for ERRAT showed that all 
models had an overall quality factor of >85%, this means that at least 85% of the non-bonded 
interaction between carbon, nitrogen and oxygen within the model were at acceptable/expected 
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distances139to one another, and this is an indication that overall the model was of sufficiently high 
quality to be used in subsequent docking studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 6: ERRAT plots for 4M48 (A), DAT (B), NET (C) and SERT (D) based on the first 320-380 
residues. ERRAT plots assess the distribution of different atom types. Values are plotted as a function 
of the position of a sliding 9-residue window. The 95% and 99% error lines on the graph show at what 
confidence level the residues can be rejected for not have the correct distribution between atom 
types. The gap shown in image A is due to a gap in the amino acid sequence which is a loop that had 
not been present in the crystal structure.  
A 
B 
C 
D 
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The results obtained from the protein validation analysis for all three models and the template 4M48 
showed that the protein structures were of an appropriate quality to be used in docking studies. 4M48 
outperforms all of the models in each of the tests, which is a reassuring indication that the models 
were not over fitted. Hence, the models could be used in experiments to ascertain what the structural 
differences between the isoforms were that could account for the differences in experimental affinity 
observed for the 21 compounds of the Iversen. 
During the lifetime of this project, a number of experimental structures of the MAT isoforms were 
placed into the public domain, and as such the docking experiments were repeated using the 
experimental structures. Subsequent to these experiments taking place, the experimental structures 
were validated in the same manner as the homology models. The results of these validation studies 
on the experimental structures are summarised in Table 3.1. 
Table 3. 1: A list of the protein models/ crystal structures and the associated protein validation results. 
Results are displayed as the percentage of amino acids that have appropriate scores/values for 
Ramachandran plot analysis, ERRAT and Verify3D protein structure validation analysis 
 
All experimental structures in Table 3.1 show improvements with respect to the quality of structure 
for ERRAT and Verify3D in comparison to the homology models used initially. The overall protein 
backbone quality is unchanged. Again, none of the residues that failed the validation tests were part 
of the binding site. 
 
Experimental 
structure/Model  
RC (%) of amino acids in 
the favoured/allowed 
region of the RC plot 
Verify (%) of residues 
with an average score of 
> 0.2 
Errat (%) Overall Quality 
factor 
4XP9 (DAT) 100 91.78 92.16 
4XPA.1A (NET) 99.8 92.35 91.98 
5I75 (hSERT) 100 99.53 87.67 
4M48 100 94.42 93.51 
DAT 100 89.67 88.36 
NET 99.7 89.24 85.77 
SERT 99.8 84.17 89.45 
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3.3.3 Docking studies 
3.3.3.1 Putative binding site identification. 
Using the Site Finder application in MOE putative binding cavities were elucidated for each of the 
homology models. These were validated by cross-referencing with literature to identify residues that 
were known to form protein-ligand interactions implicated in biological responses24,192,193. For each 
isoform, the putative binding site containing the greatest number of residues that had previously been 
reported as implicated in binding in the literature was selected from the list produced in MOE as the 
preferred binding site for docking studies.  
The MAT isoforms are listed in Table 3.2 along with the volume of the preferred binding site and a 
Propensity for Ligand Binding (PLB) 194 score calculated by MOE. The largest cavities, with the highest 
PLB scores were selected to take forward into docking studies for DAT and SERT. 
Table 3. 2: a list of the MAT homology models with associated binding site volume of the largest cavity 
identified and PLB value calculated using the MOE software.  
 PLB volume (Å3) 
Q01959 (DAT) 3.80 270 
P23975 (NET) 0.53 87 
P31645 (SERT) 3.50 249 
 
The putative binding site cavity for NET was much smaller than DAT and SERT and NET had a PLB value 
which was low in comparison to the other two isoforms. The lower PLB score was necessarily a 
consequence of the smaller putative binding site for NET, as it follows that a constrained binding site, 
such as that identified for NET, would be less amenable to binding ligands than the more accessible 
cavities identified for DAT and SERT. It should be noted that the binding cavity elucidated by MOE for 
NET, was the second binding site available out of a list of 10 possible binding sites. This was chosen 
because this second cavity contained an aspartate (Asp75) residue that has been shown to be crucial 
for forming protein-ligand interactions in NET176. 
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3.3.3.2 DAT 
Table 3. 3: A list of all the DAT binding site residues that were reported in the literature35,132 and 
binding site residues that were identified by MOE. The tables highlight any residues that failed the 
quality control tests during model validation, and which test(s) were failed. 
3.3.3.3 NET 
Table 3. 4: A list of all the NET binding site residues that were reported in the literature and binding 
site residues that were identified by MOE. The tables highlight any residues that failed the quality 
control tests, and which test(s) were failed. 
 
DAT  
   
Residues reported in  the 
literature165,195 
Faults with 
residue 
Type of fault Residue present in putative 
binding site identified by 
MOE 
D-79 no - Yes 
L-80 no - No 
A-81 yes V3D (-0.25) yes 
V-152 yes V3D (-0.09) yes 
Y-156 no - yes 
F-320 no - yes 
S-321 no - yes 
F-326 no - yes 
S-422 yes Errat (95%) yes 
G-426 no - no 
NET  
   
Residues in the 
literature176,196 
Faults with residue Type of fault Residue present in MOE 
binding site 
F-72 yes Errat (95%) yes 
D-75 no - yes 
A-145 no - yes 
V-148 yes V3D (-0.09) yes 
Y-152 no - yes 
F-317 no - yes 
F-323 no - yes 
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3.3.3.4 SERT 
Table 3. 5: A list of all the SERT binding site residues that were reported in the literature and binding 
site residues that were identified by MOE. The tables highlight any residues that failed the quality 
control tests, and which test(s) they failed. 
SERT  
   
Residues in the 
literature197,198 
Faults with 
residue 
Type of fault Residue present in MOE 
binding site 
Y-95 yes Errat (95%) yes 
A-96 yes Errat (95%) Yes 
D-98 no - Yes 
L-99 no - No 
G-100 no - Yes 
W-103 no - Yes 
R-104 no - Yes 
Y107 no - Yes 
I-172 yes V3D (-0.54) Yes 
A-173 no - No 
Y-175 no - Yes 
Y-176 no - Yes 
I-179 no - Yes 
F-335 no - Yes 
S-336 no - Yes 
F-341 no - Yes 
V343 no - No 
K-399 no - No 
D-400 no - No 
S-438 yes Errat (95%) Yes 
T-439 yes Errat (95%) Yes 
G-442 no - Yes 
E-493 no - Yes 
 
3.3.4 Docking of native substrates 
Dopamine, norepinephrine and serotonin were docked into all 3 MAT homology models to gain insight 
into where the molecular docking algorithm would place the native substrates, and how it would score 
them with respect to relative binding energies (S values) in each of the MAT isoforms. This provided 
information on how well MOE was able to dock endogenous ligands into the relevant MAT. From the 
literature there are a number of residues that have been established as playing a key role in forming 
protein ligand interactions within the three MAT. D-amphetamine, citalopram and paroxetine are 
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known form hydrogen bonds, to the Asp residues in DAT187,199. Docked conformations obtained from 
the MAT isoforms and the native substrates highlight the same well-established residues as being 
important in the formation of protein ligand interactions. These findings offer reassurance that the 
docking algorithm would be able to identify feasible docking conformations for the 21 NPS of the 
Iversen dataset and would allow conclusive results to be obtained. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C 
E F
D
B
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Figure 3. 7: Illustration of the MOE-defined putative binding cavity for A) DAT, C) NET and E) SERT 
showing the highest-ranked docked pose for A) dopamine, C) norepinephrine and E) serotonin (green 
ligand). Images B, D and F are the Protein Ligand Interaction Fingerprint (PLIF) for the respective 
docked pose. Potential hydrogen bonds being formed between ligand and protein are shown with 
dotted green arrows. B) is the docked dopamine/DAT pose with interactions between dopamine, 
Asp79200, Phe320 and Asp476200 with an S score of -4.6602 kcal/mol. D) is the docked 
norepinephrine/NET pose displaying interactions between the ligand and Asp75176 and Phe317176 and 
an S score of -4.9853 kcal/mol. F) is the docked serotonin/SERT pose with interaction between 
serotonin, Asp 98198 and Tyr 95198 and an S score of -5.3776 kcal/mol. 
Figure 3.7 A and B shows that the dopamine molecule was bound at the bottom of the putative cavity. 
This docked conformation had the highest ranked s-value when the London dG and GBVI/WSA dG 
scoring functions were used and demonstrates interaction with residues that have been shown by 
experiment to be involved in protein ligand interactions in DAT37,195. This provided confidence that the 
docking study was able to generate credible, well-established interactions between DAT and its native 
ligand. 
Figure 3.7 C and D shows norepinephrine docked in the lower part of the NET cavity, which was more 
constrained than both DAT and SERT. The docking study indicated that NE is forming the key protein-
ligand interactions reported by Schlessinger et al,  which highlights Asp75, Phe72, Tyr152 and 
Phe317176, playing important roles in norepinephrine binding  in NET. This was supported by the PLIF 
for NET and norepinephrine which suggest that the binding site elucidated by MOE was valid and could 
be carried forwards into docking studies. 
Figure 3.7 E and F shows that the highest ranked docked pose for serotonin, much like dopamine’s 
optimal docked conformation, is at the bottom of the cavity, and is shown to interact with residues 
that have been experimentally determined to be important in protein ligand binding199. This gives 
confidence, once more, that the model can be used in the docking of NPS and is likely to generate 
credible conformations for protein-ligand interactions which can help elucidate the differences in 
binding affinity between the MAT isoforms.  
The values obtained from the docking study for the MATs and their native ligands are shown in table 
3.6. This showed dopamine (DA) as having better S values (and by inference binding affinity) with NET 
and SERT than their native ligands (NE and SER respectively). Hence, the algorithm was unable to 
determine the preferential binding of dopamine with DAT (both SER and NE were predicted to bind 
more strongly) or norepinephrine with NET (SER was predicted to bind more strongly). This could be 
a consequence of limitations in the docking algorithm, the scoring function used, the putative binding 
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site elucidated by MOE, or a combination of all three of these factors. Alternatively, it may be evidence 
to support that the relative promiscuity observed for ligands which is seen between the three MAT 
isoforms is a consequence of the fact that binding sites are inherently non-selective for the majority 
of substrates. To test these hypotheses a series of further experiments, using relative rankings rather 
than absolute S scores, were conducted. 
Table 3. 6: The S scores (kcal/mol) obtained for the highest ranked poses when the native substrates 
of each of the MATs DA, NE and SER were docked into the putative binding cavities of the DAT, NET 
and SERT homology models. 
3.3.5 Docking studies using MOE 
Table 3. 7:  Table to show the relative rankings, where 1 indicates the molecule with the best predicted 
affinity, and 21 the molecule with the worst predicted affinity, for the best (i.e. most highly scored) 
docked poses of the 21 NPS of the Iversen dataset in the putative binding sites of the monoamine 
transporters DAT, NET and SERT. These are compared to the relative ranking of observed biological 
activities. Studies have been carried out using i) the Amber10: EHT force field and the London ΔG 
scoring function in MOE and ii) the MMFF94x force field and the default scoring function in MOE. 
 
 
 Dopamine (DA) Norepinephrine (NE) Serotonin (SER) 
DAT -4.6682 -4.7047 -4.7057 
NET -4.7191 -4.9835 -5.4317 
SERT -5.0198 -4.9049 -5.3776 
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  DAT NET SERT 
Ligand Biological activity 
ranking 
(DAT/NET/SERT) 
Docking 
ranking 
Using 
AMBER10 
Docking 
ranking 
Using 
MMFF94x 
Docking 
ranking 
Using 
AMBER10 
Docking 
ranking 
Using 
MMFF94x 
Docking 
ranking 
Using 
AMBER10 
Docking 
ranking 
Using 
MMFF94x 
Desoxypipradrol 1/7/17 7 16 7 11 7 9 
1-Naphyrone 2/12/4 12 20 10 6 14 3 
Naphyrone 3/6/3 1 5 2 4 1 8 
Nomifensine 4/1/13 8 17 8 10 13 2 
Amphetamine 5/2/15 5 4 5 20 9 1 
6-APB 6/3/12 18 1 17 7 18 19 
Cocaine 7/18/6 3 14 3 18 3 17 
5-APB 8/5/5 2 2 1 9 2 21 
Mephedrone 9/11/14 13 3 14 5 16 4 
Methylethcathinone 10/21/10 19 19 21 12 19 5 
Methiopropamine 11/9/19 17 8 15 16 17 6 
Methylenedioxy-N-
benzylcathinone 
12/20/21 10 7 12 13 8 
7 
(S/+)-MDMA 13/10/8 20 18 19 19 21 16 
Benzedrone 14/17/16 9 21 9 8 4 20 
5-iodo-2-aminoindane 15/8/7 16 11 13 1 10 12 
(R/-)- MDMA 16/15/11 11 15 11 15 15 10 
Fluoxetine 17/19/1 4 10 4 14 5 13 
Methylenedioxy-aminotetralin 18/16/9 6 9 6 21 6 14 
Amitriptyline 19/4/2 14 16 16 2 12 15 
Methylenedioxy-aminoindane 20/13/20 15 20 18 17 11 18 
Dimethylamylamine 21/14/18 21 5 20 3 20 11 
r2 value  0.146 0.006 0.017 0.078 0.082 0.033 
76 
 
A relative ranked score has been selected for comparing the data as there is no direct 
relationship between the scoring function S value of the docking algorithm and the biologically 
determined activity value (r2 ranging from 0.006 to 0.146). The ligands that form the best 
interactions with the MAT will have better S values and can be used to indicate a ligand’s ability 
to interact with a receptor and elicit a response. 
Table 3.7 shows the ligands in ranked order of their biological activity for DAT NET and SERT in 
the second column. The remainder of the table shows the ligands numbered according to the 
relative ranking of their S values (or docked scores) generated by MOE in the docking 
experiments that were carried out. 
 The pairwise correlation between the relative rankings according to biological activity and 
docked score give very low r2 values regardless of the force field employed (AMBER10 or 
MMFF94x). A possible reason as to why the correlation was so low may be due to the docking 
algorithm not being able to successfully distinguish between the ligand interactions with the 
MAT isoforms when forming docked poses, as a consequence of the similarity of the binding 
cavities of the MATs (Figure 3.8), and therefore not being able to effectively rank the selectivity 
of the ligands in the dataset. 
 
 
Figure 3.8: The overlaid putative binding sites of the DAT (green), NET (white) and SERT 
(magenta) homology models, elucidated using the SiteFinder module in MOE. This highlights 
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similarities in the shapes of the cavities, which could partially explain the observed promiscuity 
of binding between the three MAT isoforms and the ligands in the Iversen dataset. 
As the binding site of NET was a lot smaller in volume in comparison to DAT and SERT (Figure 
3.8), a second docking study was carried out in MOE. This study used a composite putative cavity 
that resulted from combining the top two binding sites elucidated by the software (see Figure 
3.8). The modified binding site had a volume of 341 Å3 and PLB score of 4.25. When the dataset 
was docked into this composite NET cavity an r2 value of 0.034 was obtained. This value is 
comparable to the values achieved for the docking studies on the initial cavity, and give 
confidence that the poor performance for NET was not a consequence of the constrained nature 
of the putative binding cavity. 
 
Figure 3.9: The overlaid putative binding sites of the DAT (green), composite NET (white) and 
SERT (magenta) homology models, identified using the SiteFinder module in MOE. This 
highlights similarities in the size and shapes of the cavities. 
The composite binding site (Figure 3.9) of NET is much more similar to DAT and SERT overall, 
however the opening to the cavity is much broader with NET. Despite this modification to the 
NET putative binding site, there is no significant improvement in the docking results. This, again, 
speaks to the similarities between the binding sites of the isoforms making it difficult for the 
docking algorithm/scoring function to effectively distinguish between the ligands in the Iversen 
dataset. 
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3.3.6 Docking studies using Genetic Optimisation for Ligand Docking (GOLD) 
The initial docking results obtained from MOE did not provide results that could help explain 
selectivity of ligands between the different MAT isoforms. A second docking study was carried 
out using the computational software GOLD to rule out this result arising as a limitation with the 
docking algorithm/scoring function used in MOE. GOLD uses a genetic algorithm to guide 
docking which uses the idea of evolution to develop conformational poses. The 21 compounds 
of the Iversen dataset were docked into the MAT models using GOLD (Table 3.8) and the docked 
data was ranked and compared to the biologically ranked data to see if there was a correlation 
(in the same way as for the MOE docking algorithm).  
Table 3. 8: r2 values for the correlation between the ranked biological data and ranked docking 
score values for DAT, NET and SERT using the scoring functions GOLDscore and CHEMscore 
MAT GOLDscore r2 CHEMscore r2 
DAT 0.021 0.017 
NET 0.017 0.000 
SERT 0.152 0.000 
 
Table 3.8 shows that very little correlation was obtained between ranked biological data and 
ranked docking data when using GOLD. This is consistent with the results obtained from the 
MOE docking studies and indicates that the lack of correlation between experimental and 
computational data was not likely to be as a result of limitations from a specific docking 
algorithm. 
3.3.7 Spearman’s Rank () 
The docking studies carried out in MOE and GOLD produced very low r2 values which indicates 
very little correlation between the experimentally derived data obtained from Iversen et al and 
the data produced from the docking algorithms in MOE and GOLD. Due to the complex nature 
of protein ligand interactions the ability for a single scoring function to correctly distinguish 
between these interactions is limited154.  
Spearman’s rank (Table 3.9) was employed to see if there was correlation between the way the 
results had been ranked in terms of biologically activity and ranked docked poses (S-values). 
Many docking studies have employed Spearman’s rank to evaluate the overall accuracy of 
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ranked data201, given the acknowledged lack of correlation between scoring functions and 
experimentally measured biological activity data. 
To measure the significance of the  coefficient values and the strength of the correlation 
between results critical tables were used to highlight  values that were statistically significant 
(above 90%184).  values above 0.37 are significant at 90% and  values above 0.44 are significant 
at 95%184 for a dataset containing 21 compounds. 
Overall the best performing scoring function used in terms of  coefficient was the Affinity ΔG 
function. This produced the highest overall  value for DAT (significant at 90%). However only 
the docking studies in DAT generated statistically significant results for the Spearman ranking 
experiments, with additional  values for the London ΔG, αHB and GOLDscore achieved for DAT 
also statistically significant at 90%202. 
The scoring functions in MOE are the sum of different components based on different individual 
energy terms (Chapter 2). The scores of the two components from the London ΔG scoring 
function were ranked for the 21 docked compounds and ρ values calculated by comparing these 
values to their relatively ranked biological activities. This experiment was carried out to see if 
isolated properties of a scoring function could be used to better rank the docked posed 
obtained. The results obtained for the scoring functions in the GOLD software, ChemScore and 
GoldScore, were also analysed in this way (Table 3.9). 
Table 3. 9:  coefficient values obtained for the docked ranking study conducted in MOE using 
four different scoring functions: London ΔG, Affinity, ASE and α HB (see Chapter 2 for details on 
scoring functions). ρ coefficient values calculated when only individual components (E_place and 
E_conf) of the London ΔG were used to rank the dataset. The table also includes docked ranking 
study conducted in GOLD using the two scoring functions GOLDscore and CHEMscore. Results 
that are statistically significant at 90% and above are shown in bold 
 coefficient values 
 London 
ΔG 
Affinity 
ΔG 
ASE α HB E_place E_conf GoldScore ChemScore 
DAT 0.38 0.42 0.34 0.40 0.22 0.25 0.40 0.28 
NET 0.13 0.30 0.05 0.08 0.03 -0.02 0.04 0.19 
SERT 0.30 0.28 0.13 0.28 -0.03 -0.12 0.19 0.34 
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None of the ρ values calculated using the individual components of the London ΔG scoring 
functions were significant at 90% for any of the isoforms. Table 3.9 also shows there was no 
overall improvement in ρ values when using a different docking algorithm (i.e. the GOLD 
algorithm).  
In an effort to investigate whether inherent biases in scoring function were responsible for the 
lack of significant correlation, a rescoring exercise was carried out. Ballaxy149 is a simple rescoring 
application which rescores docked poses generated in either the MOE or GOLD docking 
algorithms. The three scoring functions available via Ballaxy are MM- an AMBER203 based scoring 
function, PB – a Poisson-Boltzmann scoring functions and PLP a pair wise linear potential scoring 
function185,186,204. 
Table 3. 10: The ρ coefficient values calculated when docked poses were taken from MOE and 
then rescored using the rescoring software Ballaxy149. Results that are statistically significant at 
95 % are shown in bold 
 ρ coefficient values 
 MM PLP PB 
DAT -0.22 0.41 0.27 
NET 0.04 0.07 0.12 
SERT 0.23 0.23 0.11 
 
3.3.8 Consensus Scoring 
In a final effort to try and improve correlation between computational and experimental results 
consensus scoring was employed (see Table 3.12). The aim here was to see if combining multiple 
scoring functions (consensus score,205,206) would improve how well the ranked docked data 
would best match the ranked biological data, and is based on the premise that implicit bias in a 
single scoring function is reduced by comparing and combining the results of several 
independently derived instruments. Scoring functions from MOE and GOLD were used in 
combination with 3 scoring functions from the software Ballaxy148 (Table 3.11) to generate 
consensus rankings for each of the 21 ligands in the Iversen dataset.  
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Table 3. 11: A list of all the scoring functions used in the consensus of scoring functions.  
MOE scoring functions 
Amber10:EHT98 
Ballaxy 
Scoring functions144 
GOLD151  
Top scored S value (London ΔG) MM GoldScore  
Average of all S values (London ΔG) PLP ChemScore  
Average top 5 values (London ΔG) PB   
Affinity DG 
 
  
ASE scoring function 
 
  
Alpha HB 
 
  
 
Table 3. 12: The ρ coefficient values calculated when a consensus of scoring functions was used. 
Statistically significant results (90% and above confidence) are shown in bold. 
MAT ρ coefficient for 
consensus scoring 
 
DAT 0.38  
NET 0.05  
SERT 0.40  
 
Table 3.12 shows the results obtained for the consensus scored ρ coefficients based on nine 
different scoring functions. Both DAT and SERT produced values were statistically significant at 
90% 202 confidence.  
As there is no standardized scoring function that can be applied to molecular docking studies, it 
was expected that the individual scoring functions did not produce strong correlation 
coefficients; this is why a number of different scoring functions were employed. To gain a better 
prediction of binding affinities, different docking and rescoring programs were used in attempt 
to combat the problems associated with protein flexibility and the number of different ligand 
conformations. Studies have shown that consensus scoring can be used to improve ranked data 
correlation however these studies were conducted using crystal structures207. Using homology 
models may have limited how well consensus scoring was able to rank the docked data. Another 
limitation of the study may be due to the small dataset available. Many consensus score studies 
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use between 100208,209-1000 ligands205, as the correlation of ranked data was being analysed 
having a small dataset may not be suitable when looking at trends between ranked datasets. 
3.3.9 Experimental structures of the MATs. 
In 2016, the human SERT crystal structure180 bound to paroxetine was published. This crystal 
structure showed paroxetine had the ability to form potential hydrogen-bonding interactions 
with both Tyr95 and Asp98, as predicted by the docking studies above and that Tyr 176, Ser 438, 
Ile 172 and Phe335 also defined the binding cavity – again consistent with the computer 
modelling. This gives further confidence that molecules which bind to DAT and SERT with a high 
affinity are likely to be found towards the bottom of the cavity, as predicted by the models.  
The binding of ligands towards the bottom of the cavity is likely due to key interactions that are 
formed with the aspartate residue (DAT Asp 79, NET Asp75 and SERT Asp98). This highly 
conserved residue plays a key role in the recognition of biogenic amine DA, NE and 
SER39,40,174,176,179,187,193,210–212. It has also been reported as forming an interaction with virtually 
every known inhibitor of DAT, NET and SERT39, and hence is likely to play a key role in the binding 
of the NPS to the MATs. 
Also, after the initial computational modelling studies were conducted a series of dDAT crystal 
structures (May, 2015) co-crystallised with the ligands; dopamine, 3, 4-dichlorophenethylamine, 
D-amphetamine, methamphetamine, cocaine, β-CFT and RTI-55 were released179.  
In light of these advances, it was deemed pertinent to repeat the docking experiments carried 
out on the new crystal structures, to investigate any differences that arose between them and 
the initial studies carried out on the comparative models of the human isoform. The crystal 
structure 4XP9 complexed with D-amphetamine187, was selected as a representative from the 
4X series as this structure had the best resolution. The crystal structure was prepared for docking 
as described previously, and the Iversen dataset was docked into the crystal structure. 
Preliminary dockings studies indicated that these crystal structures improved the Spearman’s 
correlation coefficient for DAT (0.38 to 0.42, significant at 90%) and SERT (0.30 to 0.48) showing 
that the results for SERT are now significant at a 95% confidence interval. 
A newer homology model for NET (February, 2018) has also been released based on the dDAT 
crystal structure 4XPA213. Protein structure validation of this model indicates that it is of a high 
enough quality to be used in future docking studies, but this experiment was not conducted as 
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part of this study due to time constraints. The new homology model may provide results that 
have a better correlation with the biological data available. 
3.3.10 5I75 human serotonin transporter crystal structure 
In April 2016 the human serotonin transporter structure at 3.15 Å resolution was elucidated by 
X-ray crystallography by Coleman et al180. This structure was subjected to the same protein 
validation methods as the homology models. As expected, given this is a refined experimental 
structure, the crystal structure had little to no structural issues (see Table 3.1). However, when 
a docking study using the crystal structure was carried out, and compared to the results achieved 
with docking to the SERT homology model, there was no significant increase in correlation 
between relative rankings of computational and experimental data for the crystal structure 
compared to the homology model. Figure 3.11 shows a high level of conservation of the helices 
and a protein backbone RMSD value of 2.65 Å between the crystal structure and the homology 
model which is an acceptable value for the homology model to be used in docking studies214. 
However, this value is slightly higher than would be anticipated given the conserved nature of 
the secondary structural elements, and its magnitude is due to the variation in the orientation 
of the extracellular loops between the homology model and the crystal structure. 
 
Figure 3. 10:  The superimposed alignment of the SERT homology model (P31645, magenta) with 
the MOE putative binding site in red and the overlaid human SERT crystal structure (PDB 
Accession code: 5I75, cyan) with the binding site in blue. Backbone RMSD between model and 
crystal structure is 2.65 Å. 
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Figure 3.11 below shows the difference in the position of a docked molecule (fluoxetine) in the 
SERT homology model and the position of the co-crystallised molecule (citalopram) in the SERT 
crystal structure (PDB Accession Code 5I75). The crystal structure complex is shown in greater 
detail in Figure 3.12 and may provide additional information over the homology model/docking 
structures regarding where a known SERT selective197,215 ligand is likely to bind.  
 
 
Figure 3. 11: Overlaid images of: the binding site of the SERT homology model (green) with the 
highest ranked docked conformation of fluoxetine (black ball and stick) and the binding site of 
the x-ray crystal structure of human SERT (5I75, magenta) with the docked conformation of 
fluoxetine (cyan ball and stick ligand) in 5I75. The difference in bound position of fluoxetine in 
comparison to citalopram may be a result of the docking algorithm used in MOE. 
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Figure 3. 12: A) is the binding site (magenta) of 5I75 with the co-crystallised ligand, citalopram 
(black ball and stick figure). B) PLIF image of the bound citalopram in 5I75. Protein-ligand 
interactions are illustrated with green dotted lines to show interactions between side chains of 
residues and blue dotted lines to show interactions between the ligand and the protein 
backbone. 
In Figure 3.12 it can be seen that citalopram is bound at the bottom of the cavity. 5I75 has a 
narrower entrance to the lower section of the binding site (approximately 6 Å in diameter) in 
comparison to the SERT homology model (9.6 Å at the narrowest point and 13.6 Å at the widest 
point). The difference is shape of binding site could explain the increase in significant Spearman 
ranking results for the experiments carried out on the crystal structures when compared to the 
experiments carried out with the homology models. The initial SERT homology model docking 
experiments had a ρ value of 0.30 which is not significant at 90%. However, when the Iversen 
dataset was re-docked into 5I75, the crystal structure experiments obtained a ρ value of 0.48 
which is significant at 95%. This may be due to the fact that the narrow binding site entrance in 
the crystal structure provided a steric “block” against docked conformations less representative 
of what is expected in vivo i.e. by restricting the molecules to the bottom of the binding site. 
Figure 3.13: shows the overlaid binding site for 5I75 and the SERT homology model. With the 
exception of Asp98 there appears to be variation in position of side chain between model and 
crystal structure. The differences in residue orientation is quite likely the cause of an altered size 
and shape of binding site and ultimately account for the differences in docking data obtained. 
A B 
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Figure 3. 13: the overlaid binding site for the SERT homology model (residues in orange) and the 
SERT crystal structure 5I75 (residues in purple), the residues highlighted include Asp98, Tyr98, 
Tyr175, Ser336, I172, Ala96, and Phe335 with the complexed ligand Citalopram indicated with 
the black stick model. 
The binding site residues for the SERT homology model and the SERT 5I75 crystal structure are 
not aligned which indicates a shift in protein backbone, and a concomitant alteration in the 
shape of the binding cavity. This is illustrated in Figure 3.13. The carboxylate group on the Asp98 
residue differs in orientation with a maximum distance between oxygen atoms between model 
and experimental structures of 1.45 Å and the β carbons of the Ile172 residues are separated by 
a distance of 1.12 Å. The phenol ring of the Tyr95 is also not aligned between model and crystal 
structure with a maximum distance of 2.11 Å between the atoms of this residue. These 
conformational differences between binding site residues could explain why different results 
were obtained from the docking study using the crystal structure and the homology model. 
3.3.11 Investigating the Emergent DAT Crystal Structures 
Using one of the newer dDAT crystal structures (the dDAT 4XP9 crystal structure at 2.8 Å bound 
to D-amphetamine179 published in May 2015) a further “re-docking” study was carried out in 
attempt to improve ρ values for DAT, with the intention of gaining further insight into what 
differences there are between the MATs which could explain selectivity.,  
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When this crystal structure was used to dock the ligands from the Iversen paper the ρ values did 
improve (from 0.38 to 0.42), but this is not a significant difference to the results obtained 
previously. This is not surprising given that the superimposition between 4XP9 and the 4M48-
derived homology models (Figure 3.14) shows that the experimental structure and the 
homology model are very similar. 
 
 
Figure 3. 14: the superimposed alignment of the DAT homology model (based on the template 
4M48, green) and crystal structure 4XP9 (bronze). A protein backbone RMSD value of 0.729Å 
was calculated in MOE. 
The docked D-amphetamine ligand (Figure 3.15) has a conformation very similar to the 
complexed D-amphetamine ligand that was present in the structure 4XP9. The similarities 
between the experimental ligand position and the docked conformation gives confidence that 
the docking algorithm used in MOE is able to reproduce very likely protein ligand interactions, 
and that the homology model is an appropriate surrogate for the dDAT crystal structures in the 
docking experiments. 
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Figure 3.15: The overlaid binding sites of the DAT homology model (green) and the dDAT crystal 
structure 4XP9 (red). The black ball and stick figure is D-amphetamine docked into the homology 
model and the white ball and stick figure circled in black is the complexed D-amphetamine found 
in 4XP9. 
3.3.12 Investigating the Emergent NET models 
A preliminary docking study was carried out using the newly published NET homology model 
which is based on the template 4XP4179 a dDAT transporter in complex with cocaine. The 
putative binding site of the new homology model was larger in volume (174 Å3) in comparison 
to the original homology model (which had a binding site volume of 87 Å3 see Figure 3.16). Using 
the 4XP4A-based NET model a ρ value of 0.21 was obtained for the docking of the 21 ligands.  
Similar to the previous studies, a composite binding site was created for NET which combined 
the two largest cavities identified by MOE was carried out. The composite binding site had a site 
volume of 341 Å3, and the docking study carried out using this active site returned a ρ value of 
0.24. This is only slighter higher than the smaller 4XP4A-NET binding site and not significant at 
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90% confidence. When analysing the docked conformations of the ligands in the composite 
binding site it was noted that docked ligands were consistently placed in the bottom of the 
cavity, an area that was also available in the first iteration of the experiment. As such, the small 
difference between the two experiments is not unexpected. 
 
Figure 3. 16: the overlaid putative binding sites elucidated in MOE, the original homology models 
binding site is shown in white and the NET homology model based on 4XP4A binding site is 
shown in dark grey. 
3.4 Discussion 
3.4.1 Homology models 
The homology models available were able to produce valid docked conformational poses for the 
ligands based on the literature available regarding the native ligands (DA, NA and SER). However, 
as the models were very similar in topology and sequence this may have limited how structurally 
different the binding sites are, and hence how able docking experiments would be to 
discriminate between NPS binding. Sequence identify and similarity amongst all three models at 
the binding site were analysed, (Figure 3.17). The lack of variation in amino acid composition 
between the binding sites is evident, and this may have reduced the ability to identify selectivity 
amongst the MAT via docking studies.  
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Figure 3. 17: Alignment of amino acid sequences for the homology models DAT, NET and SERT. 
The highly conserved aspartate residue is highlighted by the black box. The residues highlighted 
in green show that all three models have identical residues at this position between the aligned 
sequences and the areas highlighted in red show that one or more of the residues are not 
identical. 
The residue alignment in Figure 3.17 show that there is a high level of sequence identity amongst 
the residues that are in close proximity to the conserved aspartate residues and therefore the 
binding site compositions are similar. Analysis of the binding site residues show that although 
they are not identical many of the residues are similar e.g. the three closest highlighted red 
columns to the conserved aspartate (in Figure 3.17) show a mixture of similar hydrophobic 
residues (G, A, Y, F, I and V) proving binding site similarity. Figure 3.18 shows the binding site 
residues that are conserved amongst all three MAT and are implicated in the formation of 
protein ligand interactions. There appears to be no conformational differences of the side 
chains, highlighting the structural similarity of binding sites for DAT, NET and SERT. 
 
Figure 3. 18: The overlaid binding site for DAT, NET and SERT, the conserved aspartate (dark 
blue), phenylalanine (grey), tyrosine (red), alanine (magenta), serine (cyan and orange), valine 
(green), leucine (purple) and asparagine (yellow) residues have been highlighted to show there 
are little differences in side chain orientation of the residues known to be important for protein-
ligand interactions in the MAT homology models. 
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3.4.2 Docking  
All of the models produced docked conformational poses that formed protein ligand interactions 
with residues that were known to be important, and were later confirmed as such by the 
publication of x-ray crystal structures. For the majority of results obtained for DAT, it is evident 
that the residue Asp79 forms an important role in protein-ligand interactions. This highly 
conserved aspartate in DAT, NET and SERT forms an interaction between the protonated amine 
of the biogenic amines. From a model alignment it is clear that the three aspartate residues are 
equivalent see figure 3.19. 
 
Figure 3. 19: shows the aspartate residue Asp79 in the homology models; DAT (white), Asp75 in 
NET (magenta) and Asp98 in SERT (yellow) overlaid. This image shows that this particular residue 
is highly conserved in all three MAT. The three MAT models have been aligned and 
superimposed, with DAT being coloured yellow, NET being coloured red and SERT being 
coloured red. 
The results obtained from the docking study in both MOE and GOLD showed that both 
computational algorithms were able to dock the ligands and form protein ligand interactions 
with all of the residues highlighted in Tables 3.3-3.5. This indicates that the models used were 
of a high enough standard this gives confidence that they can be used to provide valid results. 
The models used were all structurally valid as demonstrated by the protein validation methods, 
all of the binding site amino acid residues were structurally sound and did not violate any of the 
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validation tests. Newer published crystal structures show an improvement in structural quality 
and as future work these structures should be used for carrying out further docking studies. 
3.5 Conclusion 
The aim of this study was to see if the homology models available for DAT, NET and SERT were 
of a suitable structural quality, which would allow for molecular docking studies to be conducted 
in order to provide information that corresponded to the literature.  
The homology models were found to be structurally acceptable based on the data obtained from 
the protein structure validations tests carried out. The binding site application in MOE was able 
to identify valid binding site cavities that corresponded to literature findings based on studies 
conducted on MAT, using both homology models and experimental data. Residues that had 
been reported in the literature as playing an integral role in the recognition of MAT inhibitors 
were found to be in the binding sites the software had elucidated. Using the homology models, 
differences regarding the binding sites for the MAT were observed. The selected binding site for 
NET had a much smaller binding cavity in comparison to DAT and SERT, therefore to see if an 
increase in cavity size would improve correlation a composite binding site was created. The 
composite binding site for NET was created by combining the initial binding site with a second 
site that had been elucidated in MOE. The second site sat directly on top of the initial site 
however when the volume of NETs binding site was increased it did not significantly improve 
correlation between the ranked datasets (ρ value increased from 0.21 – 0.24).  
There doesn’t appear to be an obvious explanation as to why the NET homology model and 
ranked docked data achieved such low ρ values despite a number of measures taken to try and 
optimise the binding site and docking parameters. More information regarding the NET binding 
site and the mechanism in which a protein ligand interaction is formed is required.  
Table 3.14 shows that the consensus of scoring functions improved the ρ values for DAT and 
SERT but there was no improvement with the NET ρ values. This indicates that there are issues 
with the NET homology model being able to produce ranked docking conformations that are in 
agreement with experimentally derived data. Inspection of the biological data will be conducted 
in the next chapter to see if there are any associated issues that could cause erroneous results. 
The overall amino acid sequence for all the MAT homology models was over 50% identical, this 
indicate that that the models may be too similar to one another to and therefore information 
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regarding selectivity cannot be extrapolated. When focussing on the binding sites of each of the 
MAT homology models there is a percentage identity of 75%, this reinforces the idea that the 
high similarity of the models limits how well selective docking data can be obtained. 
This study was a structure-based approach to start the investigation into identifying a novel NPS. 
The homology models used for DAT and SERT were able to produce statistically significant 
correlation between experimentally derived data and the docking study results, but did not 
provide insight into the reasons for the differences in affinity for molecules between the 
isoforms. The DAT, NET and SERT homology models were found to be of a high enough quality 
to be used for docking studies, however the NET homology model did not produce docked data 
that correlated significantly to the literature values. Due to limited information being obtained 
from the MAT the next step will be to employ a ligand-based approach to investigate selectivity 
between the isoforms. Identifying physicochemical properties for chemical structures that are 
selective for one MAT over another may provide more information to help the design of a novel 
NPS.  
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Chapter 4 
Development of Quantitative Structure Activity Relationship 
Models to Identify Key Physicochemical Properties Required for 
Selectivity between DAT, NET and SERT 
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4.1 Introduction  
This Chapter focuses on a ligand-based approach to identify key differences between 
compounds that will convey selectivity for one monoamine transporters (MAT) over another. At 
the time of the study, there were no experimental structures available for any of the human 
MAT isoforms, so employing a ligand-based approach removed the need for high resolution 
crystal structures. From Chapter 3, it was highlighted that limited information regarding 
selectivity was gathered from a structure-based approach, so using a ligand-based approach has 
been employed as a complimentary technique. 
Ligand-based approaches can be used to analyse a database of compounds, identify key 
physicochemical properties and generate a predictive model of potential biological activity216,217. 
In particular, Quantitative Structure Activity Relationship (QSAR) modelling is a method widely 
employed in research and industry to achieve this117. This approach relates chemical structure, 
and calculated physicochemical properties to experimentally observed biological activity using 
mathematical regression models which can then be applied to a virtual library of compounds in 
an effort to identify novel compounds with potential to bind to the receptor of interest117. 
As previously discussed in Chapter 3, there is a large degree of promiscuity with respect to new 
psychoactive substances (NPS) and their binding to the human MAT isoforms. Compounds that 
bind to the MATs will, in general, preferentially bind to one of the isoforms (either DAT, NET or 
SERT), but will also demonstrate affinities with the other two MAT isoforms. This chapter will 
focus on a ligand-based approach to building QSAR models to identify which physicochemical 
properties, if any, a molecule requires for it to preferentially bind to one MAT isoform over 
another. 
4.2 Methods 
4.2.1 Data set preparation 
Two independent datasets35,218 were identified from the literature and combined to construct 
the dataset for the following studies35,181. In total, 31 compounds (Table 4.1) representing a 
range of different classes of NPS, and other psychoactive compounds, with experimental 
biological activity measurements for each of the monoamine transporters DAT, NET and SERT 
were used in the development of the QSAR models.  
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The compounds in the dataset were “washed” using the wash compound application in 
Molecular Operating Environment (MOE) at physiological pH (pH 7.0) in order to identify likely 
physiological protonation. The classification system presented in Table 4.1 was adapted from 
the EMCDDA classification219, and known narcotics in the dataset that fell outside of the 
EMCDDA classification were classed as “others”. 
Table 4. 1: The name, experimentally determined pKi values218 for each MAT isoform, chemical 
structure and classification of the psychoactive compounds used in the in Silico studies on DAT, 
NET and SERT. 
Compound 
    pKi 
     DAT       NET       SERT 
 
Structure Classification 
 
1. Mephedrone 
6.08 5.88 4.99 
 
Cathinone 
 
2. Methiopropamine 
6.05 6.09 4.14 
 
 
 
Phenethylamine 
 
 
 
3. Methylenedioxy-N-
benzylcathinone 
(MNB-cathinone) 
 
 
6.01 5.37 4.56 
 
Cathinone 
 
4. 5-APB 
(1-(benzofuran-5-
yl)propan-2-amine) 
 
 
 
6.30 6.33 5.78 
 
 
 
 
Phenethylamine 
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Compound DAT 
pKi 
NET 
 
SERT Structure Classification 
 
5. 6-APB 
(1-(benzofuran-6-
yl)propan-2-amine) 
6.63 6.52 5.26 
 
Phenethylamine 
 
6. Desoxypipradrol 
7.30 6.26 4.27 
 
Piperidines & 
Pyrrolidines 
 
7. 5-Iodo-2-
aminoindane (5-IAI) 
5.61 6.09 5.75 
 
Aminoindane 
 
8. Benzedrone 
5.64 5.50 4.75 
 
Cathinone 
 
9. Dimethylamylamine 
4.74 5.77 3.75 
 
 
Others 
 
10. Methylenedioxy-
Aminoindane (MDAI) 
5.12 5.78 4.93 
 
Aminoindane 
 
11. Methylenedioxy-
Aminotetralin (MDAT) 
5.20 5.64 5.65 
 
Phenethylamine 
 
12. Naphyrone 
7.28 6.70 6.63 
 
Cathinone 
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Compound DAT 
pKi 
NET 
 
SERT Structure Classification 
 
13. 1-Naphyrone 
7.32 6.27 6.45 
 
Cathinone 
 
14. 
Methylethcathinone 
6.08 5.36 5.43 
 
Cathinone 
 
15. Amitriptyline 
4.61 7.00 7.83 
 
Others 
 
16. Nomifensine 
6.90 7.07 5.56 
 
Others 
 
17. Cocaine 
6.19 5.20 5.62 
 
Others 
 
18. R-MDMA 
5.21 5.50 5.17 
 
Phenethylamine 
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Compound 
 
DAT 
 
pKi 
NET 
 
SERT 
 
Structure 
 
Classification 
 
19. S-MDMA 
5.62 5.70 5.56 
 
Phenethylamine 
 
20. S-Amphetamine 
6.54 6.20 4.78 
 
Phenethylamine 
 
21. Fluoxetine 
5.04 5.20 6.55 
 
Others 
 
22. RTI-55 
8.49 8.60 9.31 
 
Others 
 
23. WIN 35428 
7.58 7.50 6.90 
 
Others 
 
24. GBR 12935 
7.67 6.65 5.19 
 
Piperazine 
 
25. Bupropion 
5.56 5.86 4.35 
 
Cathinone 
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Compound 
 
DAT 
 
pKi 
NET 
 
SERT 
 
Structure 
 
Classification 
 
26. Nisoxetine 
6.32 8.29 6.42 
 
 
 
Others 
 
27. Desipramine 
4.10 8.40 7.21 
 
 
Others 
 
 
28. Nortriptyline 
4.86 8.47 6.79 
 
Others 
 
29. Mazindol 
7.56 8.49 6.82 
 
 
Others 
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Compound 
 
DAT 
 
pKi 
NET 
 
SERT 
 
Structure 
 
Classification 
30. Imipramine 5.01 7.17 8.11 
 
 
 
 
Others 
 
31. Citalopram 
5.00 6.00 8.27 
 
Others 
 
4.2.2 Identification of a diverse subset 
The NPS dataset (31 compounds) was uploaded into the MOE98 software. Three training sets 
were identified, one for each of the MAT isoforms (DAT, NET and SERT), using FP:MACCS 
structural keys as the diversity metric.  
Each dataset was divided into a diverse training set (80% of the dataset – 25 compounds) and a 
test set (20% of the dataset - 6 compounds), using the diverse subset application in MOE. The 
training sets for each MAT isoform were then used to build and validate QSAR models. As the 
pKi values of individual compounds varied between DAT, NET and SERT this resulted in the 
training and test sets for each of the isoforms being comprised of different compounds. 
A second method for identification of diverse subsets to create training and test sets for each of 
the MAT isoforms was also used for comparative purposes. This time, the training sets were 
compiled by looking at Tanimoto coefficients (Tc)220 across the dataset as a whole. This approach 
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was used to ensure that the training and test sets each contained compounds that represented 
the whole range of structural diversity of the dataset, as demonstrated by their Tc values. 
To this end, a similarity coefficient matrix based on structural similarity of the entire dataset, 
was produced using the open access software OpenBabel221 which calculates pairwise Tc 
between compounds. The average Tc for an individual molecule was then calculated based on 
the pairwise values obtained for all compounds in the dataset. Any compounds which were 
shown to have an average Tc of less than 0.2 were deemed significantly different from the 
remainder of the dataset, and were removed from the study. 
Having calculated average Tc values for each of the compounds, the molecules in the dataset 
were then placed into 1 log unit “bins” according to their experimental pKi value range (i.e. 4-5, 
5-6, 6-7 etc.). For each bin, the molecules that had the highest and lowest pKi values in the bin 
were placed in the training set. The remaining compounds in the bin were then analysed and 
selected for either the test or training set based on their Tc scores i.e. molecules that had the 
highest average Tc value, and hence were most like other molecules in the dataset, were placed 
in the test set. It is important that the training and test sets both represent the dataset as a 
whole in order to be able to generate and appropriately evaluate QSAR models222. 
As before, 80% of the compounds were placed in the training set, and 20% of the compounds 
were placed in the test set. The distribution of the Tc and pKi values were examined to ensure 
that the training and test sets were selected to mirror the dataset as a whole. The training and 
test sets that resulted for each of the MAT isoforms were evaluated for normality using the 
Shapiro-Wilks test223. 
4.2.3 Descriptor Selection for QSAR Models 
A molecular database (MDB) for each of the MAT isoforms was curated in MOE. This MDB file 
contained only the training set compounds identified for a specific MAT isoform and the 
biological data pertaining to that MAT isoform. A total of 435 molecular descriptors (see 
Appendix A) were calculated for each molecule using the descriptor calculator application in 
MOE. The descriptor values were scaled relative to their maximum reported values to obtain 
values ranging between -1 and 1 for all descriptors and were then correlated to the pKi values 
of the compounds i.e. a correlation matrix was produced.  
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Correlation coefficients between pKi and descriptor values that were above 0.7 (positively 
correlated) or below -0.7 (negatively correlated) were identified. The molecular descriptors 
were ranked (in descending order) in terms of absolute r2 values. The top 20% of the descriptors 
were then used as the initial set of descriptors in the construction of the QSAR models. Using 
the correlation matrix, these descriptors were systematically checked for cross-correlation 
against other descriptors in the list. If one descriptor correlated to another descriptor with a 
correlation coefficient above 0.7 or below -0.7 then the descriptor shown to correlate least with 
biological activity was removed from the list. This was to avoid over-representation of any single 
type of physicochemical property in the final QSAR models. 
4.2.4 Building and evaluating QSAR models 
QSAR models were built for each MAT isoform using both the estimated linear model (ELM) 
protocol and the Estimated Normalized Linear Model (ENLM) protocols of the QuaSAR module 
in MOE. A correlation coefficient (r2 value) and a cross-validated correlation coefficient (q2 value) 
were generated and used as measures of the initial model quality.  From these initial models, 
the molecular descriptor shown to be contributing least to explaining the variance in the data 
was removed and a new QSAR model was generated using the remaining descriptors. This 
descriptor removal process was carried out iteratively until the r2 and q2 values were in close 
proximity to one another, and the model had the highest r2 values possible using the least 
number of molecular descriptors. The resultant best model for each MAT isoform was then used 
to predict the biological activity of the compounds in the corresponding test set. The correlation 
between the biological activity and predicted activity of the test set compounds (r2) was used to 
evaluate the predictive ability of each of the models. The extreme studentized deviate test224 
was employed for outlier detection, this was applied to the test set predicted pKi values 
obtained for the optimised DAT, NET and SERT QSAR models. 
4.3 Results and Discussion  
4.3.1 Identification of the diverse subset 
Figure 4.1 shows the distribution of molecules in the FP:MACCS and Tanimoto trainings sets, 
with reference to the experimentally derived pKi, and the distribution of the activity of the 
molecules across the dataset as a whole. When comparing the distributions, it can be seen that 
the Tanimoto training set is a better representation of the distribution of molecules across the 
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dataset as a whole than the FP:MACCS-derived training set. Specifically, this is because the 
distribution of molecules in the most heavily populated area of the dataset (between pKi 5 – 7) 
for the Tanimoto-derived training set mirrors the general trend across the dataset as a whole, 
which is not the case for the FPMACCS-derived training set, which places a disproportionately 
greater number of compounds from the pKi 5-6 range into the training set, when compared with 
the dataset as a whole. 
  
Figure 4. 1: The distribution of all compounds classified by pKi value for all compounds in the 
dataset (blue), the compounds in the Tanimoto training set (orange) and the compounds in the 
FP:MACCS training set (grey). 
Both training sets identified (FP:MACCS and Tc) were used to construct QSPR models for the DAT 
isoform. As the training sets were different, the test sets used to assess the predictive ability of 
the models produced were also different. The composition of the two different test sets is given 
in Table 4.2.  
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Table 4. 2: A, The FP:MACCS DAT test set compounds, associated pKi values and average pairwise 
Tc. B, the Tanimoto DAT test set compounds, associated pKi values and average pairwise Tc. 
A  FP:MACCS 
derived test set 
pKi value Average 
pairwise 
Tc 
B Tanimoto 
derived test set 
pKi value Average 
pairwise 
Tc 
Mazindol 7.56 0.21  Mazindol 7.56 0.21  
Mephedrone 6.08 0.42 Mephedrone 6.08 0.42 
MDAI 5.12 0.35 MDAI 5.12 0.35 
Nortriptyline 4.87 0.33 Nortriptyline 4.87 0.33 
Dimethylamylamine 4.74 0.17 6-APB 6.54 0.31 
Cocaine 6.19 0.27 1-Naphyrone 7.28 0.42 
 
Given the overlap between the test set molecules, it was expected at this stage that the 
methodologies for generating the QSAR equations would be broadly equivalent, and as such it 
would be expected that models of similar robustness and predictive ability would be produced, 
regardless of the training and test set used to build and validated them. 
4.3.1.2 Initial QSAR Model for DAT – FPMACCS Derived training set 
Initial QSAR models (see Equations 4.1) for DAT were built and validated using the FP:MACCS 
training/test set and their predictivity and robustness interrogated (Table 4.2). 
 
5-descriptor model for DAT (FP:MACCS training set) 
pKi / SD (pKi) =  11.4844 -0.36724 * E_sol / SD(E_sol) -0.33315 * npr2 / SD (npr2) +0.19984 * 
PEOE_VSA-0 / SD(PEOE_VSA-0) -0.19889 * SlogP_VSA5 / SD(SlogP_VSA5) -0.30776 * vsurf_HB1 
/ SD (vsurf_HB1) 
4-descriptor model for DAT (FP:MACCS training set) 
pKi / SD (pKi) = 11.6867 -0.34777 * E_sol / SD(E_sol)-0.32113 * npr2 / SD (npr2)-0.41605 * 
SlogP_VSA5 / SD(SlogP_VSA5)-0.21456 * vsurf_HB1 / SD (vsurf_HB1) 
3-descriptor model for DAT (FP:MACCS training set) 
pKi / SD (pKi) = 11.2047 -0.44253 * E_sol / SD(E_sol)-0.35306 * npr2 / SD (npr2)-0.39015 * 
SlogP_VSA5 / SD(SlogP_VSA5) 
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Equations 4.1: 5, 4 and 3-descriptor QSAR estimated normalized linear models built using the 
DAT training set derived using the FP:MACCS structural keys in conjunction with the MOE diverse 
subset tool. 
To evaluate how well the models predicted the activity of unseen compounds the MACCS-
derived DAT QSAR models were applied to the test set (as shown in Table 4.2). The correlation 
between predicted pKi and the experimental pKi was obtained, and used as a measure of the 
predictivity of the models. The robustness of the models was assessed by comparing the r2 and 
q2 values obtained from training the model. The results of this investigation are given in Table 
4.3. 
Table 4. 3: Summary of the r2 and q2 values for the three best-performing different estimated 
normalized linear QSAR models (Equations 4.1) developed for DAT using a training set identified 
via the diverse subset application in MOE. 
Model FP:MACCS training set  FP:MACCS test set 
   r2 q2 r2 
5 - descriptor 0.73 0.52 0.19 
4 - descriptor 0.70 0.54 0.21 
3 - descriptor 0.65 0.50 0.22 
 
The FP:MACCS derived 5-descriptor model had the highest r2 value and a relatively high q2 value 
for the training set, which indicated that the model fitted the training set data well and appeared 
to be robust. However, when the model was applied to the FPMACCS-DAT test set an r2 value of 
0.19 was obtained, which indicates poor predictive ability.  The 3 and 4-descriptor models 
produced comparable r2 and q2 values (Table 4.3) to the 5-descriptor model. As a rule of thumb, 
models with fewer descriptors tend to be more generalizable117. As such, these models were 
also applied to the FPMACCS-DAT test set to see if a model with fewer descriptors would have 
better predictive ability. Marginal, but not significant, increases were observed with test set r2 
values of no greater than 0.22 obtained. This indicated that all three FPMACCS-derived models 
were not predictive and suggests that the model could be over-fitted.  
Over-fitting is a phenomenon whereby a model is able to predict, to an acceptable level, the 
activities of the compounds found in its training set, but is unable to mirror this predictivity when 
applied to an unseen test set of molecules i.e. it is not generalizable. Often this is the result of a 
physicochemical property being over represented and/or the model including more descriptors 
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than is necessary225, but given that care has been taken to remove cross-correlated descriptors, 
and the fact that the maximum number of descriptors examined in this study is five (giving a 
maximum ratio of five records to each descriptor) these reasons for poor model performance 
are unlikely. 
Over-fitting can also be a consequence of constructing the initial model using an inappropriate 
or unrepresentative training and/or test sets, which seems the most likely scenario for this 
experiment. If we examine the test set, it is noticeable that two of the compounds (nortriptyline 
and Dimethylamylamine) come from the molecules demonstrating a pKi between 4 and 5, the 
lowest end of the experimental activity range. Previous studies222 have shown that QSAR models 
can be sensitive to experimental data at the extremes of the data range, and having a test set 
containing two molecules which appear at the lowest end of the activity range could be one of 
the reasons that the model does not appear to be generalisable. 
It is also unreasonable to expect a descriptor-based QSAR model to be able to accurately predict 
the activity of a molecule that has a significantly different in terms of its chemical structure when 
compared to the molecules in the training set used to derive the QSAR model. Experiments 
showed that dimethylamylamine had an average pairwise Tanimoto similarity, when compared 
to all other molecules in the dataset of 0.17. That means, this molecule was significantly 
structurally different to every other molecule in the dataset, and hence expecting a model to be 
able to accurately predict the activity of such a disparate molecule is unreasonable.  
To test the impact of inclusion of this structure on the perceived predictive ability of the 
FPMACCS-derived DAT model, it was removed from the test set. The r2 value for the DAT test 
set (for the 3-descriptor model) increased from 0.22 to 0.63. This highlights the importance of 
the construction of appropriate test and training sets during QSAR construction and validation, 
and highlights the potential limitations of automated tools for generating diverse test and 
training sets, especially where the size of the dataset is limited. 
Although such post hoc rationalisation of results is able to explain the poor performance of a 
QSAR test set, it is of interest to identify a methodology for determining a training and test set 
which would ideally eliminate the need to carry out such analyses. As such, an alternative 
method for identifying representative training and test sets for constructing the QSAR models 
was investigated based on calculating the pairwise similarity coefficients of molecules and using 
these, alongside the known biological activity of the molecules, to manually assign test and 
training sets for the MAT isoforms. 
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4.4.1 Similarity Coefficients 
Having identified dimethylamylamine as being structurally unrelated to the other compounds in 
the NPS dataset used to construct the QSAR models, average pairwise Tanimoto coefficients 
were calculated to establish if any other compounds were distinctly dissimilar to the rest of the 
molecules in the dataset, as this had already demonstrated the potential to impact on the 
apparent quality of any models developed.  
For example, if a structurally dissimilar compound was placed in the test set without having its 
chemistry represented in the training set, it would be impossible for any model generated to 
accurately predict the activity of this dissimilar compound (any predicted values would be 
artefactual) and hence this could give an inaccurate representation of the quality of the model, 
as was the case for the FP:MACCS-derived model (Section 4.3.1.2). As such, compounds that are 
distinctly dissimilar from all others should be removed from the dataset prior to test and training 
sets being defined and models being constructed. For the purposes of this experiment an 
average Tc value of less than 0.2 was the threshold for a molecule to be considered significantly 
dissimilar to the others in the dataset. 
Only one compound in the dataset had an average Tc value of less than 0.2. Dimethylamylamine 
had the lowest average similarity coefficient of 0.17 (± 0.15) (see Figure 4.2 for all Tc data). It 
was removed from the dataset prior to the construction of the models based on the Tc-derived 
training sets and test sets.
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Figure 4. 2: Correlation matrix of the pairwise similarity coefficients for the 31 compounds in the dataset (see table 4.1 for compound ID). The more 
similar a compound is to another, the higher the value of the coefficient.  All pairwise values less than 0.20 were highlighted in red to give a visual 
representation of which compounds are most dissimilar to others in the dataset, and the final column of the correlation matrix is the average value of 
similarity coefficients for a compound in relation to the dataset as a whole. Compound 9 (Dimethylamylamine) has a much lower average Tc (0.17) in 
comparison to the rest of the dataset which indicates this molecule is structurally dissimilar to the rest of the dataset and should not be used to construct 
and validate models 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Average
1 1 0.36 0.40 0.42 0.40 0.49 0.42 0.74 0.19 0.29 0.27 0.66 0.66 0.91 0.28 0.29 0.28 0.37 0.37 0.63 0.33 0.30 0.31 0.33 0.71 0.35 0.28 0.28 0.19 0.28 0.26 0.42
2 0.36 1 0.21 0.27 0.25 0.32 0.27 0.29 0.16 0.21 0.19 0.31 0.31 0.34 0.20 0.19 0.15 0.27 0.27 0.36 0.21 0.20 0.20 0.21 0.32 0.22 0.20 0.20 0.11 0.20 0.16 0.26
3 0.40 0.21 1 0.23 0.22 0.30 0.28 0.56 0.09 0.64 0.59 0.40 0.40 0.44 0.18 0.30 0.21 0.74 0.74 0.28 0.33 0.24 0.24 0.23 0.42 0.33 0.32 0.18 0.22 0.19 0.20 0.36
4 0.42 0.27 0.23 1 0.82 0.38 0.39 0.34 0.11 0.29 0.27 0.36 0.36 0.40 0.23 0.22 0.15 0.29 0.29 0.56 0.26 0.22 0.22 0.26 0.37 0.27 0.25 0.23 0.13 0.25 0.20 0.32
5 0.40 0.25 0.22 0.80 1 0.36 0.37 0.33 0.10 0.28 0.26 0.34 0.34 0.38 0.22 0.21 0.15 0.28 0.28 0.52 0.24 0.21 0.21 0.25 0.35 0.26 0.24 0.22 0.13 0.24 0.19 0.31
6 0.49 0.32 0.30 0.38 0.36 1 0.44 0.45 0.25 0.34 0.35 0.65 0.65 0.53 0.35 0.42 0.31 0.37 0.37 0.53 0.33 0.44 0.45 0.43 0.47 0.34 0.25 0.35 0.21 0.25 0.33 0.41
7 0.42 0.27 0.28 0.39 0.37 0.44 1 0.35 0.14 0.46 0.36 0.40 0.40 0.40 0.28 0.29 0.18 0.36 0.36 0.53 0.29 0.37 0.29 0.28 0.37 0.30 0.24 0.28 0.16 0.24 0.29 0.35
8 0.74 0.29 0.56 0.34 0.33 0.45 0.35 1 0.14 0.28 0.25 0.61 0.61 0.81 0.24 0.42 0.27 0.34 0.34 0.47 0.31 0.29 0.29 0.31 0.68 0.31 0.24 0.24 0.27 0.24 0.23 0.39
9 0.19 0.16 0.09 0.11 0.10 0.25 0.14 0.14 1 0.08 0.09 0.20 0.20 0.17 0.11 0.12 0.16 0.12 0.12 0.17 0.15 0.16 0.17 0.15 0.15 0.16 0.12 0.11 0.07 0.12 0.14 0.17
10 0.29 0.21 0.64 0.29 0.28 0.34 0.46 0.28 0.08 1 0.81 0.31 0.31 0.31 0.20 0.23 0.16 0.84 0.84 0.36 0.34 0.25 0.26 0.24 0.28 0.35 0.21 0.20 0.14 0.21 0.25 0.35
11 0.27 0.19 0.59 0.27 0.26 0.35 0.36 0.25 0.09 0.81 1 0.32 0.32 0.28 0.21 0.22 0.19 0.75 0.75 0.32 0.37 0.29 0.29 0.27 0.26 0.39 0.21 0.21 0.14 0.21 0.27 0.35
12 0.66 0.31 0.40 0.36 0.34 0.65 0.40 0.61 0.20 0.31 0.32 1 1.00 0.72 0.26 0.31 0.36 0.34 0.34 0.47 0.31 0.44 0.45 0.34 0.65 0.32 0.24 0.27 0.21 0.24 0.27 0.42
13 0.66 0.31 0.40 0.36 0.34 0.65 0.40 0.61 0.20 0.31 0.32 1.00 1 0.72 0.26 0.31 0.36 0.34 0.34 0.47 0.31 0.44 0.45 0.34 0.65 0.32 0.24 0.27 0.21 0.24 0.27 0.42
14 0.91 0.34 0.44 0.40 0.38 0.53 0.40 0.81 0.17 0.31 0.28 0.72 0.72 1 0.27 0.32 0.30 0.39 0.39 0.57 0.33 0.32 0.32 0.35 0.78 0.35 0.26 0.27 0.21 0.26 0.25 0.43
15 0.28 0.20 0.18 0.23 0.22 0.35 0.28 0.24 0.11 0.20 0.21 0.27 0.27 0.27 1 0.26 0.16 0.22 0.22 0.29 0.25 0.25 0.23 0.26 0.26 0.25 0.26 1.00 0.19 0.26 0.28 0.29
16 0.29 0.19 0.30 0.22 0.21 0.42 0.29 0.42 0.12 0.23 0.22 0.31 0.31 0.32 0.26 1 0.18 0.24 0.24 0.28 0.23 0.22 0.23 0.26 0.29 0.21 0.26 0.26 0.31 0.26 0.25 0.28
17 0.28 0.15 0.21 0.15 0.15 0.31 0.18 0.27 0.16 0.16 0.19 0.36 0.36 0.30 0.16 0.18 1 0.19 0.19 0.18 0.34 0.56 0.57 0.34 0.26 0.35 0.16 0.16 0.17 0.16 0.34 0.27
18 0.37 0.27 0.74 0.29 0.28 0.37 0.36 0.34 0.12 0.84 0.75 0.34 0.34 0.39 0.22 0.24 0.19 1 1.00 0.38 0.40 0.26 0.26 0.28 0.35 0.41 0.23 0.22 0.15 0.23 0.24 0.38
19 0.37 0.27 0.74 0.29 0.28 0.37 0.36 0.34 0.12 0.84 0.75 0.34 0.34 0.39 0.22 0.24 0.19 1.00 1 0.38 0.40 0.26 0.26 0.28 0.35 0.41 0.23 0.22 0.15 0.23 0.24 0.38
20 0.63 0.36 0.28 0.56 0.52 0.53 0.53 0.47 0.17 0.36 0.32 0.47 0.47 0.57 0.29 0.28 0.18 3.80 3.80 1 0.33 0.27 0.28 0.33 0.48 0.35 0.28 0.29 0.15 0.28 0.24 0.61
21 0.33 0.21 0.33 0.26 0.24 0.33 0.29 0.31 0.15 0.34 0.37 0.31 0.31 0.33 0.25 0.23 0.34 0.40 0.40 0.33 1 0.37 0.38 0.45 0.29 0.84 0.22 0.25 0.21 0.22 0.36 0.34
22 0.30 0.20 0.24 0.22 0.21 0.44 0.37 0.29 0.16 0.25 0.29 0.44 0.44 0.32 0.25 0.22 0.56 0.26 0.26 0.27 0.37 1 0.85 0.32 0.29 0.38 0.23 0.25 0.17 0.23 0.30 0.33
23 0.31 0.20 0.24 0.22 0.21 0.45 0.29 0.29 0.17 0.26 0.29 0.45 0.45 0.32 0.23 0.23 0.57 0.26 0.26 0.28 0.38 0.85 1 0.34 0.30 0.39 0.23 0.23 0.17 0.23 0.36 0.34
24 0.33 0.21 0.23 0.26 0.25 0.43 0.28 0.31 0.15 0.24 0.27 0.34 0.34 0.35 0.26 0.26 0.34 0.28 0.28 0.33 0.45 0.32 0.34 1 0.30 0.47 0.22 0.26 0.25 0.22 0.39 0.32
25 0.71 0.32 0.42 0.26 0.35 0.47 0.37 0.68 0.15 0.28 0.26 0.65 0.65 0.78 0.25 0.28 0.26 0.35 0.35 0.48 0.29 0.29 0.30 0.30 1 0.30 0.24 0.26 0.23 0.24 0.22 0.39
26 0.35 0.22 0.33 0.37 0.26 0.34 0.30 0.31 0.16 0.35 0.39 0.32 0.32 0.35 0.25 0.21 0.35 0.41 0.41 0.35 0.84 0.38 0.39 0.47 0.30 1 0.22 0.25 0.20 0.22 0.38 0.35
27 0.28 0.20 0.19 0.27 0.24 0.25 0.24 0.24 0.12 0.21 0.21 0.24 0.24 0.26 0.26 0.26 0.16 0.23 0.23 0.28 0.22 0.23 0.23 0.22 0.24 0.22 1 0.26 0.15 1.00 0.21 0.28
28 0.28 0.20 0.18 0.25 0.22 0.35 0.28 0.24 0.11 0.20 0.21 0.27 0.27 0.27 1.00 0.26 0.16 0.22 0.22 0.29 0.25 0.25 0.23 0.26 0.26 0.25 0.26 1 0.19 0.26 0.28 0.29
29 0.19 0.11 0.22 0.13 0.13 0.21 0.16 0.27 0.07 0.14 0.14 0.21 0.21 0.21 0.19 0.31 0.17 0.15 0.15 0.15 0.21 0.17 0.17 0.25 0.23 0.20 0.15 0.19 1 0.15 0.23 0.21
30 0.28 0.20 0.19 0.25 0.24 0.25 0.24 0.24 0.12 0.21 0.21 0.24 0.24 0.26 0.26 0.26 0.16 0.23 0.23 0.28 0.22 0.23 0.23 0.22 0.24 0.22 1.00 0.26 0.15 1 0.21 0.28
31 0.26 0.16 0.20 0.20 0.19 0.33 0.29 0.23 0.14 0.26 0.27 0.27 0.27 0.25 0.28 0.25 0.34 0.24 0.24 0.24 0.36 0.30 0.36 0.39 0.22 0.38 0.21 0.28 0.23 0.21 1 0.29
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4.4.2 Diverse Tanimoto Subsets 
The Tanimoto-derived training and test sets for DAT, NET and SERT were identified using the pKi values 
as the discriminant variable. Figure 4.3 shows the distribution of pKi for the molecules for all three 
MAT isoforms, DAT NET and SERT across the dataset as a whole. It should be noted that SERT has the 
largest range of experimental pKi values (7 log units) for the molecules in the NPS dataset. The range 
of experimental pKi values for DAT and NET is smaller (5 log units for both). 
Normal distribution of the experimental values is observed for both DAT and SERT (99% confidence 
using the Shapiro-Wilks test). However, this is not true for NET. When the same statistical test was 
applied to NET, and based on the p value at the 90% confidence limit, it was determined that the 
distribution of NET is not normal (i.e. it is skewed). If data is not normally distributed, the model will 
not be able to accurately predict pKi values that fall outside of the normal distribution range. This 
potentially places inherent limitations on any predictive models developed for the NET isoform, which 
will need to be ameliorated by the careful selection of appropriate test and training sets for this MAT. 
 
Figure 4. 3: The distribution of pKi values, represented in one log unit divisions, across the NPS in the 
dataset as a whole for DAT (blue), NET (orange) and SERT (grey). 
To ensure the training sets for each of the MAT isoforms were as structurally diverse as possible, 
similarity coefficients (see Figure 4.2) were used to guide whether a molecule was placed into the 
training or test set, as described in the methods section above. This was carried out to increase the 
degree of dissimilarity between individual members in the training set, whilst ensuring the training 
and test sets were still representative of the overall dataset, with an overall ambition to achieve the 
most generalizable QSAR models possible. 
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The resultant training and test set for each of the MAT isoforms contained compounds that 
represented the spread of pKi values across the dataset as a whole (which can be seen in Figures 4.4, 
4.5 and 4.6).  
 
 
Figure 4. 4: The distribution of pKi values for the dataset compounds in the NPS dataset for DAT (dark 
blue) compared to the relative distributions in the training (blue) and test (light blue) sets used to build 
and validate the Tc-derived DAT QSAR model.  
The distribution of pKi values for both test and training set in DAT were normal (p=0.902, W=0.967, H0 
is accepted). The pKi ranges with the largest number of molecules were pKi 5-6 and pKi 6-7. Both the 
test and training sets reflected this overall distribution. Figure 4.4 shows that the trend of pKi values 
for the training set was mirrored by the test set. However, as there was only one compound (for the 
entire DAT dataset) that had a pKi of above 8, there was no capacity to have a test set compound in 
this pKi value range. 
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Figure 4. 5: The distribution of pKi values for the dataset compounds in the NPS dataset for NET (dark 
orange) compared to the relative distributions in the training (orange) and test (light orange) sets used 
to build and validate the NET QSAR model. 
The distribution of pKi values for NET did not have a normal distribution from pKi range 4-9 (p=0.902, 
W=0.876, H0 was rejected). There was an uneven distribution of pKi values with the compounds 
associated with NET. Twenty-three compounds out of the total dataset had a pKi value between 5-7, 
with only 1 compound (nortriptyline) having a pKi value in the pKi 4-5 range.  Three compounds fell 
into the 7-8 pKi range and 4 compounds were located in the 8-9 pKi range. Despite the skew of pKi 
values for the NET isoform, training and test sets were identified for NET that mirror the distribution 
of pKis across the dataset as a whole. This gives the best chance of identifying a QSAR model for the 
isoform which is robust and predictive. 
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Figure 4. 6: The distribution of pKi values for the dataset compounds in the NPS dataset for SERT (dark 
grey) compared to the relative distributions of the compounds in the training (grey) and test (light 
grey) sets used to build and validate the SERT QSAR. 
The pKi values for the compounds associated with SERT had a broader range in comparison to DAT 
and NET. The data for SERT were normally distributed (p=0.902, W=0.957, H0 is accepted). The SERT 
pKi values ranged from 3-10 for the dataset in comparison to DAT and NET which had a range of 4-9. 
The data presented in Figure 4.5 shows that the both training and test sets mirror the distribution of 
pKi across the whole dataset thereby showing training and test sets that are clearly representative of 
the dataset as a whole. 
4.4.3 Descriptor Selection 
As the pKi values for the compounds in the dataset were different for each of the MAT isoforms the 
compounds within the training set and test set for DAT, NET and SERT were different. The differences 
in training sets, unsurprisingly, gave rise to different molecular descriptors emerging as being 
important for describing the observed variance in pKi for each of the MAT isoforms. Therefore, the 
QSAR equations obtained for DAT, NET and SERT are different. Table 4.4 details the differences 
between the training and test sets for each of the MAT.  
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4.4.5 Building and evaluating QSAR models 
Table 4. 4: The names of the compounds that formed the training and test sets for the DAT, NET and 
SERT QSAR models. 
Name of compound in each training and test set 
DAT Model NET Model SERT Model 
Training set Test set Training set Test set Training set Test set 
5-APB 6-APB 1-Naphyrone 5-IAI 1-Naphyrone Amitriptyline 
5-Iodo-aminoindane Nortriptyline  5-APB Bupropion 5-APB Bupropion 
Benzedrone Mazindol 6-APB Citalopram 5-Iodo-aminoindane Cocaine 
Bupropion MDAI Amitriptyline Fluoxetine 6-APB Imipramine 
Citalopram Mephedrone Benzedrone Mazindol Benzedrone Naphyrone 
Cocaine 1-Naphyrone Cocaine WIN 35428 Citalopram Nomifensine 
Desipramine  Desipramine  Desipramine  
Desoxypipradrol  Desoxypipradrol  Desoxypipradrol  
Fluoxetine  GBR 12935  Fluoxetine  
GBR 12935  Imipramine  GBR 12935  
Imipramine  MDAD  Mazindol  
MDAT  MDAT  MDAI  
Methiopropamine  Mephedrone  MDAT  
Methylethcathinone  Methiopropamine  Mephedrone  
MNB-cathinone  Methylethcathinone  Methiopropamine  
Naphyrone  MNB-cathinone  Methylethcathinone  
Nisoxetine  Naphyrone  MNB-cathinone  
Nomifensine  Nisoxetine  Nisoxetine  
Amitriptyline  Nomifensine  Nortriptyline  
R-MDMA  Nortriptyline  RTI-55  
RTI-55  R-MDMA  R-MDMA  
S-Amphetamine  RTI-55  S-Amphetamine  
S-MDMA  S-amphetamine  S-MDMA  
WIN 35428  S-MDMA  WIN 35428  
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4.4.5.1 Development of DAT QSAR models  
In an effort to develop a robust system to identify appropriate training and test sets, and to improve 
upon the r2 values obtained for the FPMACCS-derived models outlined above, an investigation was 
carried out to determine if altering the composition of the test and training sets, to ensure that they 
are representative of the dataset as a whole, could improve the predictivity of the models.  
As such, the training and test sets for the DAT isoform werr re-distributed according to structural 
diversity, ensuring that the range of pKis identified for experimental studies were represented in both 
of the sets. This was achieved by dividing the dataset into one log unit bins in terms of pKi values and 
using average Tc values as a guide to placing molecules into either a test or training set, thus ensuring 
proportionate representation of chemical structure and observed biological activity in both the test 
and training sets (see section 4.2.2). The Tc-derived training set for DAT was then used to construct a 
new QSAR model. 
The Tc-derived DAT training set unsurprisingly identified a different set of descriptors as being 
important in predicting the variance in the dataset when compared to the FPMACCS-derived model. 
The iterative process described earlier was employed when optimising the Tc-derived QSAR model i.e. 
the molecular descriptors in the QSAR model that were ranked lowest in terms of relative importance 
for their contribution to explaining the variance in the dataset were removed one by one until an 
appropriate model, with good r2 and q2 values and a minimum number of molecular descriptors was 
identified.  
Table 4.5 shows the r2 and q2 values for the estimated normalized linear Tc-derived DAT QSAR model. 
The model built using 3 descriptors (Equations 4.2) was identified as the most appropriate as this has 
the highest r2 and q2 values which is indicative of a predictive and robust model, and comprises a 
minimum number of uncorrelated molecular descriptors. Hence, the model should be generalisable.  
When the 3-descriptor model was applied to the Tc-derived test set, an improvement in the 
correlation between the predicted and experimental pKi values over the FPMACCS-derived model was 
observed (Figure 4.7). As such, the methodology for identifying test and training sets by examining 
their experimental pKi and calculated average Tc values was used to construct test and training sets 
for the NET and SERT isoforms. 
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Table 4. 5: the r2 and q2 values for the three different estimated normalized QSAR models developed 
for DAT using the 3, 4 and 5 descriptors most highly correlated with biological activity. These models 
were built using Tc-derived training and test set.  
DAT Model DAT Tanimoto-derived 
training set results 
DAT Tanimoto-derived 
test set results 
   r2 q2 r2 
5 - descriptor 0.76 0.48 0.57 
4 - descriptor 0.71 0.40 0.59 
3 - descriptor 0.68 0.51 0.63 
 
5-descriptor model for DAT (Tanimoto-derived training set) 
pKi / SD (pKi) = 6.59630 - 0.75775 * b_max1len / SD(b_max1len) + 0.48262 * FASA_H / SD(FASA_H) -
0.38144 * opr_leadlike / SD (opr_leadlike) -0.34355 * PEOE_VSA+0 / SD(PEOE_VSA+0) - 0.26472 * 
vsurf_IW6 / SD (vsurf_IW6) 
 
4-descriptor model for DAT (Tanimoto-derived training set) 
pKi / SD (pKi) = 5.449 - 0.74460 * b_max1len / SD(b_max1len) + 0.52065 * FASA_H / SD(FASA_H) -
0.43807 * opr_leadlike / SD (opr_leadlike) -0.27305 * PEOE_VSA+0 / SD(PEOE_VSA+0) 
 
3-descriptor model for DAT (Tanimoto-derived training set) 
pKi / SD (pKi) = 5.27760 -0.70255 * b_max1len / SD(b_max1len) +0.38911 * FASA_H / SD(FASA_H) -
0.29130 * opr_leadlike / SD (opr_leadlike) 
 
Equations 4.2: 5, 4 and 3-descriptor QSAR DAT estimated normalized linear QSAR equations. The 3-
descriptor model is the most robust, and is built using the descriptors b_max1len, FASA_H and 
opr_leadlike.  
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Figure 4.7: Correlation graphs representing the 3-descriptor QSAR model performance for the Tc-
derived training and test set for DAT. (A) Plot of the predicted vs experimental values of pKi for the 
training set according to the QSAR model (r2 =0.68). (B) Plot of the predicted vs experimental values 
of pKi for the test set according to the QSAR model (r2 =0.63), no outliers were detected (P = 0.01) 
 
 
 
 
 
 
 
r² = 0.6335
1
2
3
4
5
6
7
1 2 3 4 5 6 7 8
P
re
d
ic
te
d
 p
K
i (
M
)
Experimental pKi (M)
r² = 0.6848
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8 9
P
re
d
ic
te
d
 p
K
i (
(M
)
Experimental pKi (M)
A 
B 
119 
 
4.5.1 Interpreting the 3-descriptor Tc-derived DAT QSAR model 
The most predictive DAT QSAR model was the 3-descriptor model built using the Tc-derived training 
set. A table illustrating the relative importance of the descriptors, as indicated by the QuaSAR module 
in MOE is give below (Table 4.6). 
Table 4. 6: The molecular descriptors used to build the Tc-derived 3-descriptor DAT QSAR model and 
their relative importance for describing the observed variance in the experimental data, as 
determined by MOE. 
Order of Importance Molecular descriptor Descriptor description 
1.000000 b_max1len Maximum single bond chain length 
0.790002 FASA_H Fractional hydrophobic Surface Area 
0.386015 opr_leadlike The Oprea rules lead-like assessment 
 
If we consider the QSAR model generated in more detail we observe the following. Both b_max1len 
and opr_leadlike have negative signs before the coefficients, and hence can both be considered to be 
penalty terms in the overall prediction of biological affinity. 
B_max1len is an integer describing the length of the longest consecutive single bond chain in a 
molecule. The negative coefficient for b_max1len indicates that a shorter single bond chain length will 
predict a higher pKi value. Information regarding the MAT binding sites were taken from Chapter 3 in 
an effort to contextualise this observation.  
The presence of long single bond chains may allow for a high degree of flexibility within the compound 
which may prevent strong protein-compound interaction being formed, in comparison to more rigid 
and compact compounds (e.g. Desoxypipradrol). A possible argument for this could be based on 
entropy, i.e. rigid molecules will have fewer entropic penalties associated with binding and result in a 
stronger protein-ligand interaction, and hence are predicted to have higher pKis. Again, this is evident 
when comparing RTI-55 (pKi = 8.49) and Desipramine (pKi = 4.10). This could indicate that less flexible 
compounds bind better to DAT, and hence there are steric factors involved in the binding of small 
molecules in the DAT binding site.  
Analysis of the DAT binding site (using the homology model, accession number Q01959 226,227), shows 
that there is a narrowing in the cavity towards the bottom (Figure 8), which is where the literature 
and the docking studies of Chapter 3 suggest the majority of compounds bind. The opening to the 
cavity has an approximate diameter of 10 Å and the bottom of the cavity has an approximate diameter 
of 7 Å. Compact and rigid molecules may therefore be able to better access, and bind to the bottom 
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of the cavity than more flexible ones, and be subject to fewer entropic penalties upon binding. Hence, 
this could explain why the b_maxlen descriptor is highlighted as being important in explaining the 
variance in the 3-descriptor Tc-derived DAT model. 
 
 
Figure 4. 8: A – overview of the DAT binding site (homology model, accession number Q01959) 
containing the docked ligand RTI-55 (yellow stick model). B – Zoomed in section of the DAT binding 
site, with approximate diameters (in Å) at two different regions of the binding site illustrating the 
narrowing of the binding site. 
Figure 4.8 shows RTI-55 docked into the DAT binding site. This ligand has the highest experimentally 
derived pKi value (pKi – 8.50) for DAT. RTI-55 also has the small b_max1len value of 2 (the largest being 
7) of all the molecules in the dataset. As such, it is unsurprising that the 3-descriptor QSAR equation 
predicts a high binding affinity for RTI-55 (pKi = 7.21) which is consistent with its experimentally 
determined value. 
FASA_H is a term describing the water accessible surface area of all hydrophobic atoms of a 
compound.  As there is a positive coefficient for FASA_H in the 3-descriptor DAT QSAR equation this 
implies that a greater accessible surface area (of hydrophobic atoms) equates to a higher pKi.   
The results obtained from Chapter 3 indicate that hydrophobic interactions are important binding in 
the DAT active site, as a large number of the residues that make up the binding site in DAT, and hence 
are involved in protein-ligand contact, are hydrophobic (e.g. L80, A81, V152, F320 and F326). The 
FASA_H descriptor looks at the water accessible surface area (ASA) of all hydrophobic atoms in a 
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compound, and it follows that if a hydrophobic small molecule was able to displace the water from 
the binding cavity, it would be able to form interactions with the resultant hydrophobic surface area 
of the protein.  
One hypothesis for why this descriptor is important is as follows. Given the hydrophobic nature of the 
binding cavity, it could be energetically favourable to displace the water-hydrophobic surface contacts 
and replace these with hydrophobic protein-ligand contacts. This is supported by the positive 
coefficient in the equation which indicates the more ability there is to form hydrophobic protein-
ligand contacts i.e. the greater the water accessible surface area, the higher the pKi i.e. a compound 
that can fill the bottom of the binding cavity will have a higher pKi than one which only partially fills it 
(see Figure 4.8).  This interpretation provides context as to why this descriptor was considered 
important for determining biological activity, this is supported by the high affinity observed, and 
predicted for RTI-55 which fills the DAT cavity. 
The values that a molecule can achieve with respect to the opr_leadlike descriptor can be, 1 which 
denotes that 2 or fewer violations to the Oprea228 drug like criteria have been incurred and 0 which 
indicates that the compound has 3 or more violations to the Oprea criteria. The criteria include having 
between 0-2 hydrogen bond donors, between 2 and 9 hydrogen bond acceptors, no more than 8 
rotatable bonds and between 1 and 4 rigid bonds. As the coefficient associated with this descriptor is 
negative this indicates that any compound that had a value for opr_leadlike greater than 0 would incur 
a penalty (reduction in calculated pKi value), this indicates that compounds should not adhere the 
Oprea drug-like criteria.  
All of the compounds in the DAT training set had a calculated opr_leadlike value of 1 (except GBR 
12935) which signifies that the compounds have two or less violations of the Oprea drug-like criteria. 
The opr_leadlike descriptor is a composite of a variety of physicochemical properties, but opr_leadlike 
values obtained give no information on which composite part of the descriptor has been violated. 
Therefore, little information can be extracted from this particular descriptor with respect to its 
importance in the QSAR equation. The opr_leadlike had the lowest ranked importance of the 
descriptors included in the model which means the values for these descriptors contribute least to the 
model. 
Consequently, it is likely that the descriptor acts as a “correction factor” for the predicted biological 
activities. Removing the descriptor and generating a 2-descriptor model shows the training set r2 and 
q2 values remain relatively high (r2 = 0.67, q2 = 0.50) but the test r2 values decreases from 0.63 – 0.35. 
Generating a simple 2-descriptor model, and seeing that it performs less well than the 3-descriptor 
model, demonstrates that the opr_leadlike descriptor plays a crucial role as a correction factor in 
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predictivity. To further test the hypothesis of the opr_leadlike descriptor behaving as a correction 
factor a further experiment using a modified 2-descriptor equation was applied (Equation 4.3).  
Assuming that the opr_leadlike was a correction factor, and hence would be a constant (-0.29310), 
the value at the beginning of the 3-descriptor DAT equation was modified (5.27760 -0.29310 = 4.9845)  
   pKi / SD (pKi) = 4.9845 -0.70255 * b_max1len / SD(b_max1len) +0.38911 * FASA_H / SD(FASA_H) 
Equation 4.3: 2-descriptor QSAR DAT estimated normalized linear QSAR equations built using the 
descriptors b_max1len and FASA_H. A value of -0.29310 was subtracted from the correction factor at 
the beginning of the 3-descriptor equation. 
When equation 4.3 was applied to the DAT training (minus GBR-12935) and test sets, having removed 
the small number of compounds for which the opr_leadlike value was zero, the r2 and q2 values 
remained the same. This proved that the presence of the opr_leadlike descriptor in the model was a 
simple correction factor to prevent over prediction.  
As mentioned earlier, an optimal model should have the highest r2 value (which indicates the 
predictive ability of the model) and a similar cross-validated q2 value (which accounts for how robust 
the model is). When building a QSAR, based on current practice the maximum number of descriptors 
to be used is a ratio of 1 descriptor for every 5 compounds117. For this rule to be obeyed, a maximum 
of 4 descriptors should have been used to build the QSAR models for DAT, NET and SERT. However, in 
the case of the DAT model, use of fewer descriptors produced more accurately predicted pKi values 
when applied to the test set. Regarding QSAR development, the principle of “Occam’s razor”117 is 
commonly mentioned  which suggests that a reasonable QSAR model will have a small number of 
simple descriptors and the simpler the model the better the predictive ability. Given these principles 
seem to have been borne out for the 3-descriptor Tc-derived DAT model, they were applied to 
constructing QSAR models for the NET and SERT isoforms. 
4.3.6 Development of NET QSAR models 
NET QSAR models were built using the Tc-derived training set. Equations 4.4 show the form of 3, 4 and 
5-descriptor NET QSAR models obtained. 
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5-descriptor model for NET (Tanimoto-derived training set) 
pKi / SD (pKi) = 4.06975 +0.63056 * PEOE_VSA-0 / SD(PEOE_VSA-0) + 0.52082 * PM3_HF / SD(PM3_HF) 
-0.08051 * Q_VSA_FPNEG / SD(Q_VSA_FPNEG) +0.41258 * vsurf_CW4 / SD (vsurf_CW4) -0.56082 * 
PEOE_VSA+3 / SD(PEOE_VSA+3) 
4-descriptor model for NET (Tanimoto-derived training set) 
pKi/ SD (pKi) = 0.4.92208 + 0.49132 * PEOE_VSA-0/SD (PEOE_VSA-0) + 0.36602 * PM3_HF/SD 
(PM3_HF)– 0.36034 * Q_VSA_FPNEG/SD (Q_VSA_FPNEG) + 0.42240 *vsurf_CW4/SD (vsurf_CW4) 
3-descriptor model for NET (Tanimoto-derived training set) 
pKi / SD (pKi) = 6.02884 + 0.40054 * PEOE_VSA-0 / SD(PEOE_VSA-0) - 0.39877 * PEOE_VSA+3 / 
SD(PEOE_VSA+3) - 0.42037 * Q_VSA_FPNEG / SD(Q_VSA_FPNEG) 
Equation 4.4: 5, 4 and 3-descriptor QSAR estimated normalized linear models built using the Tc-derived 
NET training set. 
The performances of the 3, 4 and 5-descriptor Tc-derived NET QSAR models with respect to their 
predictivity and robustness are summarised below (Table 4.7). 
Table 4. 7: Summary of the r2 and q2 values for the three best-performing estimated normalized linear 
QSAR models (Equations 4.4) for the Tc-derived NET training and test sets. 
NET Model NET Tanimoto training set results  NET Tanimoto 
test set results 
   r2 q2 r2 
5 - descriptor 0.66 0.44 0.11 
4 - descriptor 0.62 0.39 0.13 
3 - descriptor 0.60 0.39 0.10 
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Figure 4. 9: Plots to show the performance for the NET QSAR model (Tc-derived training and test set) 
(A) Plot of the predicted vs experimental values of pKi for the training set according to the 4-descriptor 
Tc-derived NET QSAR model (r2 = 0.62), no outliers were detected (P = 0.01). (B) Plot of the predicted 
vs experimental values of pKi for the test set according to the 3-descriptor Tc-derived NET QSAR model 
(r2 = 0.13), no outliers were detected (P = 0.01) 
4.5.2 Evaluation of NET QSAR models 
During the descriptor selection process, it was noted that only electronic descriptors were identified 
as being important for explaining the observed variance in the biological activities of the Tc-derived 
training set for the NET QSAR models. Table 4.8 details the molecular descriptors used to build the 
NET QSAR models. 
The best performing model was the Tc-derived 4-descriptor NET QSAR model, as this produced the 
highest r2 for the test set, and the r2 and q2 values obtained for the training set were similar across the 
3, 4 and 5-descriptor models. The 4-descriptor NET model returns an r2 value of 0.62 for the training 
set, but for the test set the r2 value achieved, was 0.13.  
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These results indicate that the QSAR models built for NET are not generalizable, as they are unable to 
successfully predict the biological activity of the test set compounds to an acceptable level.   
Given that care has been taken to ensure that the test and training sets were representative of the 
dataset as a whole, and that the descriptors carried forwards to construct the NET models do not show 
significant cross-correlation, the reason that the model is not generalizable is not immediately clear. 
As such it was important to examine the descriptors in more detail (Table 4.8), as well as the NET 
dataset as a whole. 
Table 4. 8: The molecular descriptors and their relative importance used to build the Tc-derived 4-
descriptor NET QSAR model. 
 
Given that these descriptors were each designed to capture electronic characteristics, they were 
checked again to ensure that they were not cross-correlated with one another (Table 4.9). None of 
the descriptors were correlated to another with an absolute correlation value of 0.7 or greater, and 
hence fulfilled the inclusion criteria outlined in the methods section above. 
Table 4. 9: Correlation matrix of the electronic descriptors used to build the 4-descriptor NET QSAR 
model. The values show that none of these descriptors correlate with one another i.e. have values 
greater than 0.7, or less than -0.7. 
  PEOE_VSA-0 PM3_HF Q_VSA_FPNEG vsurf_CW4 
PEOE_VSA-0 1 -0.03379 -0.256334588 -0.289223744 
PM3_HF -0.033790726 1 -0.602620891 -0.689260691 
Q_VSA_FPNEG -0.256334588 -0.60262 1 0.58275374 
vsurf_CW4 -0.289223744 -0.68926 0.58275374 1 
 
In an effort to understand the poor performance of the NET models, each of the descriptors used in 
the construction of the 4-descriptor model was examined. 
Order of Importance Molecular descriptor Descriptor description 
1.000000 PEOE_VSA-0 Total negative 0 van der Waals surface area 
0.542010 PM3_HF Heat of Formation (kcal) 
0.446303 vsurf_CW4 Capacity factor at -2.0 
0.153069 Q_VSA_FPNEG Fractional polar negative VDW surface area 
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PM3_HF is a molecular descriptor that calculates the enthalpy of formation, with the overall model 
indicating molecules that have a higher calculated enthalpy of formation will result in prediction of a 
greater pKi value. There was no obvious relationship between the importance of this descriptor and 
the composition of the binding site of NET. A possible explanation for this may be because the 
molecular descriptor PM3_HF is related to a diverse range of physico-chemical properties and lacks 
specificity. 
Vsurf_CW4 is a capacity factor that calculates the ratio of hydrophilic surface to the total molecular 
surface. The positive coefficient associated with this descriptor indicates that molecules with a greater 
relative hydrophilic area will equate to a higher pKi values. Similarities can be drawn between this and 
the FASA_H descriptor highlighted as being important for the DAT QSAR model, in that the descriptor 
is essentially rewarding those molecules that can form hydrophobic contacts with the hydrophobic 
residues in the putative NET binding cavity and is emphasising the importance of a molecule being 
able to fill the cavity.  
PEOE_VSA-0 is the most important descriptor identified for the 4-descriptor NET QSAR model. It is an 
electronic descriptor which accounts for the partial charge on the van der Waals surface area, in this 
case looking at the sum of the van der Waals surface area that has a partial charge between -0,05 and 
0 i.e. a surface that is very weakly negatively charged, or neutral The positive coefficient associated 
with this descriptor indicates that compounds that have a large weakly negative/neutral VSA value 
will give rise to a greater pKi value. However, due to the nature of the NET binding site it is expected 
that molecules that have positively charged regions would interact better with NET, due to the 
dominance of the Asp 75 residue on the electronic characteristics of the binding cavity (Figure 4.9). 
Q_VSA_FPNEG describes the fractional negative polar VSA, such that the partial charge is less than         
-0.2 divided by the total surface area, and is calculated based on the atomic partial charges stored in 
the MDB file for a molecule. The negative coefficient associated with this descriptor implies that any 
values obtained other than 0 would result in a penalty being applied and a reduction in predicted pKi 
value. Analysis of the NET binding site conducted in Chapter 3 did not allude to the importance 
regarding polarity of the binding site residues; to the contrary 85% of the binding site was composed 
of hydrophobic amino acid residues. Again, it is possible that this penalty arises due to the presence 
of the Asp 75 residue, and its role in determining the electronic properties of the NET binding cavity. 
The electronegative environment created by the deprotonated aspartate would repel molecules with 
an overall average negative charge – a feasible reason as to why this is a negative term in the best-
performing QSAR equation. However, these hypotheses are merely that, and no firm conclusions can 
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be drawn from these suppositions.  This prevents any meaningful data being taken from the 
descriptors associated with the NET QSAR model. 
The almost exclusive interactions by compounds, demonstrated in the docking studies, at the 
negatively charged region of the NET binding cavity (Figure 4.10) could be a reason as to why only 
electronic descriptors were suggested by MOE. Analysis of the NET binding site highlights a large 
negatively charged region (Figure 4.10). 
 
Figure 4. 10: The putative NET binding site (based on the homology model, accession number P23975). 
The binding site is coloured according to negatively (red) and positively (blue) charged regions Areas 
with no charge are coloured white. The Figure illustrates an aspartate residue (Asp75) which is 
responsible for the large negatively charged region highlighted. 
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Figure 4. 11: A PLIF diagram to show citalopram bound to the NET binding site. The PLIF shows the 
ligand tightly bound in the active site which supports the PEOE descriptor being identified as important 
in the 4-descriptor NET QSAR model. 
Given that there is little insight gained from analysis of the QSAR as to why the NET models were not 
generalizable, attention was turned to examining the dataset itself. The dataset could be the reason 
poor QSAR models were generated, as there is a narrow range of pKi values associated with NET which 
could the reason the model is not generalizable. 
The QSAR model produced for NET could potentially be limited by the uneven distribution of pKi values 
which inherently restricted how well the test set could be represented by the training set. According 
to the Shapiro-Wilks test conducted on the pKi values for NET it showed that the distribution of data 
was not normal229 and the majority of the compounds in the dataset (23/31) have a pKi between 5 
and 7. This compression of the activity range may limit how well the training set could be defined and 
therefore how well the QSAR model is able to predict activity. This was identified at the onset, and in- 
depth analysis of the NET training set was conducted to try and produce a training set that accurately 
represented the dataset as a whole. Representative test and training sets were identified, however 
despite this the experiment was unsuccessful  and it must be concluded that the most probable cause 
is the  small dataset119 with its limited range of pKi values.  
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4.6.1 Development of SERT QSAR models  
SERT QSAR models were built using the Tanimoto-derived training set. Equations 4.5 show 3, 4 and 5-
descriptor Tc-derived SERT QSAR models. 
 
5-descriptor model for SERT (Tanimoto-derived training set) 
pKi / SD (pKi) = 0.86008 -0.32863 * a_don / SD(a_don) +0.27612 * E_tor / SD(E_tor) +0.58373 * 
PEOE_VSA-0 / SD(PEOE_VSA-0) +0.12663 * BCUT_SLOGP_3 / SD(BCUT_SLOGP_3) +0.10300 * FASA+ / 
SD(FASA+) 
4-descriptor model for SERT (Tanimoto-derived training set) 
pKi / SD (pKi) = 2.10886 -0.31514 * a_don / SD(a_don) +0.25569 * E_tor / SD(E_tor) +0.57078 * 
PEOE_VSA-0 / SD(PEOE_VSA-0) +0.07779 * BCUT_SLOGP_3 / SD(BCUT_SLOGP_3)  
 
3-descriptor model for SERT (Tanimoto-derived training set) 
pKi/ SD (pKi) = 3.285274 – 0.36519* a_don/SD (a_don) + 0.25467 * E_tor/SD (E_tor) + 0.58228 * 
PEOE_VSA-0 / SD (PEOE_VSA-0)  
Equations 4.5: 5, 4 and 3-descriptor QSAR estimated normalized linear models built using the SERT 
training set devised using diverse subset derived from Tc. 
The performances of the Tc-derived SERT QSAR models in terms of their predictivity and robustness 
are summarised below (Table 4.10). 
Table 4. 10: Summary of the r2 and q2 values for the three best-performing estimated normalized linear 
QSAR models (Equations 4.5) developed for SERT using a training set identified via the Tc-derived 
training set 
SERT Model SERT Tanimoto training set Results  SERT Tanimoto 
test set results 
   r2 q2 r2 
5 - descriptor 0.88 0.82 0.73 
4 - descriptor 0.86 0.79 0.70 
3 - descriptor 0.87 0.80 0.74 
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Figure 4. 12: Graphs representing the 3-descriptor model performance for the Tanimoto training and 
test set for SERT. (A) Plot of the predicted vs experimental values of pKi for the training set according 
to the QSAR model (r2 =0.87), no outliers were detected (P = 0.01). (B) Plot of the predicted vs 
experimental values of pKi for the test set according to the QSAR model (r2 =0.74), no outliers were 
detected (P = 0.01). 
4.6.2 Evaluation and Interpretation of SERT QSAR models 
The 5, 4 and 3-descriptor Tc-derived SERT QSAR models seemed to perform equally well in terms of 
their predictivity and robustness. The near identical values obtained for the training set results for all 
models indicates that the fourth and fifth descriptors identified by MOE contribute little/nothing to 
helping further explain the variance in the experimental pKis for the SERT training set, and hence 
should not be considered further. The remaining 3-descriptor model taken forward proved to be 
generalisable as evidenced by the high r2 value obtained for the Tc-derived SERT test set. Table 4.11 
gives the descriptors used in the Tc-derived 3-descriptor SERT QSAR model, in order of importance 
with respect to their overall contribution in explaining the variance in the Tc-derived SERT training set. 
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Table 4. 11: The molecular descriptors, relative importance and a description of what they represent, 
used in building the Tc-derived 3-descriptor SERT QSAR model. 
 
PEOE_VSA-0 (described in section 4.3.6.1) is the most important descriptor identified for the SERT 
QSAR model. The positive coefficient associated with this descriptor indicates that compounds that 
have a large weakly negative/neutral VSA value will give rise to a greater pKi value. Again, as for DAT, 
this suggests, that largely hydrophobic interactions are going to be the most important factor for 
determining activity in the SERT binding cavity.  
The descriptor a_don calculates the number of hydrogen bond donor atoms (not counting basic atoms 
but counting atoms that are both hydrogen bond donors and acceptors such as -OH). The coefficient 
for a_don is negative which indicates that molecules containing fewer hydrogen bond donor atoms, 
excluding groups like protonated amines, a motif common across all of the NPS in the dataset, would 
result in higher calculated pKi values. The equation suggests the ideal is to have no hydrogen bond 
donor atoms present other than the protonated amines. 
The information obtained from Chapter 3 regarding the SERT binding site has five residues with side 
chains able to act as hydrogen bond acceptors, (D98, Y175, Y176, S336 and T439, 5 out of 23 residues) 
although the interaction between the deprotonated Asp 98 residue and any hydrogen bond donor is 
going to be significantly stronger than the interactions between the HBD and the alcoholic groups on 
the tyrosine, serine and threonine sidechains. This is evident from the docking studies, which 
exclusively show high-ranked poses demonstrating interaction between Asp 98 and the protonated 
amine groups of the NPS.  
The requirement for small molecules to have a low number of hydrogen bond donors (with the 
exeption of the biogenic amine) also fits with the first descriptor, PEOE_VSA-0, which shows, by 
inference, that hydrophobic molecules with a high degree of neutral/minimally negatively charged 
surface area will be favoured to bind in the SERT cavity via their interaction with the hydrophobic 
residues therein.   
Examination of the dataset shows that a low a_don score is consistent with compounds that have 
higher pKi values (Figure 4.12) associated with SERT e.g. RTI-55 (pki = 9.31), Citalopram (pki = 8.27) and 
Order of Importance Molecular descriptor Descriptor description 
1.000000 PEOE_VSA-0 Total negative 0 van der Waals surface area 
0.627169 a_don Number of Hydrogen bond donor atoms 
0.437357 E_tor Torsion energy 
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Imipramine (pki = 8.11) which all have a calculated a_don value of 0. Figure 4.13 shows the chemical 
structures of the compounds that have the highest 3 pki values associated with SERT and the lowest 3 
pki values associated with SERT. 
 
Figure 4. 13: chemical structure, associated SERT pKi values and a_don values for citalopram, RTI-55, 
Imipramine, Methiopropamine, Desoxypipradrol and Bupropion  
E_tor are positive values that calculate the potential torsional energy of a compound. E_tor values are 
associated with the overall flexibility of a molecule and a more flexible molecule will have a smaller 
E_tor values. RTI-55 has the greatest SERT associated pKi value and also the largest E_tor value, in 
contrast Methiopropamine has a relatively low pKi and E_tor value which indicates that molecular 
rigidity plays an important role in affinity for the SERT binding site. 
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Figure 4. 14: the chemical structures, associate SERT pKi values and E_tor values for RTI-55 and 
Methiopropamine. 
In order for a protein-ligand interaction to occur in SERT, more rigid molecules are favored. This is 
similar to DAT as SERT also appear to have a subtle narrowing of the binding site towards the bottom 
of the cavity. Figure 4.15 is a docked conformation of citalopram, the ligand fills the bottom of the 
cavity. From docking studies carried out in Chapter 3, ligands that are rigid are able to better access 
the the binding site and similar to DAT docking results rigid molecules may incur fewer entropic 
pentalties upon binding. 
 
 
Figure 4. 15: the MOE elcuidated binding site for SERT (accession code 5I75) with a docked 
conformatio of citalopram (magenta stick model) 
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SERT produced the best QSAR models (highest r2 = 0.87, q2 = 0.80, using 3 descriptors) of the three 
MAT isoforms. This could be due to the fact that the SERT dataset had the broadest range of pKi values, 
which implicitly facilitates the construction of a more generalizable QSAR model117. In addition to this, 
54% of the data set compounds had higher affinities with SERT in comparison to DAT and NET, with 
20% of the compounds categorised as Selective Serotonin Reuptake Inhibitors (SSRI)3535, therefore 
providing more information regarding the physicochemical differences that result in the different pKi 
values.  
4.7 Conclusions  
QSAR models have given insight into the properties required of NPS with respect to interaction with 
the individual MATs, DAT, NET and SERT. It was possible using molecular descriptors to highlight how 
subtle structural differences may enhance a compounds affinity for one monoamine transporter over 
another.  
Robust and generalizable QSAR models were built for both DAT (training set r2 – 0.68, test set q2 0.42) 
and SERT (training set r2 – 0.87, test set q2 – 0.80), which could be used to predict the biological activity 
of new psychoactive substances. The best performing QSAR models were those associated with SERT, 
which is unsurprising given that the dataset for this isoform displayed the widest range of pKi values 
(7 log unit span).  
From the QSAR models built, it can be seen that there are physicochemical differences that may 
convey a degree of selectivity between monoamine transporters. DAT selective compounds should be 
rigid, with shorter chains of single bonds and should contain have surface areas that are relatively 
hydrophobic to facilitate interaction between the small molecule and the DAT binding site.  
Similarly, SERT selective compounds appear to favour inflexible, charged moieties and no hydrogen 
bond donor atoms present on the compound. These key findings should be considered when 
developing DAT or SERT selective compounds. The similarity of molecular descriptors for DAT and SERT 
may go to explain why there is promiscuity between the two MAT and the subtle differences in 
descriptors between DAT and SERT should be exploited further when attempting to design novel 
compounds that are MAT selective. 
Issues arose when trying to identify different types of physicochemical features, (other than 
electronic) that correlate compounds with a large pKi value for NET. From the QSAR models produced 
it was evident that electronic descriptors were of most importance for NET, however the compression 
of pKi values could possibly be a limit in producing a generalizable model to be built for NET. 
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The results obtained from Chapter 3 and 4 have shown that the methods employed are applicable in 
identifying what physicochemical properties are required to convey selectivity between different MAT 
isoforms, and hence this gives confidence that NPS and their receptors can be exploited and 
interrogated successfully using computational methods. Therefore, the next stage of this research will 
focus on a particular category of NPS, the synthetic cannabinoids, and will use computational 
methodologies with the aim of identifying a novel library of synthetic cannabinoids that can be 
evaluated for biological activity using in vitro and in vivo techniques. 
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Chapter 5 
Identification of Novel Compounds with Predicted Affinity 
for the Cannabinoid 1 (CB1) Receptor. 
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5.1 Introduction 
The vast and rapid influx of NPS onto the market has exacerbated the overall detrimental effects of 
this group of drugs and it has become almost impossible to keep up-to-date records of known NPS. A 
review article from Drug Wise UK230 states that the rapid discovery and generation of novel NPS may 
be due to the rapid growth of the internet and the easy access of disregarded patents from 
pharmaceutical companies230.  
Having demonstrated that it is possible to gain insight into the key physicochemical properties that 
are implicated in ligand interactions with the monoamine transporters, and hence demonstrating that 
in Silico methodologies can be applied to new psychoactive compounds, the next stage of this project 
was extended to investigate the NPS class of synthetic cannabinoids (SC). This class of NPS dominates 
the market231 and there are  recent notifications of SC overdoses232–234 being reported post the 
introduction of the Psychoactive Substances act (2016). From the extensive published data on the 
number and type of synthetic cannabinoids, and the popularity amongst users for this illicit group of 
substances, it was decided to focus the next stage of the investigations on this particular class of NPS.  
At the time of this study there were 256 SC listed by the UNODC232,  making SC the most predominant 
class of NPS globally. The arrival of Spice onto the market, an umbrella term for a substances 
containing a mix of shredded plant-derived and man-made hallucinogens, typically including a cocktail 
of SC, has presented a formidable public health challenge that affects a number of different societal 
groups including the homeless235, the incarcerated87 and adolescents54. Consequently, the SCs pose 
one of the biggest public health risks in terms of continued illicit drug use, and as such research into 
the next generation of chemical scaffolds with the potential to be exploited as SC is vital. 
However, synthetic cannabinoids are by no means novel. The chemists Alexandros Makriyannis, 
Raphael Mechoulam and John W. Huffman have been investigating the medicinal properties of 
tetrahydrocannabinol (THC)-like compounds, the main psychoactive component of cannabis, for 
decades. The legitimate research conducted by Huffman, Makriyannis and Mechoulam gave rise to 
the JWH, AM and HU (respectively) synthetic cannabinoid series, which in recent years have been 
“hijacked” by the illegal drug trade community, mass produced and sold236. The compound JWH-018 
was one of the first generation synthetic cannabinoids237 reportedly abused, and approximately 130219 
novel SC molecules have been inspired by this compound. The rapid generation of new SC have 
become an urgent matter of public health concern, due to the lack of data available on the mechanism 
of action within the body234.  
As previously mentioned, one of the biggest concerns is around the abuse of Spice86,232,234,238 also 
referred to as K2, which is sold as a herbal incense product. This product, which is actually a number 
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of independently-produced products each of which results in similar psychoactive effects, has been 
reported by the EMCDDA to be emerging at and unprecedented rate85. Although each sample of Spice 
is different in its exact composition, it is common for all Spice products to contain a number of 
different SC including JWH-018, JWH-073 and CP-47,497239,240.  Numerous global reports of “zombie-
like” behaviour235,83 as a result of spice consumption have been published, and the devastating effects 
of these drugs reinforces the potential lethality of SC. 
Therefore, the following piece of research aims to identify molecules that are as chemically distinct 
from known synthetic cannabinoids, but which align to pharmacophores that suggest they will bind to 
the cannabinoid receptor 1 (CB1). This is in an attempt to identify completely novel ligands that in 
Silico modelling suggests have the potential to act as SC.  
To this end, a library of 162 known synthetic cannabinoids were used in a ligand-based drug design 
approach to develop pharmacophore models that were then used to identify novel compounds with 
potential to bind to the CB1 receptor (and hence give rise to psychoactivity). This database of 162 
compounds contains analogues from the well-established JWH, AM and HU SC series as well as other 
previously identified SC compounds that have been reported as being abused. 
This chapter will detail how the development of four pharmacophore models based on the structures 
of known SCs were used to virtually screen a molecular database consisting of approximately 17 
million compounds to produce a feasible library of molecules that had the potential to interact with 
the CB1 receptor. The compounds that were identified as potential CB1 binders were specifically 
selected so as to be structurally dissimilar to the known SC but with potential to elicit similar 
pharmacological effects 
Ultimately, thirteen molecules were identified as potential CB1 agonists based on a number of criteria 
including likely propensity for binding to the CB1 receptor, likelihood of the compound crossing the 
blood brain barrier, solubility and availability for commercial purchase. 
5.2 Method 
Figure 5.1 gives an overview of the methodology used to identify novel compounds that had potential 
to interact with the CB1 receptor. 
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Figure 5. 1: The general strategy employed in this chapter in the identification of compounds that were 
chemically distinct from known SC molecules but were predicted to have the potential to bind to the 
CB1 receptor. 
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5.2.1  Database curation 
A dataset of 162 SC was compiled into a Molecular Database (MDB) using the MOE software. The 
molecules in the database were converted into SMILES strings and screened for duplicates. These 
compounds were taken from the European Database of New Drugs (EDND)241. A second database of 
655 known Novel Psychoactive Substances (NPS) (including the 162 SC taken from the EDND241)  was 
collated and used in the development and optimisation of pharmacophore models. 
5.2.2 Clustering systems 
Initially, the SC were clustered using the Maximum Common Substructure (MCS) application in 
ChemAxon158. The cluster default parameters were used i.e. normal mode and the ‘jcsearch’ algorithm 
with the default settings (MCS mode = fast, minimal MCS size = 9, matching atom types = true, bond 
type = true, charge = true, keep rings = true, required cluster count = 1, maximal level count = 10) 
In addition, a second clustering system was employed using core chemical scaffolds as the criteria for 
clustering. For this approach, the scaffold classification system described by Uchiyama et al242 was 
used and the synthetic cannabinoids were grouped into 15 categories (benzoylindoles, carboxyamide 
derivatives, carboxyindoles, classical cannabinoids, cyclopropylindoles, cyclohexylphenols, 
naphthoylbenzimidazoles, naphthoylnaphthalenes, naphthoylindazoles, napthoylindoles, 
naphthoylpyrroles, pentylindoles, phenylacetylindoles, others and quinolinyl carboxylates).  
5.2.3 Pharmacophore development  
The pharmacophore models were built from clusters that contained 16 or more molecules. Although 
there is no direct rule for the minimum number of compounds, a leading computational software 
manufacturer (Schrödinger243) suggest that no less than 16 ligands should be used in the development 
of pharmacophore models 
All the compounds in an individual cluster were flexibly aligned with respect to one another using the 
flexible alignment module in MOE. Default settings were applied with respect to the alignment i.e. 
Iteration limit of 200 and Failure limit of 20. Flexibly aligned motifs were generated and assigned a 
value. The value corresponds to a score that quantifies the quality of the alignment for both internal 
strain and overlap of molecular features with the structural features present on the aligned motif. The 
lower the score, the better aligned all the molecules are.  
Using the top ranked/lowest scored flexibly aligned motif for each group of SCs a set of consensus 
features were assigned to the alignment to produce an initial pharmacophore model. The initial model 
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was used to search the 655 compound NPS database and “hit” ligands were identified. A hit ligand is 
described as compound that has defined features that achieve a minimum “match” size with the 
consensus pharmacophore (two features need to be matched). A buffer of 0.5 Å from the centre of a 
pharmacophoric feature is applied for the direct overlay of each feature and the hit ligands were 
ranked by lowest RMSD values, which is calculated between the query features and their matching 
ligand annotation points. 
The initial consensus pharmacophore models generated were validated by examining how well the 
model was able to identify SC from the same class used to develop the pharmacophore in the early 
stages (i.e. first ten percent of compounds in the database) in a virtual screen search, using the 655 
NPS database established previously.  
The top 10% of hits from the virtual screen, ranked according to how well they fit the pharmacophore 
model, were used to calculate an enrichment factor - a metric that is commonly used to quantify the 
performance of pharmacophore models. 
Enrichment factors (Ef – Equation 5.1) were calculated at 2, 5 and 10% of the NPS database search to 
establish how many SCs from the class of compounds used to generate the pharmacophore the model 
was able to retrieve at those intervals.  
Enrichment factor 10% = (% of relevant SC at 10% ÷ % of NPS database at 10%) 
      Number of SC ÷ number of NPS 
Equation 5.1: The equation161 used to determine the enrichment rate for first 10% of the NPS database 
screened.  
The pharmacophore model was then interrogated using a Leave One Out (LOO) approach, whereby a 
consensus feature was removed and the modified pharmacophore model was used search the 655 
compound NPS database. Enrichment factors at 2,5 and 10% were calculated for the modified 
pharmacophore, and compared to the initial model to see how the enrichment rate was affected by 
the removal of a particular feature. This iterative process was carried out until the highest enrichment 
rate was obtained using a model with the fewest possible features. 
To give an example, a generalisable pharmacophore model that is selective for a given class of 
compounds (e.g. the carboxyamides) will contain a minimum number of pharmacophoric features and 
highly rank molecules that display the pharmacophoric features of the carboxyamides during the 
virtual screening process. This will result in the proportion of the molecules from the carboxyamide 
cluster found in the first 10% of the virtual screen (i.e. the first 10% of the database ranked according 
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to how well it fits the pharmacophore model) being significantly greater than random and displaying 
an enrichment factor greater than 1 at 2, 5 and 10% of the database screened.   
5.2.4 Medoid selection 
A medoid was selected for each of the fifteen SC clusters identified. The medoid was obtained by 
creating a correlation matrix of pairwise Tanimoto coefficients (Tc) for each molecule in the cluster. 
The sum of Tc for each cluster member was calculated and the molecule that had the greatest Tc total 
value was selected as the medoid for that cluster. 
5.2.5 Database selection 
The standard drug-like library containing 17,900,742 compounds (at the time of access, November 
2014) was downloaded from the ZINC database244. The standard drug-like subset from this database 
was used in the virtual screening experiments that follow. 
5.2.6 Virtual screen of database using pharmacophore model 
The best-performing pharmacophore models generated for each of the classes of SC investigated were 
used to search the drug-like subset from the ZINC database. The Pharmacophore search application 
in MOE98 was employed (using the same parameters stated in section 5.2.3). 
The initial library of virtual hit molecules retrieved was refined to ensure the hits had similar 
physicochemical properties to known synthetic cannabinoids, and by inference had good potential to 
bind to the CB1 receptor in vitro/in vivo. This was achieved by applying filters for physicochemical 
properties that would remove molecules that did not align within the range of those properties 
calculated for known SC structures. 
5.2.7 Log PS 
The first filter applied was the molecular descriptor log PS (Equation 5.2) which was calculated as 
follows: 
log PS = - 2.19 * 0.262 * log D + 0.00683 * vsa_base – 0.009*TPSA245 
Equation 5.2: log PS is the log of the permeability-surface area coefficient246, log D is the solubility (at 
pH 7.4) calculated by ChemAxon, vsa_base is the van der Waals’ surface area due to basic atoms, and 
TPSA is the topological polar surface area. The latter two descriptors were calculated by MOE98. 
143 
 
The log PS values were calculated for 188 known cannabinoids and synthetic cannabinoids i.e. the 162 
SC identified from the EDND report and 26 endogenous cannabinoids (e.g. cannabidiol, anandamide 
& 2-arachiodonoylglycerol) identified from the literature92,247. The range of log PS values based on 
these 188 cannabinoids was recorded. 
5.2.8 Log S  
Log S values were calculated in MOE using the molecular descriptor application for the 188 
cannabinoids/synthetic cannabinoid ligands. The range of log S values identified was recorded. 
5.2.9 Chemical similarity 
The virtual hit molecules that remained after the first two filters had been applied were assessed for 
chemical structure similarity to the SC medoids associated with the pharmacophore model used for 
the virtual screen. Two different similarity metrics were used, the first process employed was MACCS 
structural keys.  
The virtual hits retrieved for a specific pharmacophore were assigned MACCS structural keys248 which 
were compared to the MACCS structural key of the medoid for the SC cluster used to generate the 
pharmacophore. A cut off value of 25% similarity was applied and any virtual hit that exceeded this 
threshold was discarded. This method was employed as calculating pairwise Tc values for large 
databases (between 4000-100,000 molecules) is time consuming. Virtual hits that were less than 25% 
similar to the cluster medoid were then analysed using a second similarity metric. Pairwise Tc values 
were calculated for the virtual hits based on the SC medoid, any ligand that had a calculated pairwise 
Tc of greater than 0.6 was removed. 
5.2.10 Clustering & Cluster Medoid Selection 
The remaining hits from the virtual screen were clustered in ChemAxon JKlustor Library MCS (see 
section 5.2.2 for parameters). A representative molecule (medoid158) was identified as described 
previously and taken forward for each of the clusters identified. Single ligands that were not part of a 
larger cluster (i.e. singletons) were treated as medoids in their own right. This step was conducted to 
ensure that the minimum number of the most structurally diverse compounds (termed virtual hit 
representatives) were carried forwards into the next stage of the experiment. 
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5.2.11 Comparison to NPS representatives  
The virtual hit representatives identified were interrogated to ensure they were structurally distinct 
from known SC. Any virtual hit representative that had a pairwise Tc of greater than 0.6 with one of 
the fifteen SC medoids previously identified was removed. 
The virtual hit representatives were also screened for any similarities towards other classes of known 
NPS. This was carried out to ensure the representative molecules carried forwards were novel with 
respect to their chemical scaffolds. Pairwise Tc were calculated, for the virtual hit representative 
molecules and 11 NPS representative ligands taken from a study conducted by Zloh  et al249. Once 
again, any compound that had a pairwise Tc of greater than 0.6 when compared to an NPS medoid 
was removed.  
Finally, pairwise Tc values were calculated for the virtual hit representative molecules and the initial 
162 SC included the molecules that were not included in developing the pharmacophore models. 
Again, any which demonstrated pairwise Tc values of greater than 0.6 were removed from the study. 
5.2.12 Molecular Docking of potential hit molecules 
The remaining virtual hits were docked into the CB1 crystal structure (PDB accession code 5GTZ250). 
The structure was prepared using the “quickprep” application in MOE. Using the site finder application 
in MOE, a binding site was elucidated based on residues implicated in protein-ligand interaction at the 
CB1 binding site. The residues in the binding cavity include Met103, Gly166, Ser167, Phe170, Val196, 
Trp356, Phe379, Ser383, Cys386 and Leu38797 . Each ligand was docked into the binding site with a 
cut-off of 15 conformational poses. The default scoring functions (London dG and GBVI/WSA dG) in 
MOE were applied.  
In addition, the SC medoid ligands were docked into the CB1 receptor. As each of the SC medoids is 
known to elicit psychoactivity, the data obtained from this docking study can be used as a benchmark 
for the virtual screening compounds docking results. The virtual screening hits were ranked in order 
of their best-performing docking score.  Virtual screening compounds that had a score of less than         
-6.55 kcalmol-1 were discarded. This cut-off value was selected as none of the benchmark medoid SC 
compounds had a docking score of less than -6.55 kcalmol-1.  
5.2.13 Final selection of possible synthetic cannabinoid candidates 
The resultant library of virtual hits was assessed for possible mutagenic properties. Potentially toxic 
groups were assigned using the Kazius set251.  Any molecules that had toxic groups were discarded. 
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Remaining molecules were then purchased and taken forward for in vitro/ex vivo screening to assess 
their potential to bind to the CB1 receptor. 
5.3 Results and Discussion 
5.3.1 Database collation 
The synthetic cannabinoid ligands were collated using databases from the European Database of New 
Drugs (EDND), EMCDDA252,253 and the UNODC254.  
5.3.2 Clustering 
A total of 162 SC were available at the time of this study.  
The initial clustering approach using JChemAxon produced 54 clusters from the 162 molecules. The 
maximum number of ligands in any of the clusters generated was four. A pharmacophore model 
generated using a small number of structurally similar ligands will produce a highly selective model, 
which would be of little use in identifying potential new scaffolds for exploitation. As such, basing a 
pharmacophore on any of the JChemAxon clusters identified is likely to limit the number of structurally 
diverse “hits” being retrieved.  
Therefore, an alternative, manual, clustering approach was employed based on common chemical 
scaffolds observed for the SC.  
The EMCDDA classifies SC into seven categories and the UNODC uses six categories (see table 5.1)  
Table 5. 1: The major structural synthetic cannabinoid groups according to the EMCDDA255and the 
UNODC256. 
Seven structural SC groups according to the 
EMCCDA 
six structural SC groups according to the 
UNODC 
Naphthoylindoles Classical cannabinoids 
Naphthylmethylindoles Nonclassical cannabinoids 
Naphthoylpyrroles Hybrid cannabinoids 
Naphthylmethylindenes Aminoalkylindoles 
Phenylacetylindoles Eicosanoids 
Cyclohexylphenols Others 
Classical cannabinoids  
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The two classification systems described in Table 5.3 could not be applied to the 162 SC used in this 
study as many of the compounds could not be assigned to one of these categories. A finer-grained 
approach was required to identify more specific structural classifications in order to produce 
predictive pharmacophores, so the SC were grouped using the clusters described by Uchiyama et al13 
(see Table 5.2). 
Table 5. 2: The 15 different categories of synthetic cannabinoids as defined by Uchiyama et al242  and 
the number of molecules within each cluster. 
Name of common structural scaffold Number of molecules in cluster 
Benzoylindoles 6 
Carboxyamide derivatives 54 
Carboxyindoles 18 
Classical cannabinoids 3 
Cyclopropylindoles 10 
Cyclohexylphenols 3 
Naphthoylbenzimidazoles 2 
Naphthoylnaphthalenes 2 
Naphthoylindazoles 2 
Naphthoylindoles 48 
Naphthoylpyrrols 1 
Pentylindoles 2 
Phenylacetylindoles 1 
Others 8 
Quinolinyl carboxylates 2 
 
Three SC clusters identified from the Uchiyama classification had at least 16 ligands (carboxyamide 
derivatives, carboxyindoles and naphthoylindoles). These were taken forward into pharmacophore 
development studies. 
5.3.3 Pharmacophore development 
The flexibly aligned molecules from the three SC clusters were used to suggest a consensus set of 
pharmacophore features. These are formed based on annotation points assigned on the aligned atoms 
or centroid annotations which are located at geometric centric of a subset of aligned atoms. The 
annotation points also describe the atom types in terms of aromatic, hydrophobic, hydrogen bond 
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donor atoms or hydrogen bond acceptor atoms. The features form spheres of different radii which 
are determined by the aligned molecules and it is the different combination of feature types and 
spatial arrangement of each sphere that give rise to a unique pharmacophore model. The individual 
models were then used to screen the ZINC drug-like subset to match any potential hit ligands. 
All pharmacophore models were developed and optimised using the same Leave One Out (LOO) 
method. Enrichment plots were used to show how the removal of a feature impacts on how efficiently 
the model is able to retrieve expected hit ligands (i.e. molecules belonging to the same class of 
compounds used to derive the pharmacophore). The performance of each model was assessed by 
plotting the number of hits retrieved at 2, 5 and 10% of the total database scanned. The virtual hits 
identified by each of the pharmacophore models were ranked by RMSD values, whereby a SC-specific 
pharmacophore model would match the majority, if not all, of the expected (specific) SC hits first 
before matching with any other ligands within the NPS database. 
The initial pharmacophore models for the three different SC classes generated without modification 
was used as a comparison for all subsequent pharmacophores in the enrichment plots. Additionally, 
each plot includes a random line. This line is used to assess whether the pharmacophore models are 
able to identify expected hit compounds better than random. 
5.3.3.1 Carboxyamide derivatives (CD) pharmacophore 
The CD pharmacophore model generated from the aligned data based on the 54 CD molecules, 
produced a seven-feature pharmacophore (see Figure 5.2) which, when tested, retrieved only three 
of the possible 54 CD molecules from the entire 655 ligand NPS database. 
  
A B 
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Figure 5. 2: (A) a diagram showing all 54 carboxyamide derived synthetic cannabinoids flexibly aligned 
and superimposed with respect to one another and (B) The seven-feature pharmacophore model 
generated from the flexible alignment of the carboxyamide derivative ligands. The Aro|Hyd (3, 4 and 
5 orange) features represent aromatic/hydrophobic moieties, the PiN (1 and 2 orange features) 
represent features located along implicit lone pair of electrons or implicit hydrogen associated with 
ring structures and the cyan features represent hydrogen bond acceptors (6 and 7 cyan features). 
From the enrichment plot (Figure 5.3) it can be seen that pharmacophore model generated based on 
all the carboxyamide derivatives was unsuccessful at retrieving expected hits from the NPS dataset. 
This indicated that despite being constructed using known carboxyamide compounds, the 
pharmacophore wasn’t discriminative for carboxyamides. An Investigation into why this might have 
arisen was carried out. 
  
 
Figure 5. 3: An enrichment plot to show how well the carboxyamide derivative pharmacophore model 
for the carboxyamide derivatives (orange line) was able to identify the carboxyamide SC in the 655 
compound NPS database. The black line indicates how a pharmacophore model would perform if 
carboxyamide SC were matched at random. The graph shows the pharmacophore is unable to identify 
carboxyamide SCs from the NPS database. 
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5.3.3.1.1 Clustering of carboxyamide derivatives  
When the original 7-feature pharmacophore model for carboxyamide derivatives was used to screen 
the 655 compound NPS database, only 3 of the expected 54 compounds were identified.  
Investigations showed that the carboxyamide derivatives, arbitrarily categorised by the scaffold-based 
categorisation of Uchiyama et al, were comprised of two structurally distinct groups based on the 
pairwise Tc calculated. This inherent diversity in the group could therefore be the reason behind the 
initial pharmacophore being non-discriminant, and as such the group was divided into two separate 
clusters based on the Tc values Cluster 1 (1-ethyl-1H-indazole-3-carbaldehydes) and Cluster 2 (2-ethyl 
- 3, 4-dihydro - 2H – pyrrole - 5 -carboxamides) (Figure 5.4). Each new cluster was flexibly aligned and 
new pharmacophore models were generated 
Table 5.3 details the compounds that make up Cluster 1 and Cluster 2. Flexible alignment scores for 
the two new clusters (Table 5.4) are lower in value than the initial flexible alignment of the 54 
compounds. This suggests a greater structural similarity, and hence better consensus, in the two new 
carboxyamide clusters when compared to the original alignment. 
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Figure 5. 4: Molecule A is the common substructure found in Cluster 1 (1-ethyl-1H-indazole-3-
carbaldehyde), which contained 29 carboxyamide derivatives. Molecule B is the common substructure 
found in Cluster 2 (2-ethyl - 3, 4-dihydro - 2H – pyrrole - 5 -carboxamide) which contained 16 
carboxyamide derivative ligands. An example of a synthetic cannabinoid with cluster A and B has been 
shown. Sections of the molecule that are different to the cluster have been coloured red. 
 The remaining 10 ligands identified from the initial carboxyamide group formed singletons and were 
not included in the generation of new pharmacophore models. 
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Table 5. 3: The names of the SC carboxyamide derivatives that were categorised into Cluster 1 and Cluster 2. 
Carboxyamide derivatives contained in Cluster 1 Carboxyamide derivatives contained in Cluster 2 
5C-AKB48 ADB-FUBINACA 5F-ADBICA 
5F-AB-PINACA ADB-PINACA 5F-AMBICA 
5F-ADB-PINACA AKB-57 5F-AMB-PICA - MMB-2201 
5F-AKB48 AMB-FUBINACA 5F-APP-PICA - PX-1 
5F-AMB       /    5F-AMB-PINACA Apinaca /AKB-47 5F-PY-PICA 
5F-APP-PINACA - PX-2 APP-CHMINACA / PX-3 ADAMANTYL-THPINACA 
5F-EMB-PINACA - 5F-AEB APP-FUBINACA ADB-CHMICA 
5F-MDMB-PINACA - 5F-ADB CUMYL-5FPINACA ADBICA 
5F-PY-PINACA CUMYL-PINACA AMB-CHMICA 
AB-CHMINACA CUMYL-THPINACA - SGT-42 CUMYL-5F-P7AICA 
AB-FUBINACA EMB-FUBINACA CUMYL-5FPICA 
AB-FUBINACA 2-fluorobenzyl isomer FUB-AKB48 CUMYL-BICA 
AB-PINACA MDMB-FUBINACA CUMYL-PICA 
AB-PINACA N-(2-fluoropentyl) isomer  MDMB-CHMICA 
ADAMANTYL-THPINACA  MDMB-FUBICA 
ADB-CHMINACA  STS-135 
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Table 5. 4: The alignment scores for the 54 CD and the two identified CD clusters (C1 and C2), more 
negative values indicate a better flexible ligand alignment. 
 
5.3.3.1.2 Pharmacophore development of 1-ethyl-1H-indazole-3-carbaldehyde 
carboxyamide derivatives (Cluster 1_Carboxyamide). 
Alignment of the 29 ligands from Cluster 1 yielded a pharmacophore model with 6 features. This model 
identified 46 CD hits from the NPS database when used as a filter in a virtual screening experiment. 
All 29 of the carboxyamide derivatives used to generate the pharmacophore were matched by the 
pharmacophore when 100% of the NPS database had been screened. 
 
Figure 5. 5: The pharmacophore model based on the flexible alignment of the 29 carboxyamide 
derivative ligands from Cluster 1 (Cluster1_Carboxyamide). The Aro|Hyd (1 and 2, orange) features 
represent aromatic/hydrophobic moieties, the PiN (5 and 6 orange) represent features located along 
implicit lone pair of electrons or implicit hydrogen associated with ring structures, the light pink 
feature (4) represents a hydrogen bond acceptor/donor region and the cyan feature (3) represents a 
hydrogen bond acceptor feature. 
  All Carboxyamide derivatives Carboxyamide 
derivatives cluster 1 
Carboxyamide 
derivatives cluster 2 
Scored value -39.851 -58.446 -82.197 
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An iterative LOO process was then carried out. This process involved the removal of a one feature at 
a time from the Cluster 1 pharmacophore shown in Figure 5.5. The modified pharmacophore models 
were then used to re-screen the NPS database to see how many of the carboxyamide derivative 
synthetic cannabinoids are retrieved at various stages of the virtual screen. Where the search 
performed better than random, an Ef was calculated at 2, 5 and 10% of the search (Table 5.5). 
This process was repeated until a pharmacophore was generated that contained the fewest number 
of features and retrieved the highest percentage of the expected synthetic cannabinoids within the 
first 10% of the NPS database virtual screen. Figure 5.6 is an enrichment plot of the first LOO 
experiment for the Cluster 1 pharmacophore. From the plot, it can be seen that removal of any of the 
features reduced the number of carboxyamide Cluster 1 compounds the pharmacophore model was 
able to detect from the total NPS database at 2, 5 and 10%, indicating that the original pharmacophore 
generated was the best-performing. 
  
Figure 5. 6: Enrichment plot of the Carboxyamide cluster 1 pharmacophore models, the numbered 
lines correspond to the feature that was removed from the original pharmacophore and how this 
affected the model’s ability to match with Cluster 1 ligands. The graph also includes a brown line that 
represents a random hit rate. 
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Table 5. 5: The calculated enrichment factor (Ef) for the Carboxyamide cluster 1 pharmacophore 
model. The table shows Ef for the original consensus pharmacophore. The Ef is given at different stages 
of the virtual screen (i.e. at 2, 5 and 10% of molecules considered). 
Pharmacophore  Enrichment factors 
 
at 2% at 5% at 10% 
original  12.1 9.6 8.3 
1 0.0 0.0 0.0 
2 5.2 2.1 2.4 
3 5.2 2.1 2.4 
4 5.2 2.1 2.4 
5 5.2 2.1 2.4 
6 5.2 2.1 2.4 
 
The enrichment plot in Figure 5.6 and the Ef value in Table 5.5 shows the initial carboxyamide cluster 
1 pharmacophore model as the best at retrieving Cluster 1 ligands in the early stages of a virtual 
screening search. The highest Ef is obtained when 2% of the NPS database has been searched where 
the Ef value of 12.1 indicates that the original pharmacophore model is 12.1 times better at selectively 
identifying Cluster 1 ligands in comparison to a model finding them at random. As such the initial six -
feature carboxyamide pharmacophore model was taken forward to use to identify potential novel SC 
scaffolds in the virtual screen of the ZINC database.   
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5.3.3.1.3 Pharmacophore development of 2-ethyl - 3, 4-dihydro - 2H – pyrrole - 5 -
carboxamide carboxyamide derivatives (Cluster 2). 
The aligned Cluster 2 carboxyamide ligands generated a six-feature pharmacophore model (see figure 
5.7) 
 
Figure 5. 7: The pharmacophore model with based on the flexible alignment of the 16 carboxyamide 
derivative ligands from Cluster 2. The Aro|Hyd (2, 3, 4 and 6, orange) features represent 
aromatic/hydrophobic moieties, the PiN (1, orange) represent a feature located along implicit lone 
pair of electrons or an implicit hydrogen associated with ring structures and the light pink feature (5) 
represents a hydrogen bond acceptor/donor region. 
Figure 5.8 shows the enrichment plot obtained using the initial carboxyamide_cluster2 
pharmacophore model, and the iterative LOO pharmacophore models, whereby one feature was 
sequentially removed, from the initial model and the resultant modified pharmacophore models used 
to search the 655 compound NPS database, to identify which model performed the best at identifying 
carboxyamides.  
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Figure 5. 8: Enrichment plot obtained from the carboxyamide cluster 2 pharmacophore searches. The 
lines show what percentage of Cluster 2 ligands have been retrieved from the NPS database as a 
function of the total database searched. Each coloured line represents a different model. The light 
blue line represents the original consensus pharmacophore model. The numbered lines represent the 
results of a search after the removal of the numbered pharmacophore feature (see Figure 5.7). The 
graph also includes a black line that represents a random hit rate. 
The enrichment plot and enrichment factors calculated (see Table 5.6) indicate that the initial 6-
feature pharmacophore model is the most successful model with respect to retrieving the greatest 
number of carboxyamide cluster 2 ligands within the first 10% of the NPS database searched. As such 
this model was taken forward and used to screen the ZINC database for potential novel SC scaffolds. 
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Table 5. 6: The calculated enrichment factors (Ef) for the Cluster 2 pharmacophore model, the table 
shows Ef for the original consensus pharmacophore and Ef when a feature has been removed. The Ef 
are given at different percentages which indicate how many carboxyamide derivatives had been found 
at 2, 5 and 10% of the NPS database search.   
 Enrichment factors 
  at 2% at 5% at 10% 
original 3.1 3.8 3.8 
feature 1 removed 0 0 1.9 
feature 2 removed 0 1.3 1.3 
feature 3 removed 0 1.3 2.5 
feature 4 removed 0 0 1.3 
feature 5 removed 0 0 1.3 
feature 6 removed 0 1.3 1.9 
 
5.4 Carboxyindole pharmacophore 
The carboxyindoles group identified by the Uchiyama257 strategy for clustering the SCs contained 18 
molecules. The initial carboxyindole pharmacophore model generated consisted of 9 features (see 
Figure 5.9). 
 
 
 
158 
 
 
Figure 5. 9: The consensus pharmacophore model based on the flexible alignment of the 18 
carboxyindole ligands. The Aro|Hyd (4, 5, 6 and 7 orange) features represent aromatic/hydrophobic 
features, the PiN (1, 2 and 3 orange) represent features located along implicit lone pair of electrons 
or implicit hydrogen associated with ring structures and the cyan (8 and 9) features represents 
hydrogen bond acceptors.  
 
Figure 5. 10:  Enrichment plot obtained from the carboxyindole pharmacophore model search, the 
lines show what percentage of carboxyindole ligands have been retrieved from the NPS database. 
Each coloured line represents a different model (it should be noted there is some overlap of data 
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points which has resulted in lines 1 and 2 not being visible). The light blue line represents the original 
consensus pharmacophore model. The different numbered coloured lines represent the results of a 
search after the removal of that pharmacophoric feature from the original pharmacophore (Figure 
5.9). The graph also includes a black line that represents a random hit rate. 
The LOO process was able to eliminate 3 features (Feature 2, Feature 3 and Feature 4) and the refined 
6-feature model (Figure 5.11) was able to retrieve 100% of the carboxyindole ligands in the dataset in 
comparison to 45% of the total compounds retrieved by the initial model. The removal of features was 
achieved using an iterative process to ensure the highest Ef was obtained using the fewest number of 
features. Removal of features 2, 3 and 4 individually resulted in an improved hit rate (see Table 5.7). 
The next step was to remove both features 2 and 3 to see if an improved Ef was obtained. An Ef value 
of 3.3 was obtained when features 2 and 3 were removed compared to 2.8 when only one feature 
was removed. Removal of features 3 and 4 provided the same Ef of 3.3 as was obtained for the removal 
of features 2 and 3. Therefore in an attempt to improve the enrichment factor further features 2, 3 
and 4 were removed this resulted in an Ef of 5.5 which demonstrates that the best carboxyindole 
model contains only six features (Figure 5.12). 
 
Figure 5. 11: The refined 6-feature carboxyindole pharmacophore model arrived at via the LOO 
methodology. The Aro|Hyd (1, 2, 3 and 4 orange) features represent aromatic/hydrophobic moieties, 
and the cyan features (5 and 6) represent hydrogen bond acceptor feature.  
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Figure 5. 12: Enrichment plot that compares the performance of the original (blue) 9-feature 
carboxyindole pharmacophore model to the 6-feature model (red) generated by the iterative LOO 
method, (see Figure 5.11). The graph also includes a black line that represents a random hit rate. 
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Table 5. 7: The calculated enrichment factors (Ef) for the carboxyindole pharmacophore model. The 
table shows Ef for the initial 9-feature carboxyindole pharmacophore model and Ef when a feature has 
been removed. The Ef are given at different stages of the search which indicate how many 
carboxyindole ligands had been retrieved within the top 2, 5 and 10% of the NPS database search. 
Pharmacophore Enrichment factors 
 
at 2% at 5% at 10% 
Initial 0 0 0.6 
feature 1 removed 2.8 3.3 1.0 
feature 2 removed 2.8 3.3 1.7 
feature 3 removed 2.8 3.3 1.7 
feature 4 removed 0 0 1.0 
feature 5 removed 0 0 1.7 
feature 6 removed 0 0 1.1 
feature 7 removed 0 0 1.7 
feature 8 removed 0 0 1.1 
feature 9 removed 0 0 1.1 
features 1 & 2 removed 8.3 5.8 5.6 
features 2 & 3 removed 8.3 5.8 5.6 
features 1, 2 & 3 removed 8.3 5.8 5.6 
 
The optimised six-feature pharmacophore model was then carried forward and used to screen the 
ZINC database for potential novel SC scaffolds. 
Analysis of the flexible alignment of the carboxyindoles and the initial consensus pharmacophore 
show that features 1, 2 and 3 are PiN centroid projections based on the π-system formed from the 
aligned aromatic rings. The PiN projections generated, place features at a 90⁰ angle to the aligned 
benzene rings and the presence of these features will restrict the number of hits found in the screen 
as only molecules that have a benzene ring in the same orientation, to that of the original 
pharmacophore will be detected. Figure 5.13 shows two benzene rings with the same apparent 
orientation with respect to the aromatic feature (2) of the pharmacophore, but one benzene ring has 
been rotated by 180⁰ relative to the other. Although the benzene ring itself has not changed position 
the associated PiN feature has also rotated by 1800, and hence the overlap of the second orientation 
with the pharmacophore is considered poor when compared to the first. The PiN features therefore 
impart a high degree of selectivity in terms of absolute orientation and ultimately place restrictions 
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on the number of ligands retrieved from a virtual screen when they are present. Therefore, it makes 
sense that the enrichment factors increase upon the removal of these features. 
 
 
Figure 5. 13: Two benzene rings that have been annotated with PiN features, the benzene ring 
depicted as B shows the direction of the PiN feature when the benzene ring is rotated by 180⁰. 
5.3.3.2 Naphthoylindole pharmacophore 
The original pharmacophore model generated for the naphthoylindole cluster a model with 8 features 
shown in Figure 5.14 
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Figure 5. 14: The consensus pharmacophore model based on the flexible alignment of the 48 
naphthoylindole derivative ligands. The Aro|Hyd (5 and 6 orange) features represent 
aromatic/hydrophobic features, the PiN (1, 2, 3 and 4 orange features) represent features located 
along implicit lone pair of electrons or implicit hydrogen associated with ring structures, and the cyan 
feature represents a hydrogen bond acceptor feature (7 and 8).  
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Figure 5. 15: Enrichment plot obtained from the naphthoylindole pharmacophore model search. The 
lines show what percentage of naphthoylindole ligands have been retrieved from the NPS database 
at different stages of the virtual screen. Each coloured line represents a different model, it should be 
noted that lines 1, 3 and 5 are present but are obscured by lines 4 and 6. The light blue line represents 
the original consensus pharmacophore model. The different numbered coloured lines represent 
models that result from the removal of that particular pharmacophoric feature (see Figure 5.14) via a 
LOO process i.e. the results of a search after the removal of a pharmacophore feature. The graph also 
includes a black line that represents a random hit rate. 
Table 5. 8: The calculated enrichment factors (Ef) for the naphthoylindole pharmacophore model. The 
table shows Ef for the initial 8 feature naphthoylindole pharmacophore and Ef when a feature has been 
removed. The Ef are given at different stages of the virtual screen which indicates how many 
naphthoylindole ligands had been retrieved at 2, 5 and 10% of the NPS database search 
 
 Enrichment factors 
 at 2% at 5% at 10% 
Initial  2.1 1.5 3.1 
feature 1 removed 2.1 1.5 3.1 
feature 2 removed 4.2 9.8 7.9 
feature 3 removed 4.2 4.7 7.9 
feature 4 removed 2.1 1.5 3.1 
feature 5 removed 2.1 9.8 3.5 
feature 6 removed 2.1 1.5 2.3 
feature 7 removed 2.1 1.5 3.5 
feature 8 removed 2.1 1.5 2.3 
features 2 & 3 removed 13.5 9.8 7.9 
 
The optimised naphthoylindole pharmacophore model was reduced from eight features down to six 
(features 2 and 3 were removed both were PiN features), the removal of these features resulted in 
the refined 6-feature naphthoylindole pharmacophore model, (see figure 5.16) having an Ef of 6.3 
when the first 2% of the NPS database search.  
When analysing the flexible alignment of the naphthoylindoles, there were two regions that were 
heavily populated by aromatic regions. The removed PiN features (2 and 3) account for the collective 
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projection features generated from the large number of aromatic rings in that particular region. The 
presence of these features imparts a selectivity with respect to the absolute orientation of aromatic 
rings that becomes too restrictive to the virtual screening approach as explained above and explains 
the reduced selectivity of the initial pharmacophore model, compared to the model that has these 
features removed, thus enabling the full range of naphthoylindoles to be detected by the optimised 
6-feature model. 
 
Figure 5. 16: Refined 6 feature naphthoylindole pharmacophore model, features are numbered in 
black. The Aro|Hyd (3 and 4 orange) features represent aromatic/hydrophobic features, the PiN (1 
and 2 orange features) represent features located along implicit lone pair of electrons or implicit 
hydrogen associated with ring structures, and the cyan feature represents a hydrogen acceptor 
feature (5 and 6).  
5.5 Medoid selection  
From each of the four SC clusters a medoid was identified and used as a benchmark to ensure the 
virtual hits selected from the pharmacophore search were structurally dissimilar to the medoids of 
the clusters of the known synthetic cannabinoids used to develop the pharmacophore models. This 
would help ensure novel scaffolds for potential SCs could be identified. 
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Table 5. 9: shows the common name and chemical structure of the SC medoids from each synthetic 
cannabinoid cluster used to develop the pharmacophores above. The portions of the first two 
molecules that have been coloured red highlight the identical moiety between the cluster 1 and cluster 
2 carboxyamide medoids. 
 
 
Synthetic cannabinoid 
cluster 
Medoid 
Name 
Medoid Chemical 
Structure 
 
Carboxyamide cluster 
1 
ADB-PINACA 
 
Carboxyamide cluster 
2 
ADBICA 
 
Carboxyindole AM-694 methyl 
substituted for Iodine 
 
Naphthoylindole JWH-018 
 
 
 
The carboxyamide medoids differ as follows. The Cluster 1 medoid contains an indazole ring whereas 
the Cluster 2 medoid contains an indole ring. The similarity of these ligands is not unexpected, as the 
medoids have been generated from the same parent SC cluster (the cluster fragment is coloured red 
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in Table 5.9).  As the majority of the naphthoylindole molecules are analogues of JWH-018, it is also 
not unexpected that this ligand is the medoid for that naphthoylindole group.  
5.5.1 Virtual library selection 
The four optimised pharmacophore models were used to screen a set of drug-like molecules in an 
attempt to identify potential unexploited chemical scaffolds for synthetic cannabinoids. There are a 
number of different types of libraries available from zinc.docking.org244, these databases include 
options such as “clean” datasets where stricter filtering rules (e.g. compounds that contain aldehydes 
and thiol groups have been removed) have been applied. This is to remove groups that may have 
unfavourable pharmacokinetic properties258. The standard drug-like259 subset was selected for the 
virtual screen (at the time of access November 2016), there were 17,900,742 molecules in the drug-
like subset.  
5.5.2 Virtual screen of database using pharmacophore model 
The four refined pharmacophore models identified in Sections 5.3.3.1- 5.3.3.3 were used to search 
the ZINC “drug-like” database. A cut-off RMSDx value of 1.5 Å was applied for a molecule to be 
considered a hit. Any compound that fell outside of this range was removed from the screening 
process. The initial virtual search conducted using the four models retrieved a total of approximately 
7.4 million hits from database.  
5.5.3 Filtration of virtual hits 
The initial virtual hit library of 7.4 million compounds was reduced in size by applying filters that would 
provide a final library of molecules that were structurally different to known SC but would have similar 
physicochemical properties. The protocol for achieving this is summarised in Figure 5.17. 
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Figure 5. 17: A diagram to show how the number of virtual hits were filtered. The numbers stated are the sum of all the virtual hits found for the four pharmacophore 
models (carboxyamide cluster 1 and 2, carboxyindole and naphthoylindole). 
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5.5.4 Filtration of hits 
The number of molecules retrieved had to be reduced to curate a manageable database of molecules 
that could be taken further for biological evaluation. 
5.5.5 Log PS 
The first filter applied to the database was log PS which is the log of permeability surface area product. 
This filter was applied as it is strongly correlated to the values obtained when calculating the log of 
the Blood Brain Barrier BBB concentration245. Experimental logBBB values were unavailable for the 
virtual hits, and could not be calculated due to the prohibitive cost of the software required. However, 
an estimation of the ability for a compound to permeate the blood-brain barrier was deemed 
important, as it is necessary for a SC to cross the blood brain barrier to elicit a psychoactive effect. For 
each SC cluster (carboxyindoles 1 and 2, carboxyamides and naphthoylindoles) a minimum and 
maximum log PS value was established based on the values calculated for all the known SC in that 
particular cluster. The range of Log PS values was -2.50 to -0.22, and any compounds from the virtual 
screen that fell outside of this range were rejected. 
5.5.6 Log S  
The second filter applied was a molecular descriptor that describes aqueous solubility. This filter was 
applied as it is necessary for virtual hits to be soluble in aqueous media as virtual hits identified will 
be evaluated for possible biological activity. The experiments to establish this will be conducted using 
a variety of different aqueous based media, and therefore it is necessary for screening hits to be 
soluble to some extent in water. The range of log S values identified was -8.93 to -2.88, and hit 
compounds that fell outside of this range were rejected. 
5.5.7 Structural similarity 
To minimise the structural similarity between the four identified SC medoids, the NPS representative 
ligands (see Table 5.11) and the virtual hits retrieved, two different similarity metrics were used. Firstly 
FP: MACCS structural keys were generated and assigned to both the virtual hits and the identified 
medoids. Any virtual hit that had a structural similarity greater than 25% to any of the medoids or NPS 
representatives were rejected. This is to ensure that the virtual hits identified were as structurally 
distinct from all known NPS as possible allowing for completely novel ligands to be identified.  
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Secondly, pairwise Tc were calculated for the virtual hits and the initial SC database (containing 162 
SC), this was carried out to identify if any of the virtual hits were similar to any known SC not just the 
SC molecules used to develop the different pharmacophore models. The highest Tc value obtained 
was 0.46 between AMB-CHMICA and compound 7, this ensures that the identified virtual hits are 
structurally different to all other categories of SC and NPS. 
Table 5. 10: A list of the NPS representatives used in the comparison between NPS classes and hit 
molecules. 
Name of NPS NPS classification as described by Zloh et al 
N-Me-2-AI Aminoindane 
2-MAPB Arylalkylamines 
Methoxetamine (MXT) Arylcyclohexylamines 
Flubromazepam Benzodiazepines 
Mephedrone (4-MMC) Cathinones 
DPT Indolealkylamines 
Fentanyl butanamide analogue Opioids 
Afloqualone Others 
25H-NBOMe Phenethylamines 
DBZP Piperazines Derivatives 
HDMP-28 (methylnaphthidate) Piperidines & Pyrrolidines 
 
5.5.8 Clustering & Cluster Medoid Selection 
Clustering was employed to identify groups of structurally similar molecules from the resulting virtual 
hits. From each identified cluster a medoid compound was identified and taken forward for further 
investigation. Medoids were identified from clusters that contained 3 or more compounds. All 
molecules in clusters with two or fewer compounds were carried forward for further investigation (i.e. 
no medoids were identified for these clusters). This approach was taken to reduce the number of 
virtual hits retrieved and would produce a library of optimised compounds which could be evaluated 
for their ability to elicit psychoactivity. 
Three of the virtual hits shared structural similarity with an NPS representative with a Tc of greater 
than 0.6 and were removed from the study, table 5.11 show the chemical structure of the virtual hits 
and the corresponding similar representative ligand. 
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Table 5. 11: shows the chemical structures of the three medoids ligands that were removed from the 
virtual hit library. The compounds were removed as they had a Tc of greater than 0.6 with the known 
NPS representatives. This was carried out to ensure the medoids used were structurally distinct from 
known synthetic cannabinoids and known NPS representatives. 
Chemical structure of hit medoid compound  Name and structure of NPS 
 
3-(3,4-dichlorophenyl)-4-methylquinazolin-
2(3H)-one 
 
 
Afloqualone 
 
 
 
 
7-chloro-5-(2-chlorophenyl)-3-methoxy-1-
methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-
2-one 
 
 
 
 
 
 
 
 
Flubromazepam 
 
 
 
8-chloro-6-(2-fluorophenyl)-1-methylene-2,4-
dihydro-1H-benzo[f]imidazo[1,5-
a][1,4]diazepine 
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The presence of 2,3,6,7,-tetrahydro-1H-1,4-diazepine group attached to two halogenated benzene 
rings was found in 2 different hit medoid compounds which accounts for the Tc value of 0.6 with 
Flubromazepam. Similarly, the 5,6-dihydropyrimidine-4 (3H)-one group that is found in Afloqulone 
was also present in at two of the hit medoid compounds and again explains the Tc value of 0.64. 
5.5.9 Similarity of virtual hits  
A library of 507 virtual hits remained. The final stage of optimising the hits to be carried forwards into 
testing was to ensure the database of hits selected were as structurally diverse as possible as this 
would ensure that the breadth of the filtered structures was captured and limit the number 
compounds being taken forward. This was achieved by calculating pairwise Tc for all the resulting hits 
and removing any ligands that had Tc of over 0.6 (the molecule with the lowest Tc value was retained) 
which produced a database of 248 ligands. 
5.5.10 Evaluation of drug likeness and toxicity 
A database of 248 ligands resulted after the application of the filters listed in section 5.4.5 - 5.4.11. 
These compounds were then analysed to ensure they all followed the drug like criteria as described 
by Lipinski259 and Oprea228. Any ligands that violated the criteria were removed. Finally, using the 
mutagen descriptor option in MOE, ligands that had known mutagenic subgroups were removed from 
the database leaving 222 potential virtual hits. 
5.5.11 Molecular Docking of potential hit molecules 
222 ligands were docked using MOE into the CB1 crystal structure (accession code 5TGZ, Resolution: 
2.8 Å). Each conformation generated by the software was analysed for the number and type of 
interactions made within the CB1 binding site. Amino acid residues that had been reported in the 
literature as being key in the interaction of ligands with the CB1 binding site97 were used, alongside 
the reported S-score values, as a benchmark for ranking the docked poses of the ligands. Amino acid 
residues of interest include Met103, Gly166, Ser167, Phe170, Val196, Trp356, Phe379, Ser383, Cys386 
and Leu38797. An example of a protein-ligand interaction fingerprint (PLIF) for a docked screening 
compound is given in Figure 5.18. From this ligand interaction diagram, it can be seen that all of the 
amino acid residues previously reported as playing a role in binding of small molecules to the CB1 
receptor (except Gly166) are either making an interaction with the ligand or are in close proximity to 
the ligand. This indicates that the likelihood of this compound being able to form an appropriate 
interaction with the CB1 receptor, and hence elicit psychoactivity, is feasible and warrants further 
experimental investigation. 
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Figure 5.18: PLIF, depicting the ligand N-benzyl-4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phthalazin-1-
amine docked in the binding site of the CB1 receptor (5TGZ97). This docked conformation produced a 
score of -8.31 Kcal mol-1, in comparison to JWH-018, a known CB1 binder, which produced a score of 
-7.52 Kcal mol-1. 
Docked ligands that had a scored value of -6.55 Kcalmol-1 or lower were highlighted as the most likely 
candidates to successfully bind to CB1 in vitro/in vivo. This cut-off value was used as the SC JWH-018 
had an average docked value of -6.55 (± 0.38) Kcalmol-1 based on 15 docked conformations. Thirty-five 
ligands scored values of -6.55 Kcalmol-1 or less, and from the 35 ligands selected 13 compounds were 
identified (due to financial limitations). To ensure the compounds were structurally dissimilar a 
correlation matrix of Tc was constructed, see Figure 5.19. 
The 13 compounds selected fulfilled all the criteria required to ensure the compounds would interact 
with the CB1 receptor and have physicochemical properties that were similar to known CB1 agonists 
therefore providing a reassuring evidence that these compounds would have the ability to elicit 
psychoactivity. 
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Figure 5. 19: correlation matrix of the pair wise Tc values for the four SC medoids (where M1, M2, M3 and M4 represent ADB-PINACA, ADBICA, AM-694 methyl 
substituted for iodine and JWH-018 respectively) and the 13 compounds selected for biological evaluation, none of the compounds have a pairwise Tc value 
of above 0.6 indicating that all 13 compounds are structurally dissimilar. 
 
M1 M2 M3 M4 1 2 3 4 5 6 7 8 9 10 11 12 13 
M1   0.50 0.33 0.31 0.30 0.23 0.22 0.18 0.14 0.13 0.16 0.17 0.27 0.26 0.21 0.24 0.25 
M2 0.50   0.54 0.55 0.24 0.24 0.24 0.20 0.11 0.14 0.11 0.16 0.27 0.29 0.30 0.22 0.29 
M3 0.33 0.54   0.88 0.19 0.23 0.26 0.15 0.15 0.12 0.15 0.14 0.28 0.30 0.25 0.22 0.32 
M4 0.31 0.55 0.88   0.18 0.23 0.24 0.13 0.14 0.12 0.16 0.13 0.28 0.29 0.26 0.20 0.30 
1 0.30 0.24 0.19 0.18   0.41 0.23 0.17 0.11 0.16 0.13 0.15 0.20 0.22 0.21 0.17 0.23 
2 0.23 0.24 0.23 0.23 0.41   0.26 0.19 0.11 0.11 0.12 0.18 0.18 0.25 0.23 0.19 0.26 
3 0.22 0.24 0.26 0.24 0.23 0.26   0.23 0.13 0.12 0.14 0.15 0.20 0.24 0.39 0.15 0.38 
4 0.18 0.20 0.15 0.13 0.17 0.19 0.23   0.08 0.10 0.11 0.12 0.14 0.18 0.21 0.11 0.21 
5 0.14 0.11 0.15 0.14 0.11 0.11 0.13 0.08   0.09 0.09 0.18 0.13 0.13 0.09 0.22 0.12 
6 0.13 0.14 0.12 0.12 0.16 0.11 0.12 0.10 0.09   0.26 0.13 0.15 0.14 0.11 0.12 0.09 
7 0.16 0.11 0.15 0.16 0.13 0.12 0.14 0.11 0.09 0.26   0.07 0.13 0.15 0.12 0.09 0.16 
8 0.17 0.16 0.14 0.13 0.15 0.18 0.15 0.12 0.18 0.13 0.07   0.13 0.12 0.19 0.27 0.19 
9 0.27 0.27 0.28 0.28 0.20 0.18 0.20 0.14 0.13 0.15 0.13 0.13   0.51 0.16 0.19 0.19 
10 0.26 0.29 0.30 0.29 0.22 0.25 0.24 0.18 0.13 0.14 0.15 0.12 0.51   0.20 0.20 0.20 
11 0.21 0.30 0.25 0.26 0.21 0.23 0.39 0.21 0.09 0.11 0.12 0.19 0.16 0.20   0.15 0.49 
12 0.24 0.22 0.22 0.20 0.17 0.19 0.15 0.11 0.22 0.12 0.09 0.27 0.19 0.20 0.15 > 0.18 
13 0.25 0.29 0.32 0.30 0.23 0.26 0.38 0.21 0.12 0.09 0.16 0.19 0.19 0.20 0.49 0.18   
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Figure 5.20 highlights the pairwise Tc values for the selected and the SC medoid, this gives confidence 
that the compounds purchased were structurally distinct from one another. 
 5.4.12 Final selection of possible synthetic cannabinoid candidates 
Table 5.12 shows the structures of the ligands that from the filtering and docking process were 
predicted most likely to bind to CB1, and hence had an opportunity to elicit psychoactive effects. These 
compounds were also chosen due to their availability for purchase. The compounds were purchased 
from MolPort. 
Table 5. 12: The chemical structures and systematic names of the final selected 13 virtual hits. The hits 
were assigned numbers which were then used for the biological evaluation. 
 
Chemical structure and systematic name of the 13 compounds purchased and taken forward for 
biological evaluation 
 
 
 
 
 
 
 
 
 
Compound 1  
N-benzyl-4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl) 
phthalazin-1-amine 
 
 
 
Compound 2  
7-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-
(1-(pyridin-2-yl)ethyl)quinolin-2-amine 
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Chemical structure and systematic name of the 13 compounds purchased and taken forward for 
biological evaluation 
 
 
 
 
 
Compound 3 
N-(2-isopropyl-6-methylphenyl)-2-oxo-2H-
chromene-3-carboxamide 
 
Compound 4  
(1E,3E)-N1,N3-bis(furan-2-ylmethyl)isoindoline-
1,3-diimine 
 
 
 
 
 
Compound 5 
(E)-2'-(3-(dimethylamino)acryloyl)-5'-
(methylthio)-[2,3'-bithiophene]-4'-carbonitrile 
 
Compound 6 
(4-(((7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)sulfinyl)methyl)phenyl)methanol 
 
 
 
 
 
 
Compound 7 
2-(2-phenethoxyphenoxy)ethan-1-ol 
 
 
Compound 8 
(E)-3-(4-chlorophenyl)-1-methyl-5-(thiophen-2-
ylmethylene)-2-thioxoimidazolidin-4-one 
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Chemical structure and systematic name of the 13 compounds purchased and taken forward for 
biological evaluation 
 
 
 
 
 
Compound 9 
8-chloro-3-methyl-10-phenylpyrimido[4,5-
b]quinoline-2,4(3H,10H)-dione 
 
Compound 10 
3-(3,5-dimethylphenyl)-2,10-
dimethylpyrimido[4,5-b]quinoline-4,5(3H,10H)-
dione 
  
Compound 11 
4-bromo-N-(3-ethynylphenyl)benzamide 
 
Compound 12 
5-[[(6-methyl-1,3-benzothiazol-2-
yl)amino]methylidene]-2-sulfanylidene-1,3-
diazinane-4,6-dione 
 
 
 
 
 
 
 
 
Compound 13 
N-(2,3-dihydro-1H-inden-5-yl)-2,4-
difluorobenzamide 
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5.6 Conclusions 
A library of known synthetic cannabinoids was used to develop pharmacophores, which in turn were 
used to identify compounds that would be predicted to have the same propensity for binding to the 
CB1 receptor as known SC, but crucially would be significantly structurally different from known SC 
and other known NPS. 
The class of synthetic cannabinoids that contained the most compounds was the carboxyamide 
derivatives. From this group, two different pharmacophore models were generated. The cluster 2 
pharmacophore model was able to retrieve 40% of the desired synthetic cannabinoid within the first 
10% of the total NPS database and at 2% of the total database screened had an Ef of 3.1 during virtual 
screening experiments. Pharmacophore models for the napthoylindole and carboxyindole synthetic 
cannabinoid clusters were also generated with Ef of 13.5 and 8.3 respectively at 2% of the total 
database screened. Both of these models were able to retrieve 22-25% of the desired synthetic 
cannabinoid ligands within the first 10% of the NPS database, and were a significant improvement 
over random, which indicates that the pharmacophore models developed were successful at 
identifying appropriate compounds from a database of known NPS. 
The initial virtual screen conducted using the four pharmacophore models generated, retrieved 
between 1.3-2.3 million hit molecules per pharmacophore model which is approximately 7% of the 
total ZINC drug-like database. The log PS and log S filters reduced the number of potential molecules 
in each SC sub cluster down to between 0.3 and 4.7% of the ZINC database. The filter that excluded 
the most ligands was the FP: MACCS similarity filter. This filter served a dual purpose by first reducing 
the number of ligands and secondly ensuring the ligands carried further into the study had no more 
than 25% structural similarity103 to the SC medoids i.e. there was more opportunity to identify a 
chemical scaffold that was truly novel/unexploited. 
The docking studies conducted using the virtual hits indicate that an interaction between these ligands 
and the CB1 receptor is feasible and could potentially lead to the identification of novel compounds 
that could bind to the CB1 receptor. The 13 compounds identified for progression into in vitro studies 
all had appropriate physicochemical properties that were determined from known SC to suggest they 
had the potential to bind to the CB1 receptor. The virtual hit compounds also showed similar 
interactions in the CB1 receptor binding site to known SC such as JWH-018 as evidenced by the docking 
studies. A Tc pairwise comparison showed that the 13 virtual hits were structurally different to known 
SC as the highest calculated Tc between the virtual hits and the medoid ligands was 0.32 (Figure 5.19). 
The next stage of this research is to screen the compounds in vitro to establish any possibility that the 
molecules identified produce a biological response. 
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Chapter 6 In Vitro and Ex Vivo evaluation of potential CB1 receptor 
ligands. 
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6.1 Introduction 
The endocannabinoid system is considered complex and has yet to be fully understood. Cannabinoid 
receptors belong to the family of G Protein Coupled Receptors (GPCRs), activation of these receptors 
initiates a biochemical cascade which ultimately alters normal neurotransmitter release260. 
Thirteen potential synthetic cannabinoid (SC) like compounds were identified as likely “hit” candidates 
from the virtual screen conducted out in Chapter 5. “Hit” candidates were molecules that were 
identified using pharmacophores used to screen a virtual library, and selected based on a number of 
physicochemical filters. The compounds were selected based on their structural dissimilarity to SC and 
purchased accordingly. It is the aim of this chapter to illustrate the approach used to identify the 
biological activity of these compounds and investigate the activation of the CB1 receptor, which can 
help indicate the potential of these compounds to elicit a psychoactive effect. The potential biological 
activity of these compounds were assessed using mammalian cell lines and immunosorbent technique 
ELISA1,2–7. A preliminary study involving electrical field stimulations (EFS), was also employed in an 
attempt to further validate these molecules as potential cannabinoid receptor agonists266–269. 
To ascertain whether the compounds of interest interacted with the CB1 receptor, a cAMP ELISA was 
carried out to assess whether there is an increase in cAMP when the cell is exposed to a compound. 
This particular assay has been extensively employed264,270,271,263,272, and a number of studies report that 
SC increase cAMP accumulation in cells located in the brain when experiments are conducted without 
the presence of the commonly used stimulant forskolin271,273,274. Forskolin directly activates adenylyl 
cyclase and increases cAMP concentrations275. The commercially available CHO-CNR1 cell-line that 
expresses the CB1 receptor was purchased and a batch growth curve was generated alongside the use 
of the MTS and LDH assays to identify growth characteristics required to optimise the ELISA 
experiment, as well as to establish initial cell-based toxicological responses to the compounds. Cell 
culture was also employed as a standalone technique to generate information about the cell growth 
profile. A study carried out by Sibaev et al, (2013) showed that the endogenous cannabinoid 
anandamide (see Figure 6.1) activates the CB1 receptors located in the ileum of rodents. The most 
commonly used rodents for this type of experiment are rat276 and guinea pig277 . As such, to obtain 
further validation on the biological activity of the screening compounds, an EFS study using rat ileum 
was carried out as evidence exists to suggest that SC depresses or has an active role in gut 
motility266,267,268.  
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Figure 6. 1: The chemical structure of the endogenous cannabinoid anandamide (N-
arachidonoylethanolamine, AEA).  
Based on the premise that the compounds selected from the virtual screen would interact with the 
CB1 receptor, the EFS study was conducted to further confirm these molecules a valid CB1 receptor 
ligand. 
This chapter will detail the methodology employed to identify possible biological activity exerted by 
the compounds of interest. The studies carried out suggest that compound 1 and compound 12 (Figure 
6.2) interact with the CB1 receptor and this could be indicative of the ability to elicit psychoactivity.  
Compound 1 also significantly increased the amount of cAMP in in vitro studies in comparison to 
MAM-2201 which is a known potent SC.  
 
 
 
 
Figure 6. 2: The chemical structure of MAM-2201 (the positive control used) compound 1 and 
compound 11, the two compounds that showed increased levels of accumulated cAMP in the cAMP 
ELISA.  
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6.2 Materials  
6.2.1 Equipment 
Fluorescent samples were analysed using the Promega Luminometer Glomax (Southampton, UK), 
colorimetric assays were read using the LabSystems Multiskan Ascent plate reader (Agilent 
Technologies Inc, California, USA). Electrical field stimulation tests were carried using Harvard 
Apparatus 30 mL organ baths (Cambridge, UK) 
6.2.2 Cell culture reagents 
Chinese hamster ovary epithelial cells (CHO-CNR1, Gene I.D 1268, passage number: 4, ECACC: 
12110601 lot number: 13A006) were purchased from Culture Collections, Public Health England 
(Salisbury, UK). Cell culture reagents for CHO-CNR1 cells included Ham's F12 nutrient mixture, trypsin 
and phosphate buffered saline (PBS) were purchased from Sigma-Aldrich, Dorset, UK. L-glutamine, 
penicillin-streptomycin and foetal bovine serum (FBS, pH 7.4) were all purchased from ThermoFisher 
Scientific (Loughborough, UK). Sterile preparation of stock solutions and chemicals were performed 
either by filtration through a 0.22 μm Whatmann sterile filter and/or autoclaving at 121°C at 1 bar for 
1 h. 
6.2.3 Selected “hit” compounds 
Thirteen compounds (see Table 6.1) were purchased from MolPort (Riga, Latvia). The positive control 
MAM-2201 was provided by an in-house library of NPS held at the University of Hertfordshire 
(purchased from Chiron Surrey, UK). The positive control was prepared following the protocol stated 
by the Home Office licence. 
Table 6. 1: Compounds that were evaluated for biological activity. 
Compound  Name Structure 
1 N-benzyl-4-(3-cyclopropyl-1,2,4-
oxadiazol-5-yl)phthalazin-1-amine 
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2 7-methyl-3-(5-methyl-1,2,4-oxadiazol-
3-yl)-N-(1-(pyridin-2-yl)ethyl)quinolin-
2-amine 
 
3 N-(2,3-dihydro-1H-inden-5-yl)-2,4-
difluorobenzamide 
 
4 4-bromo-N-(3-
ethynylphenyl)benzamide 
 
5 2-(2-phenethoxyphenoxy)ethan-1-ol 
 
6 (4-(((7-chloro-2,3-
dihydrobenzo[b][1,4]dioxin-6-
yl)sulfinyl)methyl)phenyl)methanol 
 
7 (E)-3-(4-chlorophenyl)-1-methyl-5-
(thiophen-2-ylmethylene)-2-
thioxoimidazolidin-4-one 
 
8 1-(furan-2-yl)-N-(3-{[(furan-2-
yl)methyl]imino}-2,3-dihydro-1H-
isoindol-1-ylidene)methanamine 
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9 (E)-2'-(3-(dimethylamino)acryloyl)-5'-
(methylthio)-[2,3'-bithiophene]-4'-
carbonitrile 
 
10 N-(2-isopropyl-6-methylphenyl)-2-oxo-
2H-chromene-3-carboxamide 
 
11 (E)-4,6-dihydroxy-5-(((6-
methylbenzo[d]thiazol-2-
yl)imino)methyl)pyrimidine-2(1H)-
thione  
12 8-chloro-3-methyl-10-
phenylpyrimido[4,5-b]quinoline-
2,4(3H,10H)-dione 
 
13 3-(3,5-dimethylphenyl)-2,10-
dimethylpyrimido[4,5-b]quinoline-
4,5(3H,10H)-dione 
 
Positive Control MAM-2201 ([1-(5-fluoropentyl)-1H-
indol-3-yl](4-methyl-1-naphthalenyl)-
methanone) 265,278 
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6.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The cyclic AMP multispecies competitive ELISA kit was purchased from ThermoFisher scientific 
(Loughborough, UK).  3-Isobutyl-1-methylxanthine (IBMX) purchased from Sigma-Aldrich (Dorset, UK) 
was used in the cAMP assay study. The positive control used was the known synthetic cannabinoid [1-
(5-fluoropentyl)-1H-indol-3-yl](4-methyl-1-naphthalenyl)-methanone (MAM-2201 see table 6.1). 
6.2.6 Electrical Field Stimulation (EFS) study  
Tissue preparation was conducted on site (University of Hertfordshire, UK) by fully trained personnel. 
• Wistar Rats, from Charles River, UK. 
• Each Rat is given: Aspen Wood Chew, Water, and Lab 3 Diet 
• Schedule one Procedure, Euthanized through exposure to increasing CO2 levels and followed 
by cervical dislocation. 
• Weight: 250-350g 
• Sex: Male 
Data was recorded using Labscribe iWorx (iWorx Systems, Inc Dover, UK) which was connected to the 
EFS apparatus and included the Harvard 6002 stimulator and a Harvard Variable cycle timer (Harvard 
apparatus, Massachusetts, US). 
 
 
 
 
 
 
 
 
 
 
186 
 
6.3 Methods 
6.3.1 CHO-CNR1 cell revival 
The cryovial of CHO-CNR1 (passage number 4)  was removed from liquid nitrogen storage and rapidly 
brought to 37 oC by immersing in a 37 oC. Thawed cells were dispersed in 3 mL of pre-warmed 
complete media (37 oC) and then transferred to a 15 mL centrifuge tube with an additional 7 mL of 
pre-warmed media. The cell suspension was centrifuged at 250 g for 5 min at room temperature (~19 
oC) to form a cell pellet. The old media was aspirated, and the cell pellet was then re-suspended in 10 
mL of fresh, pre-warmed complete media, and transferred to a, media-pre-wetted, T75 flask and left 
to incubate (37°C, 5% v/v CO2 humidified incubator) for 12h. After the incubation period, 15 mL of 
fresh complete media was added. 
6.3.2 CHO-CNR1 cell culture 
Cells were cultured in a Ham's F12 nutrient media that was supplemented with 8mM L-glutamine, 1% 
v/v penicillin-streptomycin and 10% v/v foetal bovine serum (FBS) and dispersed within T75 culture 
flasks. Cells were passaged when cell confluency reached approximately 90% and were maintained in 
a humidified incubator at 37 oC and 5% (v/v) CO2. As CHO-CNR1 cells are adherent, trypsin was 
required to detach cells from the bottom of the T75 flask when passaging. (Trypsinization exploits the 
enzyme trypsin to break down the proteins associated with cell adherence, after this process has 
occurred the supernatant is neutralised with complete media279. Trypsin is deactivated by protease 
inhibitors present in the added FBS280). Briefly, old media was aspirated away and, 7 mL of trypsin 
solution was added to the cells and left to incubate. Cell detachment was observed under the 
microscope, cells that were detached could be seen floating on the surface of the flask (~10 minutes). 
The trypsinized supernatant was neutralised with 7 mL of fresh complete media and transferred to a 
centrifuge tube. The supernatant was centrifuged at 250 G for 5 min at room temperature 19 oC to 
form a cell pellet. The cell pellet was then re-suspended in 10 mL, or as required in terms of 
dilution/cells per mL of fresh pre-warmed complete media, and transferred to a, media-pre-wetted, 
T75 flask and left to incubate (37°C, 5% v/v CO2 humidified incubator). 
6.3.3 Trypan blue cell viability exclusion assay 
Absolute cell counts, and estimated cell viability was carried out using the Trypan blue exclusion 
technique. 10 µL of a 0.4% (w/v) Trypan blue solution was mixed with an equal volume of cell 
suspension before being introduced into an improved Neubauer haemocytometer chamber. The four 
outermost corner squares which contained cells that had not taken up the trypan blue stain were 
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counted as being viable. Cells that had not taken up the stain remained dark blue and were deemed 
as dead cells. This is due to Trypan blue being absorbed through cell membranes that have been 
compromised. Total cell number was calculated as number of cells per millilitre of cell suspension. 
6.3.4 Cell metabolic activity assay/MTS assay  
The CellTiter 96 Aqueous One solution cell proliferation assay (Promega, Southampton, UK) was used 
to determine mitochondrial activity of CHO-CNR1 cells via the conversion of MTS to a formazan 
product accomplished by NADPH or NADH, which is produced by enzymes in metabolically active 
cells281. The methodology was followed according to the manufacturer’s instructions with the 
following amendments. A 10µl aliquot of the Aqueous One Solution reagent was added to each well 
containing 50µl cell suspension on a 96 well plate. The plate was then covered in aluminium foil and 
incubated for 90 mins in 37°C, 5% v/v CO2 humidified incubator. Absorbance was measured at 490nm 
using Multiskan ascent plate reader. MTS assay was used to determine % cell viability (respective of 
control). Complete F12 media and Triton X-100 (lysis solution) were used as background and negative 
controls, respectively.  
6.3.5 CytoTox-ONE membrane integrity assay 
The CytoTox-ONE membrane integrity assay kit (Promega, Southampton, UK) was used to determine 
LDH release (due to a compromised cell membrane) from CHO-CNR1 cells according to the 
manufacturer’s instruction with the following amendments. 50 µl of the cell supernatant was 
transferred into each well of a black 96-well plate. Triton X-100 (lysis solution), 1% v/v DMSO and 
media were used as controls.  25 µl of the CytoTox-ONE reagent was added to each well, covered with 
foil and then left for 20 min at room temperature (~19C). Next, 25µl of stop solution (provided with 
the Promega CytoTox-ONE assay kit) was added to the wells. Fluorescence was measured using 
Glomax multi detection system plate reader at 560 excitation and 490nm emission. Data obtained was 
used to determine percentage viability of CHO-CNR1 cells using the following equation; 
Percent cytotoxicity = 100 x (Experimental – Culture medium back ground) 
                      (Maximum LDH Release – Culture Medium Background)  
 
Equation 6.1: Calculation used to determine percent cytotoxicity of CHO-CNR1 cells using the CytoTox 
ONE membrane integrity assay 18,281. The maximum LDH release value was taken from cells that had 
been lysed with Triton X, the culture media background value was taken using complete media. 
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6.3.6 cAMP ELISA  
The cAMP ELISA was carried out following the manufacturer’s instructions. The compounds were 
dissolved in 1 mL DMSO which was used as the stock solution. This was diluted with complete media 
so that the final DMSO concentration within each well was 1 %. Prior to conducting the ELISA assay, 
cells were incubated with a buffer mixture of complete media and 0.5 mM of IBMX for 45 mins in 
order to stabilise any cAMP produced282. The IBMX buffer was aspirated away and cells were washed 
with wash buffer (from cAMP ELISA kit) and replaced with a 200 µL mixture of Ham’s F12 complete 
media (180 µL) and drug mixture (20 µL) at a final concentration of 1 x 10-5 mM. Cells were lysed by 
treatment of the sample with lysing reagent (200 µL of 0.1 M hydrochloric acid and 0.1 (v/v) % of 
Triton X) for 10 mins. Cell lysis was monitored by visual inspection using a microscope during this 
process, lysed cells do not have the atypical shape of CHO cells but tend to be more elliptical. The 96 
well plate was then centrifuged (600 G at room temperature for 10 mins) and the resulting cell 
supernatant was directly used for the cAMP ELISA. The assay was carried out in triplicate. The solution 
(200 µL) containing the compounds of interest were added to the wells of the cAMP ELISA. 50 µL of 
cAMP-AP conjugate was added to the well. To the same wells 50 µL of cAMP antibody was added, the 
plate was sealed using the plastic cover provided and left to incubate at room temperature on a plate 
shaker (500 rpm) for 2 h. After the incubation period, the contents of the well were emptied and 
washed in triplicate using the 1X wash buffer provided. To the wells 200 µL of pNpp (p-nitrophenyl 
phosphate) substrate solution was added and left to incubate at room temperature for 1 h (no 
shaking). After the 1 h incubation period, 50 µL of stop solution was added to each of the wells and 
the optical density was recorded at 405 nm. 
6.3.7 Cell Staining 
Cell staining was performed using ShandonTM Kwif-DiffTM stains purchased from ThermoFisher 
Scientific (Loughborough, UK). A 96 well plate containing approximated 100,000 cells per well were 
fixed using 3.7 % (w/v) paraformaldehyde (PFA, in PBS pH 7.4). Cells were washed in PBS before fixing, 
this was done to remove dead cells, debris and FBS from the sample. PFA was added and left to stand 
at room temperature for 20 min. The 96 well plate was then washed three times with PBS. The cells 
were stained following the ShandonTM Kwif-DiffTM staining procedure which consisted of adding 50 µl 
of reagent 1 (methanol) to each well. The reagent was left to stain the cells for 20 sec, removed and 
the washed with PBS. The same step was conducted using reagent 2 (eosin) and once more with 
reagent 3 (methylene blue). After the three stains had been applied to the wells, and washed with 
PBS, the cells were finally washed with deionised water and left to air dry for 1 h. 
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6.3.8 Electrical field stimulation (EFS) 
Approximately 1 cm segments of full-thickness rat ileum were prepared and cleaned whilst submerged 
in Krebs buffer (see Table 6.2 for composition). The ileum tissue was cleaned by using a pipette filled 
with fresh Krebs buffer to flush the ileum tissue. This was done until only clean buffer could be seen 
flowing through the ileum. The tissue was placed between two metal prongs which were attached to 
an electrode inside a 30 cm3 organ bath (Harvard Apparatus, Cambridge, UK). The organ bath was 
filled with 15 mL of Krebs buffer which was kept at 37oC using a heated water bath and constantly 
oxygenated with Carbogen gas (95% oxygen & 5% CO2). 
Table 6. 2: The chemical composition of the Krebs Buffer solution (pH 7.2) prepared in double distilled 
water and used throughout the EFS study. 
 
moles g/L 
NaCl 119 6.96 
KCl 4.7 0.35 
NaH2PO4 1 0.12 
MgSO4 1.2 0.14 
NaHCO3 25 2.1 
Glucose 11 1.98 
CaCl2 2.5 0.28 
 
Labscribe (iWorx, version 3.011400) was used to calibrate the transducer, determine the baseline 
tension and record all data generated during the experiment(s). Viability of the tissue was determined 
using carbachol (10-4 M)266 and then thoroughly cleaned by washing the tissue four times with fresh 
Krebs buffer. The tissue was left to rest at 37oC in Krebs buffer to equilibrate for a minimum of 10 
minutes in order to reach a stable resting basal tone. The EFS study was carried out as a single 
experiment. 
Two looped sections of cotton thread (Marvel Fabrics, Hatfield, UK) were sewn into the freshly 
prepared tissue:   one to the top and one to the bottom of the tissue section sample. The looped 
cotton threads were attached close to the edges of the dissected tissue (2-3 mm). One loop was 
attached to the bottom of the organ bath to anchor the tissue which was maintained at a tension of 
approximately 1 g, the second loop was attached to a transducer which was connected to the 
Labscribe iworks software to measure tissue contraction. The tension was maintained at a constant 
value throughout the experiment. 
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A frequency response curve (1 Hz to 60 Hz) was constructed, at supramaximal voltage of 50 V, pulse 
width, of 0.5 s, for 2 seconds every 3 minutes. 150 µL of each compound at a concentration of 10-6 M 
was added to the organ bath using a pipette immediately prior to stimulation, the change in tension 
(g) was then recorded at 1, 10, 20, 40 and 60 Hz. 
6.4 Results 
6.4.1 CHO-CNR1 cell revival and culture 
Following the revival process, cell number reached 80-90% confluency (see figure 6.3) within 
approximately 48 hours. Cells were passaged, on average, every two to three days or until the T75 
flask reached 80-90% confluency. 
 
 
Figure 6. 3: Representative image of CHO-CNR1 cells at 90-100% confluency. Cells are adhered to a 
T75 flask after 48 hrs. Images taken with a GXCAM-9 digital microscope C-mount camera (GT Vision 
Suffolk, UK) mounted on an Olympus CKX41 microscope at x4 magnification. 
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Figure 6. 4: Representative images of CHO cells A: at 4x, 10x and 20x, B: 4x, 10x and 20x, C: at 4x, 10x 
and 20x and D at 4x, 10x and 20x. Images taken with a GXCAM-9 digital microscope C-mount camera 
(GT Vision Suffolk, UK) mounted on an Olympus CKX41 microscope. Image is a randomly selected 
representative sample from 3 experiments. 
6.4.2 CHO-CNR1 cell batch growth curve 
A growth profile was generated for three different cell passage numbers (6, 8 and 11) using the trypan 
blue exclusion assay and used to elucidate the exponential growth phase. From Figure 6.5 it was 
deduced that this phase occurs between days 3-4. This information was used to best assess when to 
carry out the cAMP ELISA plate assay. For all three assays 96 well plates were used and were seeded 
with 10,000 cells per well. 
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Figure 6. 5: The growth curve of CHO-CNR1 cells over a seven-day period, using 3 different passage 
number (3, 8 and 11). For each passage number, four trypan blue counts were conducted giving a total 
n=12. Cells were grown in F12 Hams complete media and cell counts was conducted using trypan blue 
exclusion assay. Results are expressed as a mean +/- SD of three independent experiments with n =12. 
P value of 0.0001 (***) was determined relative to day 1 and day 3 using 1-way ANOVA. Post-test 
comparisons were made using Dunnett’s test at 95% confidence interval. 
6.4.3 MTS cell viability assay  
The MTS assay (Figure 6.6) was used to characterise the metabolic activity of the cells over a 7-day 
period. 
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Figure 6. 6: The absorbance values (in nanometres) obtained from the MTS assay that was carried out 
over a seven-day period. The data points with standard deviation bars are calculated based on three 
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different passages (3, 8 and 11) that were assayed in triplicate. Results are expressed as a mean +/- 
SD of three independent experiments with n =12. P value of 0.0001 (***) was determined relative to 
day 1 using 1-way ANOVA. Post-test comparisons were made using Tukeys test at 95% confidence 
interval. 
6.4.4 LDH cytotoxicity assay 
The LDH assay is used as a measure of the amount of lactate dehydrogenase present. LDH is released 
upon cell death and can be used to calculate the percentage of dead cells. Figure 6.7 shows that the 
maximum amount of LDH present is 25% after a 7-day period, this value is compared to the total cell 
death which is calculated as 100% presence of LDH. 
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Figure 6. 7: The percentage of dead CHO-CNR1 cells over a seven-day period. The percentage values 
were calculated using the % cytotoxicity equation (Section 6.3.5, Methods) Results are expressed as a 
mean + SD of three independent experiments with n =12. P value of 0.0001 (***) was determined 
relative to day using 1-way ANOVA. Post-test comparisons were made using Turkeys test at 95% 
confidence interval. 
The data obtained from these three assays conducted indicated that biological evaluation should be 
carried out 3-4 days after passaging, this is due to the percentage of LDH being relatively low and cells 
appear to be viable and able to proliferate (from data obtained from MTS and Trypan blue assays) 
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6.4.5 CHO-CNR1 cytotoxicity screening 
To ensure the compounds of interest were not cytotoxic, an MTS assay was carried out at a 
concentration of 10-5 M, this concentration was selected as it has been reported in the 
literature283,265,284 as being appropriate for the positive control MAM-2201. 
A 96 well plate was seeded with 100,000 cells per well and incubated with the compounds for 90 mins. 
Figure 6.7 details the results of the MTS assay, the graph shows that Compound 6 has significantly (P 
= 0.0001) increased the mitochondrial activity in comparison to the negative control (cells only) 
indicating no cytotoxic effect of the compounds. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 + 
C - C
0.0
0.2
0.4
0.6
0.8
*
Compound I.D
A
b
s
o
rb
a
n
c
e
 4
9
0
 n
m
 
Figure 6. 8: results (n = 6) of the MTS assay carried out after 90-minute incubation period of the 
compounds with the CHO-CNR1 cells. Results are expressed as a mean + SD of two independent 
experiments with n =6. P value of 0.0001 (*) was determined relative to negative control using 1-way 
ANOVA. Post-test comparisons were made using Dunnett’s test at 95% confidence interval. The 
positive control (C+) is the results obtained when MAM-2201 was added to the cells and the negative 
control (C-) are cells that have had no addition chemicals added. 
6.4.6 cAMP assay 
The commercially available cAMP ELISA assay includes a cAMP standard that are used to construct an 
internal calibration curve (see Figure 6.9). The calibration curve was used to quantify the cAMP 
present in the supernatant samples collected after incubation with the compounds. All results 
obtained were within the range of the internal standard curve produced.  
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Figure 6. 9: The standard curve used to determine cAMP concentrations for assayed samples. 
A number of studies conducted have shown there is a correlation between cannabinoid molecules 
and an increase in the accumulation of intracellular cAMP levels285,271,286, this is indicative of binding 
affinity for the CB1 agonists and the CB1 receptor. 
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Figure 6. 10: histogram summarising the cAMP production in treated samples, the calculated amount 
(pmol/mL) of cAMP that was present in each well for the compounds of interest (n=6), MAM-2201 
(C+, positive control) and cells that had been assayed with only the addition of IBMX (C-, negative 
control). Results are expressed as a mean + SD of three independent experiments with n = 9. P value 
of <0.001 (***) was determined relative to positive control (MAM-2201), using 1-way ANOVA. Post-
test comparisons were made using Dunnett’s test at 95% confidence interval.  
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The ELISA assay was carried out in triplicate using three different passage numbers and three different 
ELISA plates and, from figure 6.10 it can be seen that compound 1 (0.69 pmol/mL), compound 3 (0.24 
pmol/mL) and compound 11 (0.39 pmol/mL) had the highest values of cAMP present. Compound 1, 3 
and 11 produced more cAMP than the positive control which produced 0.24 pmol/milk This could 
indicate that these molecules have a higher efficacy in activating the CB1 receptor, or that the 
compounds of interest are causing a response that is responsible for the increase in cAMP. 
6.4.7 Electrical field stimulation 
Tissue viability was assessed before the compounds were screened, this was carried out by treating 
the tissue with 1 µM of carbachol; the addition of this compound induces muscle contraction and 
therefore proves the tissue was viable. Figure 6.11 shows the magnitude of the contraction after the 
addition of Carbachol, this viability test was conducted on all tissue samples used. 
Figure 6.11 is  a diagram of an evoked contraction caused by the addition of carbachol, this is 
commonly used to test tissue viability268,269,274. After the tissue was deemed viable EFS was conducted 
with only Krebs buffer in the organ bath. This was used as a negative control. Once the tissue had 
returned to a resting tension the positive control was added and contraction tension at the different 
frequencies (1-60 Hz) were recorded (see Table 6.3). After the addition of each compound, and once 
all frequencies had been applied the tissue was thoroughly washed out and left to return resting 
tension before another EFS study was carried out. 
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Figure 6. 11: EFS trace of an induced muscle contraction. The line that indicates test dose (highlighted 
in yellow) shows the point at which the carbachol was added to the organ bath. The peak shows that 
the tissue has contracted, the quantitative data is obtained by subtracting the maximum tension 
values (V2) from the resting tension value (V1). These values were obtained by placing red cursor lines 
at the base line tension and a second red cursor line at the peak of the contraction. The values for V1 
and V2 can be seen in top right-hand corner of figure 6.10 i.e. 4.730 g. 
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Figure 6. 12: Representative traces of the EFS-evoked an EFS pulse of 10 Hz is applied to A – Compound 1, B – compound 11, C – positive control (MAM-2201) 
and D – negative control (tissue and Kerbs buffer only). Compound 1 exhibited a tension change of 0.604 g, compound 11 exhibited a tension change of 0.703 
g and the positive control exhibited a relaxation wave (0.679 g) and then a contraction of 0.930 g.  The data for compounds 1 and 11 have been shown as 
these compounds exerted the greatest change in tension to comparison to all the other compounds screened. 
A B C D 
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Figure 6.12 shows the changes in tension at 10 Hz in the presence of compound 1, 12, the negative 
control and the positive control. At 10 Hz compound 1 and MAM-2201 had very similar contraction 
patterns, both had a small delay after the addition of the compound and then a large peak which was 
recorded after the EFS was applied. Compound 11 appeared to have a different effect on the tissue, a 
peak was recorded after the pulse was applied however the tissue seemed to relax and reach a resting 
basal tone much quicker in comparison to other compounds. 
Table 6. 3: The percentage increase in tension values (g) observed after the EFS had been applied to 
the tissue sample (tissue samples taken from: Wistar Rats, from Charles River, UK) at the different 
frequencies in the presence of the positive control (MAM-2201), the 13 compounds of interest and a 
negative control (Krebs buffer only) n = 1. See appendix for all EFS traces 
 
 
1 Hz 10 Hz 20 Hz 40 Hz 60Hz 
 
Percentage Increase 
Negative Control 25.1 100.0 100.0 87.7 77.2 
Positive Control - MAM-2201  22.6 25.5 51.2 49.4 40.0 
compound 1 24.1 27.3 14.0 13.3 11.9 
compound 2 6.1 44.5 66.0 54.6 44.0 
compound 3 23.2 49.4 50.6 43.4 37.1 
compound 4 20.9 56.1 59.7 49.1 39.7 
compound 5 17.6 33.2 53.1 51.6 42.3 
compound 6 21.1 30.5 59.2 57.1 52.2 
compound 7 9.9 33.3 36.6 34.1 29.3 
compound 8 13.0 27.7 36.4 32.8 25.5 
compound 9 20.1 31.9 33.1 31.7 23.3 
compound 10 10.4 30.4 35.5 26.3 20.5 
compound 11 34.8 28.3 30.2 27.9 33.1 
compound 12 16.9 30.1 30.4 54.3 52.9 
compound 13 25.0 17.8 23.6 22.3 18.1 
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The results in Table 6.3 show that after the initial evoked contraction at 1 Hz Compound 1, 3, 11 and 
13 had a percentage increase in tension value of greater than the value obtained for the positive 
control MAM-2201 (22.6%). When the frequency pulse is increase to 10 Hz Compound 1 still depressed 
the contraction - more so than the positive control, Compound 11 also displayed inhibition but not to 
the same extent as MAM-2201. Although the results do suggest that some of these compounds have 
the ability to inhibit evoked contractions at varying frequencies, more investigation is required for 
conclusive evidence to prove these compounds as being CB1 receptor ligands.  
6.5 Discussion: 
To validate the results obtained from Chapter 5 in vitro and ex vivo methods were carried out to 
establish if any of the compounds identified interacted with the CB1 receptor. In vitro and ex vivo tests 
are routinely used in the characterisation of novel drug entities. The therapeutic applications of CB1 
ligands have been extensively investigated for their uses in analgesia, appetite regulation287, nausea, 
and emesis277. The work presented in this chapter highlights how in Silico methods can be coupled 
with biological evaluation in the identification of novel CB1 receptor ligands. 
CHO-CNR1 cells  
CHO cells were used in this study as this cell line was purchased with expression of the CB1 receptor 
and has been well documented in the literature for investigations conducted using synthetic 
cannabinoids,273. A review article published in 2002 highlights how the molecules Δ9-THC, CP55940, L-
759656, HU-308 and JWH-133 were able to elicit a response from CHO cells that have been transfected 
with CB1 and CB2 receptors96. One proposed mechanism of action is that the activation of the CB1 
receptor results in changes in the amount of cellular cAMP288 which has been recorded using CHO cells 
and cAMP assays. 
Growth Curve 
A batch growth curve was produced to establish the different phases within the life cycle of this 
particular cell line. This was done to identify when the cells were actively growing which is important 
as this phase is when the cells are the most sensitive to changes in their environment289, as NPS have 
been shown to stimulate cellular responses in a wide range of cells290–292. Figure 6.5 show the four 
phases of cell growth, the lag phase where growth is very slow was seen between 24-48 hr after 
passaging as the cells are adapting to their new environment293. During the exponential phase, cells 
are known to be more active this is the ideal time to conduct any in vitro cytotoxicity testing this is 
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seen between day 3 and 4. The stationary phase can be seen at days 5-6 and the death phase is seen 
at day 7, this is typical of CHO cell growth as seen by Petrov and Tsupkina (2013)294. 
Trypan blue exclusion assay  
The determination of cell viability is crucial for cell culture when evaluating the properties of a 
compound in a biological assay295. In addition to cell viability, the number of cells within a certain 
volume of media is also important as this can be used to determine the growth rate of a particular cell 
line. Trypan blue exclusion assay was used as this method provides rapid estimation of cell number, 
cells are stained with the blue dye the viable cells do not absorb the dye and remain white in colour. 
Non-viable cells are stained blue due to a lack of integrity in the cell membrane which allows cells to 
absorb the dye296. This assay, in combination with MTS and LDH, is routinely used to determine overall 
cell health297. From the results obtained the cell growth profile is in accordance to what is reported in 
the literature298. 
MTS assay 
The MTS assay is commonly used in measuring cell viability or drug toxicity by measurement of 
mitochondrial metabolic rate299. Other cell viability assays include MTT and XTT which involves the 
enzyme mitochondrial dehydrogenase reducing the MTT/XTT to a measurable formazan product. This 
conversion is widely believed to happen in viable cells300. MTS was selected over MTT/XTT as this is a 
one-step convenient, rapid process for assessing cell viability which is sensitive and does not require 
a termination step like MTT/XTT299. The results obtained for the MTS assay shows very little decrease 
in mitochondrial activity over a 7-day period. As the cells begin decreasing in number after day 6 it 
would be expected to see a decrease in the absorbance values for the MTS from day 6 onwards. To 
gain a better understanding of the mitochondrial activity profile of this cell line the MTS assay should 
be continued post day 7. The results obtained from the MTS assay (Figure 6.6) conducted show that 
the mitochondrial activity does start to decline after day 5 which is concomitant with the results 
obtained from the trypan blue assay. However, after day 6 there is an increase in activity which is 
unexpected. To overcome this, the MTS assay could be carried out over a longer period of time to see 
if there is a more obvious trend in decline in mitochondrial activity. 
LDH assay  
The use of LDH assays in determination of cell death is widely established301. This assay measures the 
amount of lactate dehydrogenase in the supernatant. When the plasma membrane is damaged LDH 
is released into the extracellular space and used as an indication of percentage of cell death301. Other 
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types of cytotoxic assays include Neutral Red which has been reported as being less sensitive in 
comparison to LDH301 and ATP content, which is known to be a very sensitive assay but fluctuations in 
temperature and small changes during the incubation period can lead to misleading results301.  
Cytotoxicity screening 
To ensure the selected test compounds were not cytotoxic an MTS assay was conducted. A study 
carried out by Funada302 showed that, in a concentration dependent manner, MAM-2201 was 
cytotoxic and caused cell apoptosis302. Apoptosis differs to necrosis as the former is generally viewed 
as a passive event whereas necrosis is associated with acute toxic injury303. Figure 6.8 shows that the 
addition of the test compounds (with the exception of compound 6) to the CHO cells had no significant 
negative effect on mitochondrial activity. This indicates that over a short period of time these 
compounds are not cytotoxic. However, to further validate this an LDH assay should be conducted. 
Compound 6 did show significant increased mitochondrial activity in comparison to the negative 
control (cells only), this could indicate that the presence of this compound is a causing a response, but 
further investigation will need to be conducted to validate this. When comparing the results of the 
LDH and MTS assays from day 1-3 the absorbance values for MTS are relatively high and are not 
significantly decreasing, the percentage of LDH release is increasing which suggest the cells are 
growing. After day 6 the absorbance values for MTS start to increase and the percentage of LDH 
release is significantly higher which indicated the cells are actively dying.  
cAMP ELISA 
Quantification of cAMP is a widely used method to explore the functionality of synthetic cannabinoid 
agonists304, as the compounds screened were selected based on physicochemical similarities to known 
SC. It is assumed the compounds 1-13 would act as SC agonists. Many in vitro assays conducted look 
at the inhibition of forskolin induced cAMP production285,305-41, as the activation of the CB1 receptor 
has been implicated in the accumulation of cAMP.  
The compounds identified in Chapter 5 were done so on the basis that the chemical structure would 
interact with the CB1. However, information regarding the nature in which the ligand would bind was 
unknown. The majority of psychoactive CB1 ligands are full agonists97,306,307 however there are a small 
number of selective psychoactive CB1 ligands that have been identified as antagonists (SR141716A308 
and LY320135305) and the role these drugs play in cAMP production is different to the CB1 agonists, 
which could indicate although these compounds were identified as CB1 agonists they may behave as 
CB1 antagonists  
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Figure 6.9 shows that compound 1 significantly increases the production of cAMP. As this study was 
not conducted using forskolin induced cAMP production, this may indicate that activation of the CB1 
receptor is occurring273. Additionally, some studies have shown that CB1 inverse agonists are known 
to increase cAMP production308,309. The significant increase in cAMP due to compound 1 does indicate 
that there is an interaction occurring at the CB1 receptor but the compound’s mechanism of action 
will need to be further evaluated with binding assay studies. 
EFS study 
Activation of the CB1 receptor has been widely established in the reduction of gastrointestinal motility 
in vivo276,134. Compounds such as AM251, AM258, HU210 and THC have been reported in the literature 
as inhibitors of smooth muscle contraction134. The aim of this study was to see if any of the compounds 
identified in Chapter 5 activated the CB1 receptors located in rat ileum. Results from this would further 
validate the cAMP assay results and indicate that the selected compounds interacted with the CB1 
receptor and could also potentially elicit psychoactivity.  
A number of pharmacological studies conducted using EFS and rat ileum have been reported when 
validating the efficacy of known CB1 receptor ligands269,268. The mechanism in which CB1 agonists 
reduce smooth muscle contractility has been debated. One mechanism that has been proposed is  
related to reduction of acetylcholine release 268. The results obtained were done so using only one 
concentration of compound. Therefore, to further validate this particular study a dose dependant 
study should be carried out. The study should also be repeated. However, due to the available amount 
of compound and tissue samples available this was not possible. This should be considered for future 
work. When comparing the results obtained from the MTS cytotoxicity study to the EFS results, there 
does not appear to be a link between significantly different MTS values and EFS values. To further 
validate this observation more data needs to be obtained from both the EFS and MTS cytotoxicity 
studies. 
A study conducted by Izzo et al267 showed that the cannabinoid agonists WIN55,212-2 and CP55,940 
decreased muscle reflex contraction. Both compounds are known to be selective full CB1 
agonists306,307. The EFS study conducted was a preliminary investigation to see if any of the hit 
compounds would have an effect on isolated smooth muscle tissue. A negative control test using only 
the tissue sample and EFS was used as a bench mark to establish to what extent the tissue would 
contract without the addition of any chemicals. The positive control, MAM-2201, was used to see if 
this synthetic cannabinoid inhibited contraction.  
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The negative control showed a contraction of 2.942 g at 10 Hz. Figure 6.12 (D) shows the magnitude 
of the contraction and, that directly after the application of EFS, the tissue was contracting and 
relaxing which indicates the EFS pulse was strong enough to cause residual contractions. 
MAM-2201 did show a reduction in contraction in comparison to the negative control, after the EFS 
was applied at 10 Hz. Figure 6.12 (C) shows that the contraction at this frequency exerted a contractile 
force of 0.762 g which is considerably smaller than the negative control. This indicates that MAM-2201 
inhibits gut wall muscle contraction. 
Compound 1 inhibited the initial relaxation phase after direct application of EFS and the contractile 
force at 10 Hz was 0.636 g which is slightly less than MAM-2201. This may indicate that compound 1 
is able to inhibit contractions to a greater extent in comparison to the positive control. Compound 11 
also showed signs of contractile inhibition with a contraction force of 0.846 g. However, after the 
application of EFS the muscle tissue did not have the same contraction pattern to the positive control 
or compound 1 (see Figure 6.12, B). This could indicate that the relaxation phase after the application 
of EFS is completely inhibited by compound 11. Both compounds display signs of contraction inhibition 
which indicates activation of the CB1 receptor. Compound 13 appeared to initially inhibit contraction 
after the application of EFS, but as the contraction values in grams do not vary substantially when the 
frequency is increased this indicates that the tissue may not have been viable at this stage, again 
reinforcing the need to further investigate this particular study. 
Compound 1 and 11 were docked into the same binding site in CB1 receptor, the docked 
configurations were analysed and compared to MAM-2201. There are a number of amino acid 
residues (Met103, Gly166, Phe170, and Val196)97 that are integral to CB1 binding. Protein Ligand 
Interaction Fingerprints (PLIF) were constructed (see figure 6.13) for the docked poses and these 
showed that compound 1 and 11 are forming interactions with residues that have been reported in 
the literature as being fundamental to protein-ligand interaction at the CB1 binding site97. Although 
this does imply that a protein ligand interaction is likely to occur between the CB1receptor and 
compounds 1 and 11 in order to unequivocally confirm this a co-crystallised model of the protein and 
the ligands will need to be obtained.  These compounds were identified using pharmacophore models 
based on known SC, they were selected on being structurally different to known SC however they do 
share common chemical functionalities with ligands known to bind to the CB1 receptor. Due to the 
systematic identification of these compounds the expected result of the cAMP assay was that the test 
compounds would interact with the CB1 receptor.  
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Figure 6. 13: Protein Ligand Interaction Fingerprints (PLIF) for Compound 1 (A) and Compound 11 (B). 
The compounds were docked into the CB1 receptor (accession code 5TGZ) using the London ΔG and 
GBVI/WSA ΔG scoring functions, Compound 1 had a scored value of -8.29 Kcalmol-1 and Compound 11 
had a scored value of -6.72 Kcalmol-1.  
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6.6 Conclusions 
The aim of this study was to identify if any of the compounds from the virtual screen in Chapter 5 
would exhibit similar biological activity as known synthetic cannabinoids. Using CHO-CNR1 cells that 
had expression of the CB1 receptor a cAMP ELISA was conducted and the results indicate that 
compound 1 was able to increase the production of cAMP in comparison to the positive control (MAM-
2201). An increase in cAMP would indicate that the compounds identified are activating the CB1 
receptor in a similar mechanism to known SC and this could indicate that these compounds have the 
ability to cause a psychoactive effect. Initially the compounds identified were thought to act as CB1 
agonists. From the docking study conducted on these compounds they appear to bind to the same 
region as the known SC antagonist AM653897, but also form interactions with residues that are 
associated with the SC agonist JWH-018. Further work would be required to identify the mechanism 
of action for both Compound 1 and 11. 
It should be noted that both in vitro studies carried out were preliminary and would need to be further 
investigated before confirming these compounds for an interaction with the CB1 receptor. 
From previous docking studies conducted on the known synthetic cannabinoids compound 1 forms 
interactions with residues in the CB1 receptor agonists that are common to known potent synthetic 
cannabinoids (JWH-018 and MAM-2201). To ascertain where compound 1 would elicit psychoactivity 
in vivo studies would need to be carried out. 
The preliminary EFS study conducted did indicate that there was inhibition of smooth muscle 
contraction which is consistent with a physiological effect displayed by a known CB1 agonist.  
Compound 1 is displaying the type of behaviour that is consistent for known SC, this indicates 
promising results that this compound is a truly novel SC. However, to identify the compound as either 
agonist or an antagonist a more extensive experiment would need to be conducted in order to further 
validate the results. 
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Chapter 7  
General Conclusions and Future Work. 
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7.1 General Conclusions 
At the outset, the intention of the studies presented in this thesis was to determine whether or not in 
Silico methodologies, which had been successfully used in other areas to understand the subtleties 
and complexities of protein-ligand interaction, were transferable to studies on New Psychoactive 
Substances, and their associated receptors in order to increase understanding in this area. 
For example, in this project, the use of molecular docking was employed to establish whether in Silico 
methodologies could successfully rank a library of NPS in such a way that the computational results 
would mirror the biological potency values established through in vitro binding assays. Through the 
investigation of a number of different scoring functions and the implementation of consensus scoring, 
this was achieved for two of the three MAT isoforms investigated.  
It is well established that a number of monoamine transporter inhibitors have varying affinities for all 
three MAT isoforms, DAT, NET and SERT310. A wide range of NPS are also known to be MAT inhibitors, 
and as such they exhibit a large degree of promiscuity between DAT, NET and SERT. An investigation 
of the MATs binding site composition was conducted (using homology models as no experimental 
structures were available at the time) to identify differences in structure between the isoforms, 
particularly with reference to their putative binding cavities, that would explain how selectivity of a 
given NPS arose from one isoform to the next. Initial docking studies conducted to compare 
biologically derived data to computational data yielded statistically significant results for DAT only. 
This lead to the utilisation of a wide-range of different scoring functions and ultimately employment 
of a consensus of scoring functions, derived from two different docking algorithms and the use of an 
algorithm that rescored poses generated by other scoring functions, in order to improve the initial 
results by virtue of ameliorating the inherent bias of a single scoring function, which arises as a result 
of approximations in force-fields and/or the necessarily limited nature of datasets used to derive 
them. Following the iterative refinements, significant results were obtained for both DAT and SERT 
using consensus scoring.  
However, docking studies using the NET homology model and the application of different scoring 
functions/consensus approaches were unable to generate results that showed significant correlation 
between biological measurements and computational predictions. This was hypothesised to be most 
likely due to the small dataset and the skew of the distribution of biological activities from normal, for 
the NET compounds.  
The underlying reason for observed promiscuity of NPS between the MATs was also investigated. 
Results from Chapter 3 have shown that there is a high degree of structural and topological similarity 
between the MAT homology models. This lack of structural difference present between the MAT is 
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likely to have been one of the factors that made it difficult to isolate any substantial structural 
differences between the MAT which could then have been rationalised to explain the selectivity of 
NPS between one MAT isoform and the next.  
The homology models were all built using the same template, and the inherent limitations with this is 
such that a difference in the overall fold of the isoforms would not be expected given that they were 
built on the same template. This means that subtle differences in topology that occur naturally 
between the MATs would not necessarily be apparent in the models. Complementary, yet 
independent protein validation techniques were used to probe any issues of this nature, and showed 
that in the absence of experimental structures each of the models were valid to use for the 
investigations i.e. there were no major structural defects identified which would be cause for worry 
in docking experiments. However, as all models are approximations, it would be naïve to assume that 
there were no intrinsic limitations in using models to conduct these investigations rather than high-
quality experimentally determined structures.  
However, during the course of these studies, newly published crystal structures (for DAT, PDB 
Accession Code 4XP9 and SERT, PDB Accession Code 5I75) became available and a rigorous 
comparative analysis was conducted to try and identify structural differences between these crystal 
structures and the homology models that could better explain the selectivity profiles of the NPS 
investigated for these isoforms. The crystal structures were subjected to the same structural quality 
checks as the homology models, and unsurprisingly performed to a higher standard. Hence, all crystal 
structures were deemed appropriate for docking studies. Comparison of the results from the docking 
studies using the homology models with the docking studies using the crystal structures revealed 
differences in the positioning of highly ranked docked poses in the crystal structures which gave rise 
to an improvement in the correlation between observed biological activity and predicted 
computational ranking for the crystal structure experiments compared to the homology model 
docking experiments.  
Comparison of the SERT structure and model highlighted a shift in protein backbone which gave rise 
to a binding site that was a different shape to that seen in the homology model. The cavity in the 
crystal structure was more restrictive, due to a narrower opening to the site, which placed the majority 
of the highly ranked docking poses in the bottom of the SERT cavity for the crystal structure – whereas 
some highly ranked poses in the homology model showed interaction of the small molecule with 
residues that define the entrance to the cavity. An identical comparative study was conducted on the 
newly published DAT crystal structure a slight improvement in docking results, for similar reasons (i.e. 
a more restricted binding cavity) over the homology modelling studies. However, the crystal structures 
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showed there were no obvious structural differences identified in the binding cavities between the 
DAT and SERT isoforms that could be used to explain the differences in affinity for a given NPS. 
There was no crystal structure for NET published. However, a newer NET homology model (4XP4a) 
was published, and this was used to highlight differences between it and the NET homology model 
used in the initial experiments. Although this model (4xP4a) gave rise to a larger binding site it did not 
significantly improve the docking results. 
These studies showed the MATS were very similar in topology and structure, which may be the reason 
as to why a docking algorithm was unable to definitively identify the subtle differences that could 
result in selectivity.  Even high-quality crystal structure did provide conclusive insight into the key 
protein-ligand interactions being formed between NPS and the MATs to explain the reasons behind 
isoform selectivity, although useful insights into the key interactions between NPS and the MAT 
isoforms were identified. Similarities in the DAT and SERT binding cavities highlighted a plausible 
reason as to why there is such a high level of promiscuity amongst MATs. As such, alternative 
approaches to investigate selectivity were needed.   
Where Chapter 3 detailed a structure-based approach to understanding selectivity, the inherent 
limitations of scoring functions, homology models and the structural similarity between MATs 
afforded modest results in trying to understand what gives rises to selectivity amongst MAT.  
Therefore, the next step was to prosecute a ligand-based approach, which would switch the focus to 
the small molecules that bound to the MATS and would utilise an understanding of the 
physicochemical properties of the NPS to gain insight into selectivity. Predictive computational models 
were successfully generated to identify the key physicochemical properties required to explain the 
differences in affinity for known NPS binding to the three different monoamine transporters. This use 
of QSAR models provided further insight into the properties required of NPS with respect to forming 
protein-ligand interaction with DAT, NET or SERT.  
QSAR models have been exploited for specific groups of drugs such as benzodiazepines311, 
cathinones312 and tricyclic antidepressants313 however up until the work described in this thesis there 
was no study conducted on specific monoamine transporter isoforms. A number of QSAR models for 
DAT, NET and SERT that incorporated models with varying numbers of molecular descriptors were 
investigated as part of these studies, and the models that yielded the highest r2 and q2 values for each 
isoform were analysed for generalizability using NPS test sets. 
A 3-descriptor DAT QSAR model was built using the descriptors b_max1len, FASA_H and opr_leadlike, 
which account for steric, hydrophobic and drug-like physicochemical properties respectively. The 
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highest-performing model developed for SERT also included three molecular descriptors PEOE_VSA-
0, a_don and E_tor, which describe hydrophobic, electronic and steric properties respectively. 
Although the molecular descriptors for DAT and SERT are different, similarities between the two sets 
of molecular descriptors can be extrapolated. The steric descriptors used in the DAT and SERT QSAR 
models both described a preference for relatively inflexible molecules. Additionally, both equations 
identified hydrophobic interactions being integral for determining activity for DAT and SERT. The 
differences in descriptors for DAT and SERT that did arise included the fact that DAT selective 
molecules should not adhere to opr_leadlike criteria. Investigating this in greater detail suggested that 
this term was in fact a simple correction factor.  As with the structure-based approach, although the 
exact descriptors in each of the QSAR models were different, the properties they were describing were 
comparable, yet further evidence to support the observed promiscuous binding of the NPS between 
these two MAT isoforms. The DAT and SERT pKi values were normally distributed and from this robust 
and generalisable models were built for these two isoforms. 
The four molecular descriptors associated with the NET QSAR model only accounted for electronic 
properties and did not produce a robust or generalisable QSAR. A potential reason for this could be 
the dataset used in the development of the NET model. The biological data available for this isoform 
was not normally distributed, unlike DAT and SERT, and this may have limited the ability to generate 
any generalisable QSAR model built based on the NET pKi values, despite the steps that were taken to 
ensure that the training and test sets were representative of the dataset as a whole.  
Data obtained from Chapter 3 highlighted that the MAT binding cavities are not significantly different 
so it may be expected that all three isoforms would produce very similar QSAR equations. For the two 
isoforms that produced predictive models (DAT and SERT) it would appear on first inspection that this 
was not the case given that the investigations showed that different descriptors were identified for 
the QSAR models for each isoform. However, when these descriptors were examined in greater depth, 
it was found that the properties they are describing are closely related – hence the QSAR models are 
similar. The information obtained from Chapter 4 provided a deeper insight into the type of 
interactions formed between NPS and MAT, and helped to improve the understanding around why 
there is a degree of promiscuity associated with NPS and the MAT isoforms.  
Having identified that molecular modelling techniques were applicable to aiding understanding of the 
NPS, attention was then focussed on using them to identify previously unexploited chemical scaffolds 
with the potential to be developed into the next generation of NPS. The development of 
pharmacophore models based on known synthetic cannabinoids in combinations with a systematic 
filtering process allowed for the identification of a library of completely novel chemical structures that 
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were predicted to have the ability to interact with the CB1 receptor and possibly elicit psychoactive 
properties. 
A ligand-based approach was utilised in Chapter 5 to identify these pharmacophores and subsequently 
potential new scaffolds for SC. The methodology employed was developed to ensure that novel 
molecules identified using virtual high throughput screening were structurally dissimilar to known SC, 
but retained both the predicted ability to bind to the CB1 receptor, and a range of physicochemical 
properties similar to known SC, so as to maximise the possibility of the compound binding to the CB1 
receptor. To this end, the systematic methodology developed in Chapter 5 outlines a thorough 
workflow that can be applied to maximise the possibility of identifying active compounds against the 
CB1 receptor whilst maintaining complete novelty in chemical structure. 
A limitation of this study was the number of molecules available per class of structurally dissimilar 
synthetic cannabinoid. Pharmacophore models could only be built for three different SC classes, which 
meant that the broad range of structural diversity that is present within the SC was not exploited to 
its full potential. This is likely to have reduced the number, and the structural diversity, of virtual hits 
returned by the screening process. However, a large number of structurally diverse molecules were 
returned from the screens with the pharmacophores that had been generated, and as such the 
experiment was successful. 
Shortly after this study was conducted the human CB1 crystal structure was published. Docking of the 
virtual hits into the binding cavity of CB1 was used as an additional filter, and to prioritise which 
compounds were purchased for the biological testing experiments. Moving forwards, the availability 
of an experimentally derived structure allows for a structure-based approach to be conducted, this is 
an avenue that should be further explored for novel CB1 agonists/antagonists. 
The successful outcome of the virtual screening experiments led to the purchase of a number of 
compounds with the potential to bind to the CB1 receptor. Both in vitro and ex vivo techniques were 
conducted to evaluate the biological activity of the novel compounds identified.  The use of cAMP 
biological assays provided quantitative data that showed the majority of the “hit” compounds 
identified did have an effect on the cAMP production of CHO cells that expressed the CB1 receptor. 
This could be an indication of an interaction with the cannabinoid receptor being formed. However, it 
should be noted that the experiments conducted in Chapter 6 do not categorically show that the CB1 
receptor has been activated by the compounds screened.  
The cAMP assay conducted was done so without the presence of Forskolin which has previously been 
employed in many CB1 activity-based studies, Forskolin was not employed due to financial and time 
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constraints. This study was conducted as preliminary investigation to see if the hits screened showed 
any interaction with the CB1 receptor by altering the amount of cAMP present.  
To provide a definitive answer on the biological activity of these compounds a more sophisticated 
binding assay would be required. Future work could include the use of a radiolabelled binding assay 
to provide quantitative data for the hit compounds that are shown to impact on cAMP production. 
As there were limitations associated with the cell-based assay employed, a secondary biological 
experiment was conducted using whole tissues samples. This approach was used as there are 
established methodologies that have been published using cannabinoids and ileum tissue, and to 
provide a complementary study for the non-definitive cell-based assay. 
The preliminary Electrical Field Stimulations (EFS) did show that in the presence of compound 1 and 
compound 12 the tissue sample demonstrated an increased contraction period, which is consistent 
with the activation of the CB1 receptors commonly found in ileum tissue. Again, the EFS study 
conducted does not explicitly prove that the virtual hits are interacting with the CB1 receptor but does 
act as additional evidence, alongside the results from the cell-based assay that these hits are causing 
a biological response that could be due to an interaction of the virtual hits with the CB1 receptor. 
Therefore, the preliminary data has shown that two of the thirteen compounds screened show greater 
affinity to the CB1 receptor in comparison to a known potent SC. Traditional high-throughput virtual 
screening (HTVS) projects will achieve approximate hit rates of 0.1%314. The in Silico methodology 
employed in this study has showed a potential hit rate of 15.4% which is substantially greater than 
typical HTVS experiments, and demonstrates the power of the tool as an agent for identifying 
bioactive molecules. 
Overall, this research has shown that in Silico techniques are applicable in the rationalisation of 
observed biological activity for the NPS and in the development of wholly novel potential NPS., given 
that computational techniques made it possible to systematically search a library of over 17 million 
compounds and produce a small library of compounds some of which displayed promising results with 
respect to biological activity in two independent, yet complementary, studies. 
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7.2 Future Work 
The biological experimental data obtained highlighted two compounds that show a likely interaction 
with the CB1 receptor. Future work will be focused on the development of a complete 
pharmacological profile for each of the compounds. The utilisation of a newly developed G-protein 
coupled receptor (GPCR) activation assay based on NanoLuc binary technology4 can be applied to 
profile biological activity of the molecules identified in Chapter 5. In addition to this, a more extensive 
study using rat ileum and known CB1 antagonist would reveal the mechanism of action of identified 
hits, and would establish whether the molecules are in fact CB1 agonists.  
Future work conducted on compound 1 and compound 12, will produce a series of synthetic analogues 
that can then be investigated for their affinity with the CB1 receptor. Molecules of interest will be 
investigated for viable synthetic routes and the compounds will be synthesised and characterised 
using standard analytical techniques such as nuclear magnetic resonance (NMR) and liquid 
chromatography mass spectroscopy (LCMS). The characterised molecules will then be examined for 
biological activity using cAMP ELISA using the same methodology as outlined in Chapter 6. Structure 
activity relationships (SAR) can be elucidated that will provide information on how to produce 
molecules with an increased potency, and potentially selectivity, for the CB1 receptor. De novo design 
strategies can also be employed alongside the virtual screening results to identify further novel 
scaffolds that have the potential to be developed into SC. 
Chapter 5 highlighted 35 compounds that when docked into the CB1 receptor had a greater binding 
score than a known potent SC (MAM-2201). Due to financial and time constraints these compounds 
could not be acquired, so future work will also look into investigating these compounds. If funds can 
be identified, it would be of interest to repeat the initial cell-based assays in conjunction with 
Forskolin, as the use of this compound has been well documented in the literature in determining the 
activity of potential CB1 agonists. In depth EFS studies will also be conducted on the synthesised 
molecules to provide more evidence that an interaction at the CB1 receptor is occurring. Radioligand 
binding assays can also be conducted to provide a full biological profile and prove definitively that the 
synthesized molecules are biologically active. The most potent molecule can then be subjected to 
further development to produce a library of analogues. Which can then be docked into the crystal 
structure of the CB1 receptor to provide information on which analogues are most likely to form and 
interaction and therefore be an indicator of potential psychoactivity.   
Finally, another avenue of research that can be investigated is structure-based drug design, utilising 
the recently published CB1 crystal structure and all of the known SC to generate a consensus 
pharmacophore based on the interactions of all of the different categories of SC and not just those 
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with large enough numbers to be exploited via ligand-based strategies. This approach for developing 
novel SC could lead to the identification of compounds with distinct chemical scaffolds additional to 
those already identified in this thesis, and provide further routes for investigation into the next 
generation of new psychoactive substances.  
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Appendix 
Electrical field stimulation trace in the presence of Carbachol
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Electrical field stimulation trace in the presence of the positive control MAM-2201 
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Electrical field stimulation trace in the presence of compound 1 
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Electrical field stimulation trace in the presence of compound 2 
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Electrical field stimulation trace in the presence of compound 3 
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Electrical field stimulation trace in the presence of compound 4  
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Electrical field stimulation trace in the presence of compound 5 
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Electrical field stimulation trace in the presence of compound 6 
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Electrical field stimulation trace in the presence of compound 7 
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Electrical field stimulation trace in the presence of compound 8 
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Electrical field stimulation trace in the presence of compound 9 
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Electrical field stimulation trace in the presence of compound 10 
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Electrical field stimulation trace in the presence of compound 11 
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Electrical field stimulation trace in the presence of compound 12 
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Electrical field stimulation trace in the presence of compound 13 
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